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Abstract 
The incidence of oesophageal adenocarcinoma is rising. Overall survival rates 
remain poor. Traditional methods of staging oesophageal adenocarcinoma fail to 
identify patients at high risk of early disease recurrence after surgical treatment with 
curative intent. Circulating tumour cells have been reported to offer prognostic 
information in patients with certain tumour types including breast, prostate and 
colorectal. The majority of studies have focused on circulating tumour cell 
enumeration in patients with metastatic disease.  Little is known about the role of 
circulating tumour cells in oesophageal adenocarcinoma or of the importance of 
circulating tumour cells in patients without metastatic disease. 
Cultured oesophageal adenocarcinoma cell lines were used to develop and validate 
a novel method for detection of tumour cells in whole blood. The method used 
positive depletion of normal blood cell populations before imaging the cells with an 
Imagestreamx image flow cytometer. A panel of fluorescently-conjugated antibodies 
against EpCAM, cytokeratins, survivin, CD45 and DAPI were used to discriminate the 
tumour cells. 
A consistent recovery of 48% was achieved across a range of concentrations of 
cultured oesophageal adenocarcinoma cells added to whole blood. Blood samples 
from 25 patients undergoing staging for oesophageal adenocarcinoma without known 
distant metastatic disease were studied. Circulating tumour cells were identified in 5 
patients, range 2 – 85 per 5 ml whole blood. Circulating tumour-associated 
macrophages were identified in a single patient. No difference in overall survival was 
demonstrated between those patients with circulating tumour cells compared to those 
without.  
The developed method produces high quality images allowing for the detection and 
characterisation of circulating tumour cells. Heterogeneity within the circulating 
tumour cell population was observed. Circulating tumour cells may be identified in a 
significant number of patients with oesophageal adenocarcinoma without radiological 
evidence of distant metastatic disease.  
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Chapter 1. Introduction 
 
1.1 Oesophageal Cancer 
Oesophageal cancer is the eighth most common cancer worldwide. In the United 
Kingdom, it is the thirteenth most common cancer and accounts for three per cent of 
all cancer cases. The incidence in males is approximately double that in females; it is 
the eighth most common cancer in males in the United Kingdom. It affects most 
commonly people over the age of 60 (Figure 1.). The overall prognosis for patients 
with the disease remains very poor. The five year survival for all patients diagnosed 
in the United Kingdom is only 15%. This low survival rate is because approximately 
two thirds of patients have advanced and incurable disease at the time of 
presentation and diagnosis. Clearly, novel approaches to the earlier diagnosis and 
treatment of oesophageal cancer are required. 
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Figure 1.1 The average number of new cases of oesophageal cancer per year in the UK and the 
age-specific incidence rates between 2009-2011. 
The incidence of oesophageal cancer per 100,000 males remains nearly double that for females 
although the total number of cases in both sexes gradually converges with increasing age due to 
differences in overall life expectancy. Figure reproduced from (Cancer Research UK Oesophageal 
Cancer Incidence Statistics) 
 
1.1.1 Symptoms 
The commonly described symptoms of oesophageal cancer include dysphagia and 
weight loss. These symptoms are usually associated with advanced disease (Bowrey 
et al., 2006). More rapid investigation of patients who present to their general 
practitioner with these symptoms has been shown to reduce the time to diagnosis but 
has no benefit on survival (Sharpe et al., 2010). In early stages, oesophageal cancer 
may be asymptomatic or present with more subtle symptoms.  The links between 
heartburn, Barrett’s metaplasia and oesophageal adenocarcinoma are well 
recognised (Lagergren et al., 1999). Heartburn and reflux are therefore potential 
early symptoms of oesophageal adenocarcinoma, although they are more commonly 
associated with non-malignant pathology (Rubenstein et al., 2011). Recent 
awareness campaigns, including the national ‘Be Clear on Cancer’ campaign in 
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2015, have focused on the importance of individuals reporting their persistent 
heartburn to allow for earlier investigation and an earlier diagnosis of oesophageal 
cancer to be made. 
 
1.1.2 Diagnosis 
The gold standard investigation for patients suspected of having oesophageal cancer 
is flexible oesophago-gastro-duodenoscopy (Adams et al.). This procedure allows 
visual assessment of any tumour and permits biopsies to be taken for histological 
confirmation (Figure 1.2). A small proportion of patients have their tumour identified 
first by computed tomography scan (Bettegowda et al.) or by contrast barium 
swallow. 
 
 
Figure 1.2. Examples of oesophageal adenocarcinoma detected at oesophago-gastro-
duodenoscopy.  
In both images an irregular, thickened tumour (A) is easily distinguished from the normal smooth 
squamous mucosa (B) of the distal oesophagus. 
 
1.1.2 Histological subtypes 
There are two common histological subtypes of oesophageal cancer; 
adenocarcinoma and squamous cell carcinoma. Rarer subtypes include small cell 
cancer and neuroendocrine tumours. Squamous cell carcinomas arise from the 
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native squamous mucosa of the oesophagus and may occur throughout the 
oesophagus.  By contrast adenocarcinomas usually arise within the distal third of the 
oesophagus. The incidence of the two subtypes demonstrates considerable 
geographical variation. In Eastern countries, virtually all oesophageal cancer is 
squamous cell carcinoma. By contrast in the West, although both subtypes of cancer 
are encountered, adenocarcinoma is more prevalent. The incidence of oesophageal 
squamous cell carcinoma in the West has remained relatively stable but incidence 
rates of oesophageal adenocarcinoma continue to rise (Vizcaino et al., 2002). The 
highest reported incidence of oesophageal adenocarcinoma is in the United Kingdom 
(Bollschweiler et al., 2001). 
 
Histological subtype Risk Factors 
Squamous cell carcinoma  • Smoking 
• Alcohol 
• Hot drinks 
• Family history 
• Riboflavin deficiency 
• Vitamin A and C deficiency 
• Corrosive strictures 
• Achalasia 
• Tylosis palmarum 
Adenocarcinoma  • Gastro-oesophageal reflux (Hahn et al.) 
• Barrett’s metaplasia of the oesophagus 
• Obesity 
 
Table 1.  Risk factors for the two common histological subtypes of oesophageal cancer. 
 
The aetiology and risk factors differ considerably for the two common histological 
subtypes of oesophageal cancer as shown in Table 1.1.  Oesophageal 
adenocarcinoma is most commonly caused by gastro-oesophageal reflux (Lagergren 
et al., 1999; Rubenstein and Taylor, 2010). Risk factors for oesophageal 
adenocarcinoma therefore include factors that increase the risk of acid reflux. Acid 
reflux can lead to a cellular change to the normal lining of the oesophagus. The 
stratified squamous mucosa undergoes a process of glandular metaplasia. This 
metaplasia is known as Barrett’s metaplasia of the oesophagus (figure 1.3). It is 
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estimated that Barrett’s metaplasia of the oesophagus affects up to 2% of the UK 
population (Jankowski et al., 2010). Within the Barrett’s mucosa, dysplastic changes 
may occur to the epithelial cells. These changes are defined as low or high grade 
dysplasia and when identified have a high rate of progression to the development of 
invasive adenocarcinoma. This progression rate is estimated to be between 0.22-
0.26% per year for patients with known Barrett’s oesophagus (Bhat et al., 2011; Hvid-
Jensen et al., 2011). The progression from acid reflux, Barrett’s metaplasia of the 
oesophagus and subsequent development of oesophageal adenocarcinoma is 
therefore well established (Lagergren et al., 1999; Rubenstein and Taylor, 2010). The 
increasing rates of obesity amongst the UK and other Western populations have 
contributed to the increased incidence of oesophageal adenocarcinoma. 
 
 
Figure 1.3. Endoscopic appearance of Barrett’s oesophagus.  
A clear distinction is observed between the pale pink normal oesophageal squamous mucosa (A) and 
the darker abnormal Barrett’s mucosa (B) in the lower third of the oesophagus during flexible 
oesophago-gastro-duodensoscopy (Adams et al.). 
  
Oesophageal adenocarcinoma and squamous cell carcinoma are recognised to be 
very different diseases in terms of pathogenesis, tumour biology and prognosis 
(Siewert and Ott, 2007). In the past, both histological types of oesophageal cancer 
have been studied together and reported in combined series which means that it is 
not possible to compare and interpret results for the two histological types. It is now 
recommended that squamous cell carcinoma and adenocarcinoma should be 
reported separately. Because of the higher incidence of oesophageal 
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adenocarcinoma within the UK and its rapid increase, this study has focused on 
oesophageal adenocarcinoma alone.   
 
1.1.4 Staging 
Staging describes the extent of a patient’s tumour both in terms of local growth of the 
primary tumour and dissemination to lymph nodes or other metastatic sites. It 
separates patients with the disease into prognostic groups upon which treatment 
decisions can be based. Oesophageal adenocarcinoma is staged according to the 
Union for International Cancer Control (UICC) TNM classification. The TNM staging 
system was devised for all solid tumours by Pierre Denoix and is now maintained by 
the UICC.  This classification provides information on the primary tumour (T), lymph 
nodes (N) and distant metastatic (M) disease. The most up-to-date version of the 
TNM classification for oesophageal adenocarcinoma is the 7th Edition. (Figure 1.4A) 
(Rice et al., 2010). The primary tumour is classified from T1 to T4 depending on the 
depth of invasion through the oesophageal wall. T4 disease represents local invasion 
into adjacent structures. Tis refers to carcinoma in-situ and is regarded as a pre-
malignant condition which lacks the characteristic invasion seen in malignancy. It is 
more commonly referred to as high grade dysplasia. Nodal disease is classified from 
N1 to N3 according to the number of nodes that are involved with metastatic tumour 
deposits. Finally, distant metastatic disease is classed as M1 with M0 used to 
describe the absence of such disease spread. A tumour is therefore described, for 
example, as T3N1M0.   
Individual tumour stages are further classified into stage groups as detailed in figure 
1.4B. Stage groups provide prognostic information; a more advanced stage group 
has a worse survival. Stage four represents distant metastatic disease. Common 
sites for metastatic dissemination of oesophageal adenocarcinoma include the liver, 
lungs and bone. Involvement of lymph nodes that are very distant from the tumour, 
for example in the neck, are also classified as metastatic (M1) disease.  
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Figure legend on next page 
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Figure 1.4. The UICC TNM staging classification (7th edition) for oesophageal adenocarcinoma. 
A. Schematic of the TNM classification. The multiple layers of the oesophageal wall are illustrated. T 
stage (Tis-T4) is determined by the depth of invasion of the primary tumour. Tis represents in-situ 
disease in which the tumour has Nodal stage (N0-N3) reflects the number lymph nodes involved with 
tumour. Distant metastatic disease is classified as M0 (No metastatic disease) or M1 (metastatic 
disease present). Figure reproduced from (University Hospitals Cleveland, USA) B. Stage groups 
according to the UICC TNM classification. Individual TNM stages are grouped together according to 
prognostic information.  
 
Staging is essential to allow appropriate treatments to be planned for patients (see 
section 1.1.7). Patients with stage 4 disease have incurable disease and are only 
suitable for palliative therapies. Locally advanced (T4) oesophageal adenocarcinoma 
describes tumours that have directly invaded adjacent structures for example the 
aorta or lung and hence may not be suitable for curative treatment. For patients who 
are suitable for treatment with curative intent, staging informs the selection of 
appropriate treatment modalities, for example peri-operative chemotherapy and 
surgery. The most commonly used peri-operative chemotherapy is only offered to 
patients with either T3 or node positive (N≥1) disease (Cunningham et al., 2006). 
Definitive TNM staging requires histological examination of the resection specimen.  
Current pre-treatment staging of patients includes radiological assessment of the 
disease.  The radiological staging protocol for oesophageal adenocarcinoma is more 
complicated than for most other tumour types because of the anatomical location of 
the oesophagus, its proximity to other structures such as the heart, lungs and aorta, 
and the complex lymphatic drainage from the oesophagus into both the thorax and 
abdomen. A summary of the staging pathway for oesophageal cancer is provided in 
Figure 1.5. All patients undergo a computed tomography (CT) scan (Bettegowda et 
al.) that provides information about the size and position of the primary tumour, the 
involvement of local lymph nodes and the presence of distant metastatic disease. A 
significant proportion of patients will be found to have incurable disease by CT scan 
alone and will undergo no further staging tests. Those patients whose disease is 
classed as curable by CT scan will frequently undergo both endoscopic ultrasound 
(EUS) and positron emission tomography-computed tomography (PET-CT). 
Endoscopic ultrasound involves an ultrasound probe attached to the end of a 
gastroscope that allows accurate determination of the depth of tumour invasion (T 
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stage) and local nodal involvement. PET-CT utilises the increased metabolism of 
glucose by tumour cells compared with native tissues. Fluorodeoxyglucose (18F-
FDG), a radiolabelled glucose analogue, is injected intravenously and is detected 
within tumour sites by the positron emission tomography scan. This scan is combined 
with a traditional CT scan to generate the combined PET-CT images. PET-CT may 
identify low volume distant metastatic disease that is not easily identified by 
conventional CT scanning. Patients with lymph nodes within the chest may also 
undergo an external neck ultrasound to identify involved lymph nodes in the neck. 
These nodes are outside the surgical field and cannot be removed at surgery.  A 
small number of patients require a staging laparoscopy if the tumour crosses the 
gastro-oesophageal junction into the proximal stomach. This laparoscopy involves 
inserting a camera inside the abdominal cavity under general anaesthesia and 
investigates peritoneal spread of the tumour, the presence of low volume ascites and 
if the tumour is invading adjacent structures such as the diaphragm.  
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Figure 1.5. Staging pathway for patients diagnosed with oesophageal adenocarcinoma.  
All patients undergo a CT scan. Subsequent tests are performed sequentially. The identification of 
metastatic disease at any stage will stop the pathway as patients are no longer eligible to treatment 
with curative intent. 
 
What is common to all of these staging modalities is that they are able to detect 
macroscopic disease. There are limitations to the accuracy of all radiological tests 
and in particular, low volume metastases are difficult to identify and characterise. At 
present, the assessment of microscopic metastases does not form part of the pre-
treatment staging process for oesophageal adenocarcinoma.  
Alongside the staging pathway, a careful assessment of a patient’s fitness is 
required. This assessment is an essential part of planning treatment options. Patients 
undergo rigorous testing using formal Cardio-Pulmonary Exercise Testing (CPX). 
Numerous physiological parameters including anaerobic threshold and V02 max are 
calculated based upon controlled exercise on a static bike. CPX helps to assess and 
stratify an individual’s ability to tolerate surgical resection, however the precise value 
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of CPX testing in predicting cardiopulmonary complications following 
oesophagectomy is unclear (Forshaw et al., 2008; Moyes et al., 2013).  
 
1.1.5 Junctional Tumours 
The classification of tumours that arise within five centimetres of the gastro-
oesophageal junction is complex due in part to a lack of a consensus definition of the 
gastro-oesophageal junction. The junction may be defined anatomically or based 
upon the site of change in the mucosa from squamous to columnar. The junction is 
frequently obscured by tumour which makes identification difficult. Junctional tumours 
are almost invariably adenocarcinomas but there is considerable debate as to 
whether they should be managed as oesophageal or gastric tumours.  The most 
widely accepted definition was first described by Siewert and Stein (Siewert and 
Stein, 1998). This classification describes three types of junctional tumour based 
upon the anatomical location of the centre of the tumour (Table 1.2).  For the 
purposes of clinical management, type 1 tumours are considered to be oesophageal 
cancers and type 3 gastric. The management of type 2 lesions is more complicated. 
Both total gastrectomy via an abdominal approach and trans-thoracic 
oesophagectomy have been proposed as the surgery of choice for this patient group, 
reflecting the ability of cells from these tumours to metastasise to lymph nodes in 
both the abdomen and thorax (Mariette et al., 2011). It is important that all three 
types of junctional tumours are not grouped with oesophageal adenocarcinomas for 
the purposes of reporting. Only true oesophageal adenocarcinomas or type 1 
junctional tumours are included in this study.  
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 Description 
Type 1 
Adenocarcinoma of distal oesophagus which infiltrates the gastro-
oesophageal junction from above. The centre of the tumour is 
within 1-5 cm above the cardia 
Type 2 
True carcinoma of the cardia arising from gastric cardia 
epithelium or short segments with intestinal metaplasia at the 
gastro-oesophageal junction. The centre of the tumour is within 1 
cm above and 2 cm below the cardia. 
Type 3 
Gastric carcinomas that infiltrate the gastro-oesophageal junction 
from below. The centre of the tumour is within 2-5 cm below the 
cardia 
 
Table 1.2. Siewert and Stein classification of tumours of the gastro-oesophageal junction 
 
1.1.6 Anatomical Considerations 
The oesophagus consists of a cervical, thoracic and abdominal component. The 
average distance from the teeth to the gastro-oesophageal junction is 40 cm. It is 
composed of several layers as illustrated in figure 4A. Unlike the majority of the 
gastro-intestinal tract there is no outer serosal layer. The blood supply and lymphatic 
drainage is complex. The lower third of the oesophagus is a site of communication 
between the portal and systemic circulations.  Arterial blood supply to the upper third 
is derived from the inferior thyroid artery, to the middle third direct from the aorta, and 
to the lower third from the left gastric artery. Venous drainage is equally divided 
between the inferior thyroid vein, azygos vein and left gastric vein. Lymphatic 
drainage is equally complex. Lymph drains to nodal groups within both the chest and 
abdomen. The nodal groups are described in tiers as illustrated in Figure 1.6. This 
varied blood supply and lymphatic drainage means that there is considerable 
variation in the ways in which tumour cells metastasise in oesophageal 
adenocarcinoma. Lymph node involvement in particular is possible in both the chest 
and abdomen (Dresner et al., 2001). The treatment of oesophageal cancer with 
either surgery or radiotherapy must therefore take into account the impact of this 
complex anatomy.  
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Figure 1.6. The extent of nodal dissection performed during oesophagectomy.  
The nodal locations are displayed anatomically and divided into three fields of dissection. A standard 
subtotal oesophagectomy is performed with en-bloc dissection of the abdominal and thoracic fields 
(two field dissection). Cervical field nodes are removed only with more proximal oesophageal cancers, 
the majority of which are squamous cell carcinomas. Reproduced from (Griffin SM et al., 2013) 
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1.1.7 Treatment 
 
Surgery 
The mainstay of curative treatment for patients with oesophageal adenocarcinoma is 
surgical resection which is called oesophagectomy. The most common procedure is 
a two stage oesophagectomy with two field lymphadenectomy. Briefly, the stomach is 
mobilised via an abdominal incision and draining lymph node groups are resected. 
The right gastric and right gastro-epiploic vessels are preserved to ensure an 
adequate blood supply to the stomach. The oesophagus and surrounding tissue and 
nodes are mobilised via a right thoracotomy and the mobilised stomach is pulled up 
into the chest. The distal oesophagus and upper stomach is resected (Figure 1.7A). 
The residual stomach is anastomosed to the proximal oesophagus to restore 
gastrointestinal continuity (Figure 1.7B).  
There is potential for the manipulation of a tumour during surgery to lead to tumour 
cell dissemination. Such concerns were first raised by Turnbull in 1967 in colorectal 
cancer and led to the development of a no touch surgical technique in which 
lymphovascular pedicles were divided before the tumour was handled. The no touch 
approach led to improved survival of colorectal cancer patients (Turnbull et al., 1967). 
In view of the nature of the oesophageal blood and lymphatic supply, such an 
approach to oesophagectomy is not possible. Tumour handling is kept to a minimum 
but cannot be avoided entirely. 
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Figure 1.7. Subtotal oesophagectomy 
A. Surgical resection specimen following oesophagectomy for oesophageal adenocarcinoma. The 
specimen has been opened to allow visualisation of the tumour. The oesophageal mucosa (oes.) 
above the tumour appears normal as does the gastric mucosa below the tumour (gas.). B. Diagram of 
the major anatomical consequences of oesophagectomy. The mobilised stomach can be seen 
anastomosed to the residual oesophagus in the thorax to restore continuity of the gastrointestinal 
tract.   
 
Oesophagectomy represents very major surgery and a major physiological insult to 
the patient.  Historically oesophagectomy was associated with a very high rate of 
post-operative complications. Patients were in hospital for approximately three weeks 
and between 20 and 30% of patients died during the post-operative hospital stay.  In 
modern, specialist high-volume centres mortality rates of around 2% are achieved 
now with lengths of stay in hospital as low as seven days. The rate of morbidity 
following oesophagectomy remains fairly high however with up to 20% of patients 
experiencing a significant complication in the immediate post-operative period.  As 
mentioned in section 5.1.4, all patients undergoing surgery will have undergone CPX 
testing. CPX has been reported to be predictive of complications in patients 
undergoing an oesophagectomy (Onat et al.).  
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Improvements in post-operative survival have led to a much better understanding of 
the impact of oesophagectomy on quality of life. Patients take on average between 
nine and twelve months to recover their baseline quality of life following 
oesophagectomy (Jacobs et al., 2014) with energy levels in particular taking the 
longest to recover. Many of these patients will undergo adjuvant chemotherapy 
during this recovery period which can impact further on their quality of life. A 
proportion of patients never regain their baseline quality of life following treatment.  
The length of the recovery period from surgery means that there is no role for 
oesophagectomy in patients with metastatic oesophageal cancer. There is no 
survival benefit by undergoing resection. The median survival for patients with 
metastatic or locally advanced oesophageal adenocarcinoma undergoing palliative 
chemotherapy is approximately nine months (Webb et al., 1997) which is less than 
the time taken to recover baseline quality of life after surgery. All surgery is, for these 
reasons, performed with curative intent, which contrasts with the majority of other 
gastrointestinal cancers for which palliative resections are frequently performed. 
 
Endoscopic mucosal resection 
Patients who present with early, stage T1 oesophageal adenocarcinoma may be 
suitable for endoscopic mucosal resection. This endoscopic technique involves a 
submucosal injection of fluid that ‘lifts’ the mucosa and submucosa away from the 
muscle layers of the oesophagus. A piece of the mucosa and submucosa 
approximately one centimetre in diameter is then removed using cautery. This 
procedure can be considered a safe treatment for patients with stage T1a cancers 
that are confined to the mucosa and achieves good long-term oncological outcomes 
(Pech et al., 2014). Oesophagectomy is not required for these patients because 
patients with T1a disease should not have nodal metastasis (Griffin et al., 2011) and 
hence all of the disease can be removed endoscopically. Unfortunately, the number 
of patients who present with early oesophageal adenocarcinoma remains low, with 
only approximately ten per cent of patients staged with T1a disease.  Patients with 
stage T1b tumours (involving the submucosa) may also be treated with this approach 
however in this group of patients the risk of lymph node metastases is approximately 
12% (Griffin et al., 2011). Endoscopic resection alone risks leaving disease behind 
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and therefore it is usual practice to offer all such patients with T1b disease a 
subsequent oesophagectomy.  
 
1.1.8 Non-surgical Treatments 
An important improvement in the outcomes of patients undergoing oesophagectomy 
for adenocarcinoma has been the development of peri-operative chemotherapy and 
chemoradiotherapy.  The UK based MAGIC trial demonstrated a 13% five year 
overall survival benefit for patients with locally-advanced adenocarcinoma of the 
lower third of the oesophagus, junction or stomach who were treated with three 
cycles of neo-adjuvant ECF (epirubicin, cisplatin and fluorouracil) chemotherapy and 
three cycles of adjuvant ECF chemotherapy compared with those who underwent 
surgery alone (Cunningham et al., 2006). The results of this study have formed the 
basis of current treatment guidelines in the UK. Other countries in the West have 
favoured the use of pre-operative combination chemo-radiotherapy. The Dutch 
CROSS trial demonstrated a significant overall survival benefit for patients treated 
with neo-adjuvant carboplatin and paclitaxel chemotherapy in combination with 
radiotherapy (41.4 Gy in 23 fractions) compared with patients undergoing surgery 
alone (van Hagen et al., 2012). A new trial (Neo-AEGIS) comparing the CROSS and 
MAGIC protocols is currently recruiting within the United Kingdom (Keegan et al., 
2014).  
A small proportion of patients with oesophageal adenocarcinoma may be offered 
curative treatment with either radical radiotherapy or radical chemo-radiotherapy. It is 
accepted that the outcomes from such an approach are inferior to those of surgery, 
with or without peri-operative chemotherapy. Radical radiotherapy or chemo-
radiotherapy is therefore used as treatment in patients who are not fit for 
oesophagectomy or who do not wish to undergo surgery. It is only an option in 
patients with a relatively locally confined tumour. An early study of radical 
radiotherapy included patients with oesophageal adenocarcinoma and squamous cell 
carcinoma and reported three and five year survival rates of 27% and 21% (Sykes et 
al., 1998). The addition of chemotherapy to radical radiotherapy leads to a further 
improvement in survival with five year survival rates of 30% reported (AlSarraf et al., 
1997).  
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Patients who have advanced, incurable disease at the time of diagnosis may be 
treated with palliative chemotherapy or palliative radiotherapy. These same 
treatments may be appropriate for patients who are not fit enough for major surgical 
resection. A proportion of patients are not sufficiently fit for any active treatment.  
 
1.1.9 Outcomes 
Historically, outcomes following oesophagectomy for adenocarcinoma were dismal. 
Post-operative mortality rates exceeded 20 per cent and disease recurrence rates 
were high. The one year survival following oesophagectomy in 1990 was as low as 
21% (Muller et al., 1990). Outcomes have fortunately improved steadily over the last 
twenty years. Improvements likely result from the centralisation of services, with 
fewer centres treating a greater number of patients, more accurate disease staging, 
better peri-operative care and improved neo-adjuvant and adjuvant oncological 
treatment. The UK national post-operative 90 day mortality rate is now only 3.2%.  
High volume centres now achieve five year survival rates of between 40-50%. 
Survival is related to the stage of disease, with early stage cancers having much 
more favourable outcomes than more advanced stages. 
 
1.1.10 The Northern Oesophago-Gastric Cancer Unit 
The Northern Oesophago-Gastric Cancer Unit (NOGCU) is the largest centre for the 
management of both oesophageal and gastric cancer in the United Kingdom (Figure 
1.8). Approximately 300 patients with oesophageal cancer are staged each year and 
100 oesophagectomies performed. On average two thirds of patients with 
oesophageal cancer have oesophageal adenocarcinoma.  
 
19 
 
 
Figure 1.8. Funnel plot of the number of resections performed and 30 day mortality rates for all 
UK oesophago-gastric surgical units.  
The 30 day mortality rates against the number of patients treated with surgical resection are 
illustrated. The mortality rate across all units combined (audit average) is demonstrated by the straight 
dotted line. The Northern Oesophago-Gastric Cancer Unit (NOGCU) which performs more resections 
than any other unit is identified by the red circle has a mortality rate below the national average. 
Modified from (National Oesophago-gastric Cancer Audit - 2015) 
 
Within the NOGCU, outcomes following oesophagectomy have improved steadily. In 
the last 20 years, a total of 1047 patients have undergone oesophagectomy. 
Amongst these patients the overall five year survival is 38% (Dent et al., 2014). 
Analysis of the whole period in five year cohorts demonstrates that overall survival 
has improved steadily with time. For those patients included in the most recent five 
year cohort, the overall five year survival following oesophagectomy is 49%. In-
hospital mortality following oesophagectomy over the same time 20 year period has 
fallen from 7.5% to 1.9%. 
 
1.1.11 Disease recurrence 
Patients who undergo oesophagectomy for adenocarcinoma are at risk of disease 
recurrence either locally at the site of resection or in the form of distant metastatic 
disease. This metastatic disease is due to spread of tumour cells via the circulation. 
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Approximately half of patients have distant disease at the time of diagnosis of their 
recurrence (Dresner et al., 2000). Unfortunately despite rigorous radiological staging, 
a proportion of patients develop recurrent disease early during the post-operative 
recovery.  Given the lengthy recovery period following oesophagectomy, recurrence 
in the first six to 12 months after surgery may be viewed as a failure of staging and 
treatment. Patients who recur within this timescale may be considered for palliative 
chemotherapy but only if they have made a sufficient recovery from surgery to be 
able to withstand this additional treatment. It is likely that patients who develop early 
recurrence following surgery would have had an improved quality of life if they had 
received palliative chemotherapy alone. 
The higher the stage of disease the higher the risk of disease recurrence. Attempts 
have been made to identify risk factors within stage groups for very early recurrence. 
In oesophageal squamous cell carcinoma, tumour size and number of involved lymph 
nodes have been reported to be associated with early recurrence (Matsumoto et al., 
2013: Shimizu et al., 2012). At present these associations are not sufficient strong to 
be used to alter management decisions on an individual case basis.  
 
1.2 Circulating Tumour Cells 
Circulating tumour cells are created from the intravasation of cancer cells into the 
blood stream from primary or metastatic tumours (Figure 1.9).  
 
 
 
 
Figure 1.9. Schematic representation of the development of circulating tumour cells.  
Following cancer cell invasion, intravasation occurs leading to the release of free tumour cells into the 
bloodstream. Adapted from (Kalluri and Weinberg, 2009) 
Haematogenous spread is an important means by which tumours disseminate and 
develop distant metastatic sites. Metastatic disease plays a major role in determining 
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cancer prognosis. The study of circulating tumour cells aims to better understand and 
identify the development of this metastatic disease.  
The ability to detect individual tumour cells within the bloodstream was first reported 
by Thomas Ashworth in 1869 in Australia (Ashworth, 1869). Individual tumour cells 
were discovered post-mortem in the femoral vessels of patients who had died of 
cancer. These cells were morphologically identical to those from the primary tumour.  
One of the appeals of circulating tumour cell analysis as a means of studying and 
understanding tumour dissemination is the ease of obtaining samples from patients. 
Simple peripheral blood venepuncture is a routine part of the treatment of all cancer 
patients and additional sampling required for circulating tumour cell analysis poses 
no additional risks to patients. By contrast, biopsy of metastatic tumour sites 
frequently involves painful and technically demanding procedures that are invasive 
and carry significant risks to the patient. A major challenge in circulating tumour cell 
analysis however is the large number of normal blood cells amongst which a very 
minor population of tumour cells must be identified.  There may be as few as one 
circulating tumour cell per one billion normal blood cells (Table 1.3). The white blood 
cell population is particularly relevant as these cells are the closest in size and 
density to the circulating tumour cell population. The ability to investigate circulating 
tumour cells as both a research and clinical tool depends on the development of 
reliable technologies with which to identify circulating tumour cells. It is vital that any 
method used to detect circulating tumour cells is sensitive enough to identify this rare 
cell population and specific enough to provide confidence in the cells being detected.   
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Type of cell Number of cells per ml of fresh blood 
Erythrocyte (Red blood cell) 5,000,000,000 (range from 4.4 to 5.9 x 109) 
Leukocyte (White blood cell) 7,000,000 (range from 3.9 to 10.6 x 106) 
Platelet 295,000,000 (range from 150 to 440 x 106) 
Total 5,302,000,000   
Reported CTCs Range from 0.2 to >1000 
 
Table 1.3. The types and numbers of different types of cells in human blood 
 
1.2.1 Methods of circulating tumour cell detection 
In response to the growing interest in circulating tumour cells over the last decade, a 
large number of techniques have been developed to identify circulating tumour cells. 
The ideal method for analysis of circulating tumour cells would be one in which all 
cells in the blood could be imaged and analysed. To achieve such an approach is 
unrealistic in view of the number of cells involved and hence enrichment of the 
sample is required. Enrichment aims to reduce the number of normal blood cells 
analysed without affecting the circulating tumour cells.  
Enrichment relies upon differences in characteristics of the circulating tumour cells 
and normal blood cells. Broadly speaking, enrichment may consist of positively 
selecting the circulating tumour cells based on specific characteristics, or positively 
depleting the normal blood cells. Selection may be based upon physical, for example 
size, density or charge of the cells, or biological characteristics, for example specific 
antigen expression. In an ideal situation, enrichment would separate the circulating 
tumour cells from all other cells in the blood without losing any of the circulating 
tumour cells from the sample. In reality methods of enrichment are a balance 
between the purity of sample achieved and the loss of circulating tumour cells. The 
percentage of circulating tumour cells that remain after enrichment represents the 
recovery during the process. Following enrichment, the circulating tumour cells are 
enumerated based upon characterisation of the cells that distinguishes them from 
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any residual blood cells. This characterisation is most commonly achieved by 
analysis of antigen expression by immunofluorescence or immunocytochemistry. 
A review published in 2012 discussed 43 technologies that had been developed or 
were in the process of being developed to enrich, enumerate or characterise 
circulating tumour cells (Parkinson et al., 2012). Some methods of enriching samples 
are not followed by characterisation of the circulating tumour cells (Vona et al. 2000; 
Desitter et al. 2011). The authors of the review acknowledged that the assays have 
not been compared directly. With so many available methods, blood from a single 
patient may give different results depending upon which approach is used. This 
variability is a major disadvantage when trying to encourage clinicians to adopt the 
evaluation of circulating tumour cells in their clinical practice as it will undoubtedly 
undermine confidence. More information is required to understand which 
technologies are best, or perhaps more appropriately, which technologies are best 
for differing aspects of circulating tumour cell assessment.   
The majority of clinical studies reported have relied on positive selection of tumour 
cells that express a single biomarker (Tibbe et al., 1999; Nagrath et al., 2007; 
Maheswaran et al., 2008; Sequist et al., 2009; Talasaz et al., 2009; Gleghorn et al., 
2010; Stott et al., 2010). The antigen chosen most commonly is epithelial cell 
adhesion molecule (EpCAM).  
The only clinically approved method for circulating tumour cell enrichment and 
detection is the CellSearch® platform. This platform received FDA approval in 2008 
for use in predicting prognosis in patients with metastatic breast, colorectal and 
prostate cancer.  
 
1.2.2 CellSearch® (Veridex) 
The CellSearch® platform relies upon positive selection of circulating tumour cells 
using magnetic beads conjugated to antibodies against EpCAM. The method 
provides both enrichment and limited characterisation of circulating tumour cells. The 
objects selected are detected with fluorescently-conjugated antibodies against 
cytokeratins 8, 18+ and/or 19+ and CD45 and with a nuclear stain, DAPI. Cells are 
loaded into a magnetic cartridge that pulls the cells to a single focal depth where they 
are imaged. Circulating tumour cells are identified through visual inspection of the 
images generated and are defined as objects that express cytokeratin and have a 
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nuclear signal but do not express CD45. Developed in the late 1990s, CellSearch® 
received FDA approval in 2008 for use in clinical practice. The quality of the 
circulating tumour cell images collected by the CellSearch® platform is illustrated in 
Figure 1.10.  
 
 
Figure 1.10. Examples of circulating tumour cell images captured using the Cellsearch® 
platform from blood samples of cancer patients. 
Cells have been labeled with a fluorescently conjugated antibody to cytokeratin (green) and with DAPI 
(purple) nuclear stain. A. Examples of typical intact circulating tumour cells. B. Examples of clusters of 
circulating tumour cells or unusual shaped cells. Images reproduced from (Allard et al., 2004) 
 
The principle role of CellSearch® is the enumeration of circulating tumour cells. The 
concentration of circulating tumour cells detected with CellSearch® in patients 
undergoing treatment for metastatic breast, colorectal and prostate cancer has been 
shown to be associated with poor survival (Cristofanilli et al., 2005; Cohen et al., 
2008; de Bono et al., 2008). In breast cancer for example, a circulating tumour cell 
level of more than 5 cells per 7.5 ml of blood is associated with a poorer prognosis in 
terms of both disease free progression and overall survival than a circulating tumour 
cell level of 5 or less per 7.5 ml. (Cristofanilli et al., 2004).   
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There are important considerations when interpreting the data obtained with the 
CellSearch® platform. Only objects that are EpCAM positive are captured by the 
CellSearch® platform. There is considerable heterogeneity in EpCAM expression in 
established epithelial cancer cell lines (Sieuwerts et al., 2009), epithelial tumour cells 
may undergo epithelial mesenchymal transition (see section 1.3.2) and EpCAM 
expression may be influenced by cell cycle stage (Trzpis et al., 2007). The EpCAM 
status of disseminated tumour cells in the bone marrow has been reported to change 
following chemotherapy (Thurm et al., 2003). 
Using the CellSearch® platform, circulating tumour cells have been detected in 
patients with metastatic disease of several different tumour types (Allard et al., 2004). 
The number of circulating tumour cells detected varied considerably both between 
tumour types and between individual patients with the same tumour type. 
By definition, circulating tumour cells should not be present in healthy people and 
patients with non-malignant diseases. Blood samples taken from 145 healthy women 
identified a circulating tumour cell in eight samples using the CellSearch® platform 
(Allard et al., 2004). In the same study 14 out of 199 women with non-malignant 
breast disease also had at least a single detectable circulating tumour cell.  The only 
explanation for such a finding is either non-malignant epithelial cells in the blood an 
inaccuracy in the classification of objects identified with CellSearch®. It is very difficult 
to be certain that atypical and clustered cells such as those demonstrated in Figure 
1.10B are all in fact circulating tumour cells. 
 
1.2.3 Imagestreamx (Amnis) 
The Imagestreamx is an image flow cytometer that combines the capabilities of a 
fluorescence-activated cell sorting (FACS) machine with the additional benefits of 
high resolution microscopy. A total of 12 images of each cell are captured including 
brightfield, darkfield and up to ten fluorescent images at a rate of up to 5,000 cells 
per second. Cells can be labelled simultaneously with multiple fluorescently-
conjugated antibodies against specific antigens. Combining the speed and sensitivity 
of FACS with the ability to characterise cells and identify subcellular locations of 
antigens makes the Imagestreamx image flow cytometer an extremely powerful tool 
for rare cell detection.  
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Cells in suspension pass into a flow cell and are focussed into a single stream. 
Illumination is provided by five lasers with excitation at 405nm, 488nm, 561nm, 
642nm and 785nm. An infra-red laser provides an additional darkfield image. The 
fluorophores with which the antibodies are labelled are selected based upon their 
excitation by the different lasers and emissions. There are three objective lenses 
(x20, x40 and x60 magnification) through which light may pass. Light is then passed 
through two arrays of dichroic mirrors. Each set reflects light of different bandwidths 
and produces six separate images, giving a total of 12 images per cell which are 
captured by a two 12-bit charge coupled device (CCD) cameras.   
The data captured by the Imagestreamx image flow cytometer is analysed with the 
IDEAS® software. This software allows selection of the imaged cells based upon 
various cell characteristics such as cell or nuclear area or specific antigen 
expression. This post-imaging selection facilitates the accurate identification of rare 
cell populations.  
A single study has purported to compare directly analysis of the Imagestreamx and 
CellSearch platforms, after addition of PANC-1, pancreatic adenocarcinoma cells, to 
blood (Lopez-Riquelme et al., 2013). The authors reported that at low PANC-1 cell 
concentrations, the accuracy of enumeration was lower with the Imagestreamx than 
CellSearch®. This study was however invalid because the authors used different 
methods of sample preparation and enrichment for the two platforms and analysed 
very small sample numbers. Different methods of sample preparation and enrichment 
may be associated with different losses of cells and hence differences in the total 
number of cells available to be detected. It is therefore very difficult to interpret the 
results from this study. 
 
1.2.4 Reverse transcriptase-PCR 
Not all circulating tumour cell research aims to identify individual cells. A common 
surrogate analysis is the detection of circulating tumour specific mRNA within the 
blood of patients by reverse transcriptase-PCR. The mRNA quantified is taken as a 
measure of circulating tumour cell levels. In the literature many authors report the 
detection of circulating tumour cells when they are actually reporting detection of 
circulating mRNA (Setoyama et al., 2007; Cao et al., 2009).   
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Using this approach, levels of mRNA detected have been reported to predict 
prognosis in patients with several different tumour types. Whole blood samples may 
be used although enrichment by density centrifugation is used frequently prior to the 
cell lysis step.  
There are a number of concerns with the use of RT-PCR to analyse circulating 
tumour cells. RT-PCR has been demonstrated to have a high false positive rate of up 
to 29% in individuals who do not have cancer. A possible explanation for this is 
illegitimate gene expression in normal cells (Ko et al., 2000) in which large numbers 
of normal cells expressing tumour specific markers at low levels. 
 
1.3 Biomarker Selection 
There are no reliable oesophageal adenocarcinoma specific biomarkers, which 
means that detection of circulating tumour cells in patients must rely upon biomarkers 
that would identify cells in patients with other types of cancer. Using multiple 
biomarkers to detect the cells is preferable to reliance on single antigen expression 
which does not take into account the potential for heterogeneity within the circulating 
tumour cell population. Analysis of multiple biomarkers increases the probability that 
circulating tumour cells will be detected or increases the percentage detected.  
 
1.3.1 EpCAM 
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that 
mediates calcium-independent cell-cell adhesion. It was first identified in 1994 
(Litvinov et al., 1994). It is expressed predominantly on the basolateral cell 
membrane of most human simple, pseudo-stratified and transitional epithelia. It is not 
expressed in squamous stratified epithelia or by non-epithelial cells. 
Within the gastrointestinal tract there are marked differences in EpCAM expression 
(Balzar et al., 1999). The normal oesophageal stratified squamous mucosa does not 
express EpCAM. EpCAM is detected in columnar epithelium at the gastro-
oesophageal junction and within the glandular gastric mucosa. This differential 
expression of EpCAM is apparent in Barrett’s metaplasia of the oesophagus in which 
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the normal squamous mucosa of the oesophagus is replaced by a glandular mucosa 
that expresses EpCAM (Wong et al., 2006).  
EpCAM is expressed in most carcinomas of epithelial origin but is not expressed by 
normal non-epithelial cells or by cancers of non-epithelial cells. EpCAM is distributed 
much more uniformly throughout the cell membrane in cancer cells than in normal 
epithelia because of the loss of polarisation of malignant cells. EpCAM is reported to 
play a role in tumour proliferation through the induction of gene transcription (Maetzel 
et al., 2009). The role of EpCAM in tumour development is controversial. Conflicting 
evidence reports that increased expression of EpCAM may be linked to both 
improved and decreased survival across a range of tumour types (van der Gun et al., 
2010).  
EpCAM expression has been demonstrated in oesophageal adenocarcinoma by 
immunohistochemistry (Kumble et al., 1996; Went et al., 2004; Anders et al., 2008). 
In a study of 138 patients undergoing oesophagectomy, EpCAM expression was 
detected in 97.8% of the specimens (Kimura et al., 2007). The authors reported a 
potential prognostic role for the level of EpCAM expression. Survival rates of patients 
with higher levels of EpCAM expression within the primary tumour were significantly 
higher than those with low-level expression. Further, high serum EpCAM mRNA 
levels measured by RT-PCR were an independent marker of good prognosis.  
EpCAM is an ideal biomarker for circulating tumour cell detection as it is not 
expressed by any normal blood constituents. As discussed above, it is used for the 
initial selection of cells in the CellSearch® methodology. 
  
1.3.2 Epithelial mesenchymal transition 
Epithelial mesenchymal transition is the process by which cells of epithelial origin 
lose some of their normal epithelial phenotype and instead develop a mesenchymal 
phenotype. Epithelial cells lose their cell-cell adhesions and become motile and 
invasive. This process plays an important role in the development of invasive cancer 
and metastatic disease (Lee et al., 2006). Metastatic cells within the bone marrow of 
patients with breast cancer have been demonstrated to show changes in protein 
expression in keeping with epithelial mesenchymal transition (Willipinski-Stapelfeldt 
et al., 2005). There is not uniform agreement as to the role or importance of epithelial 
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mesenchymal transition within cancer development. The expected morphological 
changes are rarely seen in primary tumour specimens and histologically, metastatic 
and primary cancer tissue is very similar. These observations have led to speculation 
that epithelial mesenchymal transition may be a transient process which may be 
reversed following tumour cell dissemination (Brabletz et al., 2001).     
This change in phenotype is associated with changes in protein expression within 
individual epithelial cells. These changes in protein expression are important when 
considering the protein expression of circulating tumour cells. The role of EpCAM 
within the process of EMT is complex. There are marked differences in EpCAM 
expression between epithelial and mesenchymal tissues (Went et al., 2004). EpCAM 
expression has been reported to be decreased in breast cancer cells that have 
undergone epithelial mesenchymal transition (Santisteban et al., 2009). In 
oesophageal adenocarcinoma, a dynamic expression of EpCAM throughout tumour 
progression has been reported (Driemel et al., 2014). High levels of EpCAM were 
associated with tumour proliferation where as low levels were linked to migration, 
invasion and dissemination.  
The potential for the process of epithelial mesenchymal transition to affect studies of 
circulating tumour cells is significant, particularly for methods such as CellSearch® 
that depend entirely on EPCAM selection of circulating tumour cells. Such an 
approach may leave subpopulations of circulating tumour cells undetected (Gorges 
et al., 2012). Epithelial mesenchymal transition has itself been reported in circulating 
tumour cells (Yu et al., 2013) using methods of circulating tumour cell detection 
independent of EpCAM expression. In a study of 168 patients, with a variety of 
tumour types including gastric and colonic adenocarcinoma, circulating tumour cells 
were identified in 107 patients (Wu et al., 2015). Epithelial, mesenchymal and mixed 
phenotype circulating tumour cells were identified in all tumour types. These findings 
highlight the importance of developing methods of circulating tumour cell detection 
that are able to detect heterogeneous subpopulations of cells.  
 
1.3.2 Cytokeratins 
Cytokeratins are proteins of keratin-containing intermediate filaments that are found 
in the cytoplasm of human epithelial cells. They form part of the intracytoplasmic 
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cytoskeleton. There are a large number of different cytokeratins and the relative 
expression of each is determined by the type of epithelium. All epithelia may be 
classified by their cytokeratin expression profile. When epithelia undergo malignant 
transformation, the cytokeratin profile remains unchanged. Cytokeratins associated 
with oesophageal adenocarcinoma include 7, 8, 18 and 19. (Moll et al., 1982). A 
specific cytokeratin pattern (cytokeratin 7 positive and cytokeratin 20 negative) has 
been demonstrated as an effective method of distinguishing oesophageal from 
gastric adenocarcinomas (Driessen et al., 2004).    
Cytokeratins are not found in non-epithelial cells and hence are also not found in 
normal blood constituents. Like EpCAM, cytokeratins have been used widely for the 
detection of circulating tumour cells and their detection forms part of the identification 
of circulating tumour cells with the CellSearch® method. Measurement of circulating 
cytokeratin 19 mRNA has been used to estimate circulating tumour cell burden in 
oesophageal squamous cell carcinoma (Yin et al., 2012).  
 
1.3.3 Survivin 
Survivin is an inhibitor of apoptosis (Fruscio et al.) and as such plays an important 
role in the regulation of cell apoptosis (Li et al., 1998). It is also known as baculoviral 
inhibitor of apoptosis repeat-containing 5 (BIRC 5). Survivin is not found in normal 
differentiated tissue but is expressed in the majority of tumours (Ambrosini et al., 
1997). Expression of survivin in tumours leads to the disruption of normal cell survival 
regulation. Survivin inhibits caspase 9 activation. If caspase 9 is not activated, its 
substrate pro-caspase 3 is not activated by cleavage, which in turn prevents PARP 
from being cleaved. PARP is cleaved during apoptosis both to prevent ongoing DNA 
repair but also to preserve NAD and ATP pools for the apoptotic process. Preventing 
PARP cleavage therefore prevents apoptosis from occurring. A common method by 
which chemotherapy drugs function is through the induction of apoptosis. The 
inhibitory effect of survivin on apoptosis is therefore a mechanism by which tumour 
cells may be drug resistant (Zaffaroni et al., 2002). 
Overexpression of survivin has been demonstrated in oesophageal adenocarcinoma 
cell lines and in human adenocarcinoma samples by both RT-PCR and 
immunohistochemistry (Malhotra et al., 2013) (Rosato et al., 2006). Inhibition of 
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survivin in cell lines resulted in an increase in apoptosis. Survivin expression has also 
been shown to increase in the progression through Barrett’s metaplasia of the 
oesophagus to oesophageal adenocarcinoma. Immunohistochemical analysis of 
biopsies from 72 patients demonstrated an increase in both the intensity and extent 
of survivin expression as patients progressed from normal mucosa through non-
dysplastic Barrett’s mucosa, low grade dysplasia, high grade dysplasia and finally 
adenocarcinoma (Puccio et al., 2015). The association of survivin expression with 
progression suggests a potential role for the inhibition of survivin to both prevent and 
treat oesophageal adenocarcinoma.  
Circulating survivin mRNA detected by RT-PCR has been used to estimate 
circulating tumour cell burden in patients with both oesophageal squamous cell 
carcinoma (Cao et al., 2009) and oesophageal adenocarcinoma undergoing surgical 
resection (Hoffmann et al., 2007). In squamous cell carcinoma, high levels of survivin 
expression within the primary tumour are associated with an increased risk of tumour 
recurrence (Ikeguchi and Kaibara, 2002). High levels of expression in oesophageal 
adenocarcinoma have not been demonstrated to offer such prognostic information 
(Rosato et al., 2006).   
 
1.4 Clinical Value of Circulating tumour cells 
The main focus of circulating tumour cell research has been how the concentration of 
circulating tumour cells relates to prognosis.  Given the increasing clinical use of 
circulating tumour cells in patients with both metastatic and early stage breast 
cancer, it has been recommended that enumeration of circulating tumour cells should 
be included in the staging pathway for these patients. The 8th edition of staging 
classification from the American Joint Committee on Cancer (AJCC) for breast 
cancer includes circulating tumour cells within its definition of metastatic disease 
(Giuliano et al., 2017).  If circulating tumour cells are to be used in this way, they 
must provide additional prognostic information in addition to that already available 
from traditional radiological and histological staging. If the presence of circulating 
tumour cells is simply a marker of metastatic disease that has been detected by 
cross-sectional imaging for example, no additional information is provided by their 
inclusion in the staging pathway. Trials that have examined the value of circulating 
tumour cell enumeration in relation to prognosis frequently do not include a 
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comparison with radiological imaging (Cristofanilli et al., 2005). Cross-sectional 
imaging of patients with metastatic cancer undergoing chemotherapy is a routine part 
of oncological follow up. Circulating tumour cell analysis must offer more than a 
surrogate marker of the radiological response to treatment.  
The introduction of novel agents that target specific molecular characteristics of 
cancer cells has driven exploration for biomarkers with which to inform accurate 
stratification of patients. Current biomarker measurements rely upon surgical 
resection or invasive biopsies to obtain information about the biomarker profile of the 
primary tumour cells. Circulating tumour cells provide an opportunity to obtain a non-
invasive biopsy from which information about the biological properties, or 
pharmacodynamic response to novel therapeutics, of disseminated malignant cells 
may be obtained.  
 
1.4.1 CTCs in Oesophageal Cancer 
There is less literature about the role of circulating tumour cells in oesophageal 
cancer compared with many other tumour types. Most studies have focused 
exclusively on oesophageal squamous cell carcinoma (Koike et al., 2002; Tanaka et 
al., 2010). This is largely because the studies originate from geographical regions 
where squamous cell carcinoma predominates. Whilst a recent meta-analysis has 
suggested poorer outcomes for circulating tumour cell-positive patients with 
squamous cell carcinoma (Wang et al., 2017), results are reported frequently in 
mixed series of gastrointestinal cancers that commonly include gastric and colorectal 
cancers. (Huang et al., 2003; Hoffmann et al., 2007; Hiraiwa et al., 2008) These 
mixed series make interpretation of the specific results for oesophageal cancer very 
difficult. Whilst oesophageal, gastric and colorectal cancers do all originate from the 
gastrointestinal tract they are very different diseases with very different outcomes 
and should not be analysed in combination.  
The majority of studies have used RT-PCR to detect cell-free mRNA as a surrogate 
measure of circulating tumour cells. The most commonly used tumour markers are 
squamous cell carcinoma-associated antigen, carcinoembryonic antigen and survivin 
(Kaganoi et al., 2004; Liu et al., 2007; Cao et al., 2009). Studies have also reported 
the detection of Np63 protein expression by RT-PCR, and detection of p16, E-
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cadherin and RARβ expression by methylation-specific polymerase chain reaction 
(MSP) (Koike et al., 2002; Ikoma et al., 2007).  
A number of studies have reported the detection of circulating cancer specific mRNA 
in patients with squamous cell carcinoma without obvious metastatic disease 
(Nakashima et al., 2003; Kaganoi et al., 2004; Setoyama et al., 2007; Hashimoto et 
al., 2008). The majority of these studies have sampled patients prior to 
oesophagectomy. One weakness of these studies is that they all include patients 
who have undergone differing neo-adjuvant chemotherapy or radiotherapy regimens. 
Direct comparison of results is therefore difficult and there is significant variation in 
the number of patients found to be positive for circulating mRNA prior to surgery. 
Detection rates of circulating mRNA of between 9.3% and 33% of oesophageal 
squamous cell carcinoma patients have been reported.    
During or immediately following oesophagectomy, a higher proportion of patients are 
found to be positive for circulating mRNA (Nakashima et al., 2003; Kaganoi et al., 
2004). This increase suggests that the process of handling the tumour during surgery 
may lead to shedding of tumour cells into the circulation. Such tumour cell 
dissemination mirrors results of similar studies of the impact of surgical resection in 
colorectal and gastric cancer (Ikeguchi and Kaibara, 2005; Park et al., 2012). As 
discussed earlier, it is impossible to avoid some tumour handling during 
oesophagectomy.  
Several studies have attempted to correlate circulating mRNA measurements with 
clinical outcome. All of these studies have relatively small numbers of patients and 
hence statistical adjustment for other confounding known influences on survival is 
difficult. Nevertheless, higher recurrence rates and reduced survival have been 
reported in patients with circulating mRNA compared to those without (Hashimoto et 
al., 2008) (Cao et al., 2009).  
There are very few studies in oesophageal squamous cell carcinoma looking at the 
detection of circulating tumour cells themselves rather than circulating mRNA. Using 
the CellSearch® platform, circulating tumour cells have been detected in patients with 
both non-metastatic and metastatic oesophageal squamous cell carcinoma prior to 
commencing treatment (Hiraiwa et al., 2008). Unfortunately, this study compared 
combined gastrointestinal tumours and so further interpretation is difficult. Another 
study using CellSearch® reported the value of palliative chemotherapy or 
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chemoradiotherapy in 38 patients with metastatic or recurrent oesophageal 
squamous cell carcinoma (Tanaka et al., 2015). Circulating tumour cells at first follow 
up were independently predictive of survival.   
The literature about circulating tumour cells in oesophageal adenocarcinoma is even 
more limited. A study in which survivin mRNA was measured by RT-PCR to detect 
circulating tumour cells in patients with a variety of gastrointestinal tumours included 
eight patients with oesophageal adenocarcinomas. Across all tumour types and 
locations, the levels of pre-operative survivin expression were higher than those 
measured after resection of the primary tumour in two thirds of the patients. Such a 
combined approach to the analysis makes interpretation of oesophageal 
adenocarcinoma specific results very difficult (Hoffmann et al., 2010).  
A study of circulating tumour cells in 43 patients with oesophageal adenocarcinoma 
or oesophageal squamous carcinoma without metastatic disease included 14 
patients with resectable adenocarcinoma (Bobek et al., 2014). Circulating tumour 
cells were detected in 11 of these 14 patients (78.6%). Circulating tumour cells were 
detected using a size-based filtration method and classified as tumour cells based on 
morphological analysis. Isolated circulating tumour cells were placed into culture and 
a maximum culture time of 14 days was achieved. There are a number of important 
concerns about this study. The patients studied include type 3 junctional tumours 
which are better considered as gastric cancers. Data on the staging process that 
patients underwent is not provided. It is surprising that a higher proportion of patients 
with resectable cancer had circulating tumour cells than patients with more advanced 
non-resectable tumours.  
The combining of junctional and gastric adenocarcinoma makes the interpretation of 
results difficult in another study of 62 patients with advanced junctional or gastric 
adenocarcinoma undergoing chemotherapy. This study included 25 junctional 
adenocarcinomas (Kubisch et al., 2015). Circulating tumour cells were analysed by 
immunomagnetic enrichment of cells that express mucin 1 and EpCAM followed by 
real-time PCR analysis of keratin 19, mucin 1, EpCAM and survivin. Patients who 
had detectable circulating tumour cells at baseline had a significantly shorter median 
progression-free survival. Only 14 of the 25 junctional adenocarcinomas were type 
one tumours (table 1.2). Care must therefore be taken when extrapolating these 
results to patients with oesophageal adenocarcinoma. 
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A pilot study was designed to assess the levels of circulating tumour cells in patients 
with advanced oesophagogastric adenocarcinoma undergoing palliative 
chemotherapy and to measure the impact of treatment on the circulating tumour cell 
levels. The CellSearch® platform was used. Circulating tumour cells could be 
identified using this method however the study was ended prematurely after inclusion 
of only nine oesophageal and two junctional tumours due to the loss of commercial 
funding (Sclafani et al., 2014). A similar study again using the CellSearch® platform 
measured circulating tumour cell levels in a small group of patients with either 
oesophagogastric adenocarcinoma or pancreatic adenocarcinoma (Piegeler et al., 
2016). Whilst they found circulating tumour cells in seven out of eight pancreatic 
cancer patients, only one of the eight oesophagogastric patients had circulating 
tumour cells detected.  
 
1.4.2 The potential role for circulating tumour cells in the management of 
oesophageal adenocarcinoma 
For circulating tumour cells to become a clinically relevant tool they must add value 
to the management of patients. Where this value is added will differ between tumour 
types and the stage of patients’ disease. There is great potential for circulating 
tumour cells to play an important role in the management of oesophageal 
adenocarcinoma. There are however a number of important considerations.    
At present treatment options for patients with advanced oesophageal 
adenocarcinoma are limited. The median survival for patients with metastatic 
adenocarcinoma is nine months (Webb et al., 1997). Palliative chemotherapy offers a 
modest median survival benefit of five to six months. There are few chemotherapy 
regimens available for this treatment. The use of circulating tumour cells purely as a 
means of predicting survival in such a cohort of patients may be limited. Circulating 
tumour cell enumeration may inform that a patient is in a group that on average will 
do better or worse. This enumeration is unlikely to provide accurate prognostic 
information for a single patient and should not be regarded as representing 
personalised medicine. It may be hard to justify the cost and time required for routine 
circulating tumour cell testing in this context.  
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It is possible however that in the future circulating tumour cell detection and 
characterisation may be used to predict response to palliative chemotherapy or to 
identify patients who are not responding to treatment. In this way patients who will, or 
are receiving, no benefit form chemotherapy agents can be identified and hence not 
be exposed to unnecessary side effects. This would have a major impact on quality 
of life in this patient group by allowing patients to switch to second line agents or to 
have their chemotherapy stopped altogether.  
Circulating tumour cells may provide information about the biology of a tumour that 
could be used to help guide treatment decisions. There is growing interest in the 
potential use of anti-HER2 treatments in the management of oesophageal 
adenocarcinoma. The recent STO3 trial included a sub-study of the feasibility of 
including a trastuzumab treatment arm in the neo-adjuvant treatment of patients with 
resectable oesophageal and junctional tumours (Smyth et al., 2016). Analysis of 
HER2 expression by circulating tumour cells may provide a non-invasive means to 
confirm the HER2 status of patients with advanced disease. Currently HER2 testing 
is performed on biopsies which are usually of the primary tumour. HER2 status in 
circulating tumour cells has been demonstrated to differ from that of the primary 
tumour in a large number of patients with breast cancer. (Fehm et al., 2010). The 
number of patients with a HER2-negative primary tumour but HER 2-positive 
circulating tumour cells was between 32 % and 48 % depending on the circulating 
tumour cell assay used. Differences have also been reported in oesophageal cancer.  
Out of a total of 97 patients with oesophageal adenocarcinoma 14% had a HER2-
positive primary tumour. The HER2 status of involved nodal disease and distant 
metastatic disease matched that of the primary tumour in 95 % and 86 % of cases 
respectively. (Schoppmann et al., 2011).  The authors concluded that routine 
sampling of metastatic tissue to obtain HER2 status is not warranted in all patients 
because taking biopsies from metastatic lesions is frequently technically difficult, 
painful and associated with significant risks to patients. It is possible that the HER2 
status of circulating tumour cells will be a much closer match to that of metastatic 
tissue deposits than the status of the primary tumour. This is likely to be of particular 
relevance where there is a time lapse between treatment of the primary tumour and 
development of metastatic disease.  
Another potential role for circulating tumour cells in oesophageal cancer is at a much 
earlier stage of the disease process. Circulating tumour cell detection may become a 
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part of the staging process for oesophageal adenocarcinoma as is recommended in 
breast cancer. Circulating tumour cell detection in patients who have no radiological 
evidence of metastatic dissemination may help to identify patients at risk of early 
disease progression. For patients undergoing oesophagectomy, this would include 
those patients at risk of early disease recurrence. Oesophagectomy has no role in 
the palliative setting but some patients who undergo surgery with curative intent, 
develop recurrence within 12 months of their operation. There is no question that if 
this recurrence could be predicted these patients would be better served being 
treated with palliative chemotherapy alone rather than undergoing surgery with the 
associated major impact that surgery has on quality of life for nine to 12 months post-
operatively. Circulating tumour cell concentrations may also have the potential to 
guide the selection of patients for neo-adjuvant treatment and those who would be 
better undergoing unimodality treatment with surgery.  They may provide a better 
marker of systemic response to neo-adjuvant chemotherapy than the current 
methods which rely heavily on either radiological or histological response.  
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1.5 Aims and objectives 
 
1. Develop a novel method with which to detect, enumerate and characterise 
circulating tumour cells in patients with oesophageal adenocarcinoma. 
 
2. Assess the concentration of circulating tumour cells in oesophageal 
adenocarcinoma patients without radiological evidence of metastatic disease. 
 
3. Evaluate the potential of biological characterisation of circulating tumour cells 
in patients with oesophageal adenocarcinoma.  
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Chapter 2. Materials and methods 
 
2.1 Commercial cancer cell lines 
A panel of commercially available oesophageal adenocarcinoma cell lines were 
selected to validate the methodology for detection of circulating tumour cells. Several 
oesophageal cancer cell lines have been shown to be cell lines from other tumour 
types (Boonstra et al., 2010).  Only cell lines corresponding to true oesophageal or 
type one junctional tumours (see section 1.1.5) were selected. Details about the 
origin of the selected cell lines are included in table 1. All of the selected cell lines 
grew as adherent cultures with the exception of the ESO-51 cell line which grew in 
suspension.  
 
Cell line name Histology Origin of cell line 
SK-GT-4 
Well differentiated adenocarcinoma 
arising from Barrett’s mucosa 
Established in 1989 from an 89 year old Caucasian 
male. 
OE33  
(JROECL33) 
Poorly differentiated adenocarcinoma 
arising from Barrett’s mucosa 
Established in 1993 from a 73 year old female 
FLO-1 Adenocarcinoma 
Established in 1991 from the primary tumour of a 68 
year old Caucasian male 
OAC-P4C 
Adenocarcinoma (Initially classified as 
a junctional tumour. Since reclassified 
as non-Barrett’s oesophageal 
adenocarcinoma) 
Established in 1996 from the primary tumour of a 55 
year old Caucasian male 
 
OE19 (JROECL33) 
 
Moderately differentiated type 1 
junctional adenocarcinoma 
Established in 1993 from the primary tumour of a 72 
year old Caucasian male 
ESO-51 
Adenocarcinoma arising in Barrett’s 
metaplasia 
Established in 2000 from primary tumour of 74 year 
old Caucasian male 
 
Table 2.1. Histology and origin of selected oesophageal adenocarcinoma cell lines.  
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2.2 Tissue Culture 
All cell culture was performed in a containment level II laminar flow microbiological 
safety cabinet. SK-GT-4 (DSMZ, Braunschweig, Germany), OE33 (DSMZ, 
Braunschweig, Germany), OAC-P4C (DSMZ, Braunschweig, Germany), OE19 
(DSMZ, Braunschweig, Germany), and ESO-51 (DSMZ, Braunschweig, Germany) 
oesophageal cancer cells were grown in RPMI media supplemented with 10 % foetal 
calf serum (FCS). FLO-1 (DSMZ, Braunschweig, Germany) cells were grown in 
DMEM media supplemented with 10% foetal calf serum. All other reagents were 
purchased from Sigma-Aldrich, Poole, UK, unless stated otherwise.  
Cells were maintained in exponential growth at 37°C in a humidified atmosphere, 
supplied with 5% CO2 and discarded after the 30th passage. Cells were confirmed to 
be mycoplasma free at regular intervals (MycoAlert mycoplasma detection kit: Lonza, 
USA). An example of SK-GT-4 adherent cells in culture is included in Figure 2.1. 
 
 
Figure 2.1. Oesophageal adenocarcinoma cell line in culture.  
Example of confluent SK-GT-4 cells in adherent cell culture.  
 
2.3 Immunofluorescence 
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised 
and resuspended in fresh medium. Cells were counted with a haemocytometer and 1 
x 106 cells were plated onto 400 mm2 sterile coverslips in medium and incubated at 
4o C for 12 hours. The adherent cells were fixed with ice cold methanol for 20 
minutes and then washed with 3 x 5 minute washes with phosphate buffered saline. 
Cells were blocked with 5% BSA in PBS solution and incubated in the dark with 
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conjugated antibodies against EpCAM (Alexa Fluor® 488 anti-human CD326 Clone: 
9C4, Biolegend, Catalogue No. 324209.) and cytokeratins (Mouse anti-cytokeratin 
pan antibody, clone C11, FITC, Millipore, Catalogue No. CBL234F.) at a 
concentration of 1:100 for 1 hour at room temperature. Cells were washed for 3 x 5 
minutes in phosphate buffered saline and mounted on glass slides with DAPI 
mounting media and imaged with a Leica DMR fluorescent microscope. Images were 
captured with Spot Advanced Software. 
 
2.4 Image flow cytometry (Imagestreamx) 
Samples were analysed with an ImagestreamX (Amnis, USA) Mark II image flow 
cytometer (Figure 2.2) with an eight µm core at 60 mm/s with seven per cent Speed 
Beads®. Speed Beads® are a calibration reagent used to monitor the flow and focus 
of the Imagestreamx image flow cytometer The Imagestreamx image flow cytometer 
can process a volume between 20 and 200 µl. For cell line experiments, a volume of 
60 µl was chosen. The Imagestreamx image flow cytometer has five lasers which 
excite at 405, 488, 561, 592 and 658 nm. Light emitted by the fluorescently-labelled 
cells is collected through an objective lens. There are three available objectives: x20, 
x40 and x60.  
Two CCD cameras, each spatially resolved into 5 distinct spectral bandwidths, 
capture twelve images (six per camera) of each object passing through the core. 
These includes brightfield images and up to ten fluorescent images. Images are 
captured over a range of wavelengths between 430 and 745 nm. Channels 1 and 9 
are reserved for brightfield images with the remaining ten channels capturing the 
fluorescent images. The maximal rate at which objects are imaged is dependent on 
the objective lens used. The rates are 4,000 objects per second at x20, 2,000 objects 
per second at x40 and 1,200 objects per second at x60. It is possible to capture all 
objects that pass through the core including the Speed Beads®. Alternatively objects 
meeting defined criteria, for example size or specific fluorescence, may be captured. 
Capture of objects with a diameter greater than 50 µm was selected to eliminate the 
Speed Beads® from the analysis whilst ensuring that no cellular objects were lost.  
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Figure 2.2 Imagestreamx Mark II image flow cytometer.  
Schematic illustrating the mechanism of action of the Imagestreamx Mark II. The two CCD cameras 
capture twelve images (six per camera) of each object passing through the core contained within the 
flow cell. Five lasers excite the objects passing through the core at wavelengths from 405-642nm. 
(Images courtesy of STEMCELL Technologies™).  
 
2.5 Compensation Matrix 
There is spectral overlap between channels in the Imagestreamx image flow 
cytometer. An individual fluorophore will emit light that is predominantly captured 
within a single channel. There will also be some light captured in the adjacent 
channels. When using multiple fluorophores, this overlapping of light capture could 
lead to false positive results. A compensation matrix is therefore required for every 
sample processed on the image flow cytometer in order to remove this spectral 
overlap.  
A compensation matrix is calculated after analysis of reference samples for each 
fluorophore being used. These reference samples are created by incubating cells 
with a single fluorophore. Only 500 cells are analysed for each reference single 
colour control sample. The fluorescence data for each reference sample is then 
combined by the IDEAS® software to create the final compensation matrix. When 
experimental samples are processed, this matrix must be applied to the raw image 
data before further sample analysis occurs. 
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2.6 Antibody labelling of samples for image flow cytometry 
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised 
and 1 x 106 cells fixed by incubation in 4% formaldehyde in phosphate buffered saline 
for 20 minutes at room temperature, or Phosflow Lyse/Fix buffer (BD, Oxford, UK), 
and permeabilised by incubation in Perm/Wash buffer (BD, Oxford, UK) for one hour 
at room temperature. Cells were incubated with 1:20 anti-pan-cytokeratin (clone C-
11) PE (Cayman Chemical, USA) and 1:50 anti-survivin Alexa Fluor® 647 (Cell 
Signalling, USA) in phosphate buffered saline for 30 minutes at room temperature. 
Membrane antibodies and nuclear stains were added and incubated for one hour at 
room temperature: 1:20 anti-CD45 (clone H130) V450 or PE:Cy7 (BD Biosciences, 
USA); 1:20 anti-EpCAM CD326 (clone 9C4) Alexa Fluor® 488 (Biolegend, USA); 
DAPI or DRAQ5 (Biostatus, UK) in phosphate buffered saline. Cells were washed in 
500 µl of Perm/Wash buffer and recovered by centrifugation at 500 g for five minutes 
and either analysed immediately or stored as a pellet at 4 oC until analysis. The cells 
were resuspended in phosphate buffered saline in a minimum volume of 60 µl for 
analysis on the Imagestreamx image flow cytometer.  
Cells were visualised with an ImagestreamX image flow cytometer with the lasers set 
to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x20, 
x40 and x60 objective with the wavelengths for the collection channels set at:  480-
560 nm, EpCAM; 560-595 nm, cytokeratins; 642-745 nm, survivin; 745-800 nm, 
CD45; 430-505 nm, DAPI.  
 
2.7 Analysis of patient samples 
Whole blood samples were obtained from patients undergoing treatment for 
oesophageal adenocarcinoma at the Newcastle-upon-Tyne NHS Foundation Trust. 
Patients attended a staging clinic at the Northern Oesophago-Gastric Cancer Unit. 
As part of this clinic, all patients are reviewed by a surgeon and undergo routine 
blood sampling. Patients gave informed consent and had blood taken for analysis of 
sampled for circulating tumour cells at this clinic appointment. In this way patients 
were not inconvenienced by additional trips to hospital or extra blood tests. A single 8 
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ml sample of blood was taken from each patient, Routine blood samples were taken 
prior to the circulating tumour cell sample to act as the blood discard.  
Objects were classified as circulating tumour cells if they were nucleated, with a 
cellular morphology and did not express CD45. To account for potential 
heterogeneity within the circulating tumour cell population all objects meeting these 
criteria were inspected irrespective of the expression of EpCAM, cytokeratin and 
survivin. Samples were inspected by a single person with no formal ‘double reading’. 
Where doubt existed a second opinion was sought from with an individual with 
experience of circulating tumour cell research. 
Ethical approval for the study was obtained from the Newcastle and North Tyneside 
Research Ethics Committee (Appendix 1).  Blood samples were collected in Transfix 
(Cytomark, UK) collection tubes to store for up to 24 hours at 4 oC or BD Vacutainer 
EDTA tubes (BD Biosciences, USA) for immediate use. With all blood samples an 
initial draw of 4 ml of blood was discarded to prevent contamination with epithelial 
cells. All samples were processed within 48 hours of sampling to reduce the potential 
for any sample degradation. All patients were assigned an anonymised identification 
code. Patient clinical data was recorded for each patient in accordance with ethical 
approval. Follow up of patients was in accordance with routine clinical practice and 
consisted of regular clinical review without routine radiological or endoscopic 
examination. In addition whole blood samples were obtained from healthy volunteers 
(Appendix 2). 
 
2.8 Recovery of cancer cells form whole blood  
The SK-GT-4 cell line was chosen for the cell recovery experiments because this cell 
line easily trypsinises into predominantly single cells which ensures accurate cell 
counting. Confluent SK-GT-4 cells were trypsinised and fixed in 4% formaldehyde in 
phosphate buffered saline before being resuspended in phosphate buffered saline. 
Cells were counted with a Neubauer haemocytometer and diluted with phosphate 
buffered saline to a final concentration of 20,000 cells per ml. Initial experiments 
analysed a single concentration of 2000 cancer cells in five ml of whole blood 
collected from healthy volunteers. An aliquot of 100 µl of the prepared cell 
suspension was added to the blood sample. This concentration of 2000 cells per ml 
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of blood is considerably higher than the expected concentrations of circulating 
tumour cells. Once the full protocol had been developed, further experiments 
analysed a range of cell concentrations. SK-GT-4 cells were trypsinised, fixed and 
resuspended. From a stock suspension of 20,000 cells per ml of blood two serial 
dilutions of one in 10 were made and 100 µl of each suspension were added to five 
ml of blood to give a total of 2000, 200 and 20 cells.  
    
2.9 EasySep™ 
EasySep™ provides a column-free isolation method to purify cell populations based 
on specific cell membrane antigen expression. Cell populations can be positively 
selected based on their own membrane antigen expression or negatively selected by 
selecting other cell types from the sample.  For the purpose of detecting circulating 
tumour cells, a negative selection was used. The white blood cells in the sample 
were depleted based on their expression of the membrane target antigen CD45.  
Figure 2.3 demonstrates this depletion of white blood cells. Antibodies against CD45, 
bound in tetrametric complexes were added to the cell suspension in a 15 ml round 
bottomed Falcon tube and incubated for 15 minutes at room temperature (Figure 4A). 
Dextran-coated magnetic nanoparticles were added and incubated with the cell 
suspension for an additional ten minutes The cell suspension was placed within a 
specific EasySep™ ‘Big Easy’ magnet for ten minutes. The magnet and tube were 
inverted for a maximum of two seconds to pour off the un-retained cell suspension 
(Figure 4B). CD45 positive cells, representing the white blood cell population were 
retained within the tube by the magnetic field. The unretained cell suspension was 
centrifuged at 500 g for five minutes and the cell pellet resuspended in Perm/Wash 
buffer ready for analysis. 
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Figure 2.3. Depletion of white blood cells with the EasySep™   
(A) The EasySep™ magnetic particles bind to the tetrametric antibody complex which is in bound to 
the surface target protein. (B) Following incubation, the magnet containing the round bottomed Falcon 
tube is inverted. (Images courtesy of STEMCELL Technologies™).  
 
2.10 Final protocol for analysing patient samples  
The finalised protocol for detecting circulating tumour cells in patient samples 
processing is described below. Details about the development of this protocol can be 
found in chapter 4.  
Five ml of 5% bovine serum albumin in AutoMACS rinse solution (Miltentyi Biotec, 
Germany) was added to a 50 ml Falcon tube and rotated for 5 minutes. The bovine 
serum antigen solution was decanted from the Falcon tube and five ml of whole 
blood was added to the Falcon tube and stored at 4 oC for 15 minutes. 50 µl of 
human FcR blocking reagent (Miltenyi Biotec, Germany) was added to the blood and 
stored at 4 oC for a further 15 minutes. The FcR blocking reagent blocks the binding 
of antibodies to human FC receptor–expressing cells such as B cells, monocytes and 
macrophages, increasing the specificity of antibody binding to the cancer cells. 
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45 ml of BD Phosflow Lyse/Fix buffer 1:20 (v:v) (BD Biosciences, USA) was added to 
the blood sample and the Falcon tube inverted vigorously 8-10 times to mix the cell 
suspension and incubated at 37 oC for 10 minutes. The sample was centrifuged at 
500 g for 8 minutes and the cell pellet resuspended in one ml of RoboSep™ buffer 
(STEMCELL Technologies, UK) and then transferred to a 14 ml round bottomed 
polystyrene Falcon tube with a siliconised pipette tip. 
The original 50 ml Falcon tube was washed with one ml of RoboSep™ buffer which 
was then again transferred to the 14 ml Falcon tube with the same siliconised pipette 
tip. This washing of the Falcon tube was repeated a further three times. The 14 ml 
Falcon tube was then centrifuged at 250 g for 5 minutes and the pellet resuspended 
in 500 µl of RoboSep™ buffer. 
25 µl EasySep™ whole blood CD45 depletion cocktail (STEMCELL Technologies, 
UK) was added to the cell sample with a fresh siliconised pipette tip and stored at 4 
oC for 15 minutes. 50 µl of the EasySep™ magnetic nanoparticles (STEMCELL 
Technologies, UK) were added with a siliconised pipette tip and the sample stored at 
4 oC for 10 minutes. 4.5 ml of RoboSep™ (STEMCELL Technologies, UK) buffer 
were added to the sample and the Falcon tube placed without the cap on in “The Big 
Easy” EasySep™ magnet (STEMCELL Technologies, UK) at room temperature for 
10 minutes.  
The supernatant was poured off for two seconds into a 15 ml Falcon tube and 
centrifuged at 500 g for 5 minutes. The cell pellet was resuspended in 200 µl of 
perm/wash buffer and transferred to a siliconised eppendorf using a siliconised 
pipette tip. The 15 ml Falcon tune was washed a further four times using 200 µl of 
perm/wash buffer and the same siliconised pipette tip. The sample was centrifuged at 
500 g for 5 minutes and the pellet resuspended in 100 µl of perm/wash solution. 
At this stage the sample was labelled for analysis on the Imagestreamx as described 
in section 2.6.  
 
2.11 Statistical Analysis 
The areas of individual cells were measured directly by the IDEAS® software. Data 
was presented as means ± standard errors of the mean. An unpaired t-test was used 
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to compare data between two groups and a one-way ANOVA for multiple groups. All 
graphs were produced using GraphPad Prism 6. Survival analysis was plotted as 
Kaplan-Meier curves using GraphPad Prism 6 and curves compared with log-rank 
testing.  
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Chapter 3. The use of image flow cytometry to detect and 
characterise oesophageal adenocarcinoma cells 
 
3.1 Introduction 
The ability to detect circulating tumour cells relies upon the accurate identification of 
the tumour cells. The circulating tumour cells must be easily distinguished from 
normal blood constituent cells. A definition of what constitutes a tumour cell, based 
upon morphological features or the expression of specific antigens, is required. The 
most widely used method in clinical practice is the CellSearch® platform which 
identifies circulating tumour cells based upon the expression of EpCAM and epithelial 
cytokeratins and the lack of expression of CD45 (Allard et al., 2004). A number of 
different methods of identifying circulating tumour cells have however been described 
(Parkinson et al., 2012).  
The Imagestreamx image flow cytometer captures high resolution images of both cell 
morphology and cellular immunofluorescence and allows accurate characterisation of 
cells. It is able to capture these data whilst imaging up to 5000 cells per second. This 
chapter details the development of a method with which to identify and characterise 
oesophageal adenocarcinoma cells using the Imagestreamx image flow cytometer. 
Fluorescently-conjugated antibodies against specific antigens were identified and 
validated with a panel of oesophageal adenocarcinoma cell lines and white blood 
cells.  
 
3.2 Results 
3.2.1 Image acquisition and quality using Imagestreamx 
Imagestreamx image flow cytometry combines high resolution immunofluorescence 
with the high-speed processing of flow cytometry. A comparison of the images 
produced with conventional immunofluorescence and with the Imagestreamx image 
flow cytometer and is shown in Figure 3.1. Images of EpCAM and cytokeratin 
expression by SK-GT-4 oesophageal adenocarcinoma cells detected by conventional 
immunofluorescence allow the different intra-cellular localisations of the membrane 
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bound EpCAM and cytoplasmic cytokeratins to be observed (Figure 3.1A and C). 
The cells are adherent to a glass coverslip and have a characteristic flattened 
polygonal morphology.  
The image flow cytometer images individual cells in suspension. For each cell, 
images that incorporate fluorescence from the antibodies and nuclear dyes used are 
captured with two separate cameras in addition to brightfield images. Images of SK-
GT-4 cells captured with an image flow cytometer are in suspension and 
demonstrate different morphology, with the cells appearing spherical (Figure 3.1 B 
and D). The images demonstrate the differences between the EpCAM and 
cytokeratin localisation. The EpCAM immunofluorescence is particularly high and is 
concentrated along the plasma membrane. The cytokeratin immunofluorescence is 
slightly less intense than the EpCAM immunofluorescence and is detected more 
evenly throughout the cytoplasm. The high quality images allow both the detection 
and localisation of target antigens. This is seen at all magnifications but is especially 
clearer when moving from x 20 to x 40 magnification. The difference between x 40 
and x 60 magnification is as expected less pronounced (Figure 3.1 B). The images of 
individual cells are displayed in rows to allow easy visual comparison. The IDEAS® 
software allows for rapid qualitative and quantitative analysis and comparison of 
large numbers of these images. With traditional immunofluorescence, analysis of 
such large numbers of cells would be more difficult and labour intensive. 
The greater the magnification, the higher the quality of images captured. The 
increased quality is at the expense of the speed of image acquisition. The maximum 
rate of imaging is 5000 cells per second at x 20 magnification, 2000 cells per second 
at x 40 and 1200 cells per second at x 60. For most applications x 40 magnification 
was chosen as a compromise between speed and image quality. The intracellular 
morphology can be appreciated easily at this magnification (Figure 3.1B. ii). Speed of 
processing is less important for experiments with cell lines but is a crucial 
consideration for analysis of patient samples (Chapter 4).  
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Figure legend on next page 
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Figure 3.1 Comparison of images captured by traditional immunofluorescence and 
Imagestreamx image flow cytometry.  
A and C. SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 
resuspended in fresh medium. Cells were counted using a haemocytometer and 1 x 106 cells were 
plated onto sterile coverslips in medium and allowed to adhere overnight. The adherent cells were 
washed and fixed with ice-cold methanol and washed with PBS. Cells were blocked with 5% BSA 
solution and incubated in the dark with conjugated antibodies against EpCAM (Alexa Fluor® 488) (A) 
and cytokeratin (FITC) (C) for 1 hour. Cells were washed and mounted on glass slides with DAPI 
mounting media and imaged using a Leica DMR fluorescent microscope. Images were captured with 
Spot Advanced Software. B and D. SK-GT-4 cells were grown to 80 % confluence in routine culture 
medium, trypsinised and 1 x 106 cells fixed with 1 % formalin.  Cells were permeabilised by incubation 
with 0.3 % saponin, incubated with a pan cytokeratin antibody and subsequently with DAPI (D) or 
incubated simultaneously with antibody against EpCAM and with DAPI (B). Cells were visualised with 
an ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 and 658 nm. 
Images of cells labelled with EpCAM and DAPI were collected with a x20 (B.i.), x40 (B.ii) and x60 
(B.iii.) objective with the wavelengths for the collection channels set at:  480-560nm, EpCAM; 430-
505nm, DAPI. Images of cells labelled with cytokeratin and DAPI were collected with a x40 objective 
with the wavelengths for the collection channels set at: 560-595 nm, cytokeratins; 430-505nm, DAPI 
(D). 
 
 
3.2.2 Image Compensation 
Cells labelled with a single fluorescently-conjugated antibody are detected primarily 
in a single one of the image flow cytometry collection channels. The extent to which 
the emission from each fluorophore is restricted to a single channel is dependent on 
the fluorophore used, the wavelength of the excitation laser and the wavelength of 
the collection channel. Figure 3.2 illustrates the channels in which common 
fluorophores are collected with the image flow cytometer.  
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Figure 3.2.  Common fluorophores and the corresponding excitation lasers and collection 
channels for the Imagestreamx image flow cytometer 
Each camera captures six channels corresponding to overlapping wavelengths of emitted light. 
Examples of the common fluorophores that will emit light that will be captured in each channel are 
included in the figure. The wavelength of the laser excitation required for the emission for each 
fluorophore are also illustrated. Channels one and nine capture a brightfield image only. The 
maximum number of fluorphores that could be used simultaneously is therefore ten.  
 
No single fluorophore has a sufficiently narrow emission spectrum to allow it to be 
collected (or for its emission to fall within) a single channel. Consequently, for any 
fluorophore there will be some collection of the fluorescence in other channels. This 
collection in other channels is called spectral overlap and is greatest in the 
immediately-adjacent collection channels and reduces as the collection channel 
wavelengths moves further away from that of the primary collection channel. Without 
correction, this spectral overlap would prevent the simultaneous analysis of multiple 
fluorophores. The adjustment of the data to analyse only signal collected within the 
primary detection channel is termed compensation. 
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Figure 3.3A illustrates the effect of compensation on the images captured by the 
image flow cytometer. The original images collected are from a cell labelled with a 
pan-cytokeratin antibody conjugated to PE (Figure 3.3Ai). Whilst the greatest 
fluorescence signal is seen in channel 3, fluorescence is also detected in channels 2, 
4 and 5. There is no image in channel 1 as the brightfield image is not collected when 
acquiring the single colour controls. The data collected for the single colour control 
are analysed to calculate the average percentage of the total fluorescence that is 
collected in each channel.  For each cell that is imaged this percentage of total 
fluorescence collected in the primary channel is subtracted from the fluorescence 
collected in the secondary channels.  
Images of the same cell after compensation has been carried out illustrate that 
fluorescence is detected only in the primary channel (Figure 3.3Aii). A graphical 
representation of the effect of compensation is also provided.  
The importance of compensation is clearer with analysis of multiple fluorophores. 
Figure 3.3B includes multiple images of a single cell without and with compensation 
having been applied. Without compensation fluorescent signal appears to be 
detected in all channels (Figure 3.3Bi) whilst after compensation is performed, signal 
is only visualised in those channels corresponding to the fluorophores being used 
(Figure 3.3Bii). When comparing the EpCAM and cytokeratin images individually, 
compensation leads to a slight reduction in the intensity of fluorescence but the 
expression is more specific and more easily localised within the cell. The 
membranous EpCAM for example is more easily identified after compensation.   
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Figure 3.3. The effect of compensation on image intensity using image flow cytometry  
A. SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 
cells fixed with 1 % formalin.  Cells were permeabilised by incubation with 0.3 % saponin and 
incubated with antibody against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and incubated subsequently 
with DAPI. Single colour controls were generated for cytokeratins and for DAPI by incubation of further 
cells with each of these alone. Images were collected with a x40 objective with the wavelengths for the 
collection channels set at:  560-595 nm, cytokeratins and 430-505nm, DAPI. Cells were visualised 
with an ImagestreamX flow cytometer with the lasers set to emit at 405, 488, 561 and 658 nm. A 
compensation matrix was generated from the single colour controls using INSPIRE® software. An 
example of an imaged cell both before (i) and after (ii) the compensation matrix was applied is 
included along with a graphical representation of the percentage of the fluorophore detected in 
secondary channels as measured by the INSPIRE® software. B. SK-GT-4 cells were grown to 80 % 
confluence in routine culture medium, trypsinised and 1 x 106 cells fixed with 1 % formalin.  Cells were 
permeabilised by incubation with 0.3 % saponin and incubated with antibody against cytokeratins 4, 5, 
6, 8, 10, 13, and 18 and incubated subsequently with antibody against EpCAM and with DAPI. Single 
colour controls were generated for EpCAM, cytokeratins and for DAPI by incubation of further cells 
with each of these alone. Images were collected with a x40 objective with the wavelengths for the 
collection channels set at:  480-560nm, EpCAM; 560-595 nm, cytokeratins and 430-505nm, DAPI. 
Cells were visualised with an ImagestreamX flow cytometer with the lasers set to emit at 405, 488, 561 
and 658 nm.  A compensation matrix was generated from the single colour controls using INSPIRE® 
software. An example of an imaged cell both before (i) and after (ii) the compensation matrix was 
applied is provided.  
 
3.2.3 Image selection using image flow cytometry 
Once images have been captured by the image flow cytometer it is important to 
identify appropriate cell populations for further analysis. Cell populations can be 
distinguished easily using the IDEAS® software (Figure 3.4.)  
Consideration of the total area of each object and the aspect ratio of the object 
provides a simple means by which to identify the different cell populations as 
illustrated in Figure 3.4A. The aspect ratio describes the proportional relationship 
between the width and height of an object (width divided by height). Areas have been 
selected on the scatter plot to define four populations of cells (Figure 3.4B). The first 
area which encompasses the smallest objects corresponds to Amnis Speedbeads® 
(Figure 3.4Bi). As discussed in Chapter 2, these beads are part of the calibration of 
the image flow cytometer. They are not fluorescent. The second area contains 
objects that have an aspect ratio close to one and contain single cell images (Figure 
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3.4Bii)  The highest density of objects is located within this selected population. The 
large numbers of cells within this population is in part a reflection of the SK-GT-4 
cells which are easily trypsinised into a predominantly single cell suspension. This 
cell line is therefore ideally suited to analysis with the image flow cytometer.  
The third and fourth areas represent pairs or groups of cells (Figure 3.4Biii and iv). 
These objects have a correspondingly larger area but lower aspect ratio. Whilst 
single cells were selected principally for analysis, the ability of the image flow 
cytometer to image groups of cells is important when considering imaging circulating 
tumour cells which may not all be single cells. 
The populations illustrated in Figure 3.4 were gated using IDEAS® after image 
collection. It is possible to gate the images at the time of collection. In this way, only 
objects that lie within a defined area of the scatter plot are collected. This allows a 
very specific population of objects to be collected. The major disadvantage of this 
approach is that it may limit the heterogeneity of the sample and populations must be 
defined before the start of the collection process.  
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Figure 3.4. Selection of single cell images using image flow cytometry  
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells 
fixed with 1 % formalin.  Cells were permeabilised by incubation with 0.3 % saponin, incubated with 
antibody against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and incubated subsequently with antibody 
against EpCAM and with DAPI. Cells were visualised with an ImagestreamX flow cytometer with the 
lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective 
with the wavelengths for the collection channels set at:  480-560nm, EpCAM; 560-595 nm, 
cytokeratins; 430-505nm, DAPI. A. Following image collection a scatter plot of object area against 
aspect ratio was generated using IDEAS® from which populations of objects were selected. B. Images 
of representative objects from each selected population are displayed. The coloured labels (i.- i.v) 
correspond to the selected populations of objects in figure A.  
 
3.2.4 Quantification of fluorescence 
The immunofluorescent images captured using the image flow cytometer are easily 
inspected visually but the Imagestreamx image flow cytometer is also able to collect 
quantitative information about the immunofluorescence. A number of different 
methods by which the quantitative fluorescence collected may be analysed were 
considered (Figure 3.5).  
Figure 3.5A shows a histogram of the total fluorescence intensity of the EpCAM 
immunofluorescence of the 5000 Sk-GT-4 single cells as generated using the 
IDEAS® software. There is a range of fluorescent intensity demonstrated. We 
evaluated three possible ways of deriving a single quantitative measure of EpCAM 
expression by the cells (Figure 3.5B). The simplest involves visual inspection of the 
cells to determine whether there is immunofluorescence corresponding to EPCAM 
expression within the cell. Cells at the lower intensities are inspected and a 
population of positive cells selected as demonstrated by the red line in Figure 3.5A. 
In these SK-GT-4 cells 99.4% of cells were positive for EpCAM expression based on 
this arbitrary threshold. This is consistent with the known expression of EpCAM in 
this positive cell line.  
Alternatively it is possible to calculate the median and mean intensity of 
immunofluorescence across all of the imaged cells. As indicated in Figure 3.5B these 
correspond to an intensity of 4.9 x 105 and 5.4 x 105 respectively. These values have 
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the advantage of being easily comparable between cell lines. Clearly information 
about the heterogeneity of EpCAM expression will be lost if a single quantitative 
measure is selected.  
 
 
Figure 3.5. Methods of quantification of fluorescence captured by image flow cytometry  
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells 
fixed with 1 % formalin.  Cells were permeabilised by incubation with 0.3 % saponin, incubated with 
antibody against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and incubated subsequently with antibody 
against EpCAM and with DAPI. Cells were visualised with an ImagestreamX flow cytometer with the 
lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective 
with the wavelengths for the collection channels set at 480-560 nm, EpCAM and 430-505 nm, DAPI. 
A. A histogram of the total intensity of immunofluorescence between 480 and 560 nm for 5000 
individual cells from the EpCAM antibody was generated using the IDEAS® software. B. A threshold 
for visible EPCAM positivity was defined after inspection of the images (downward pointing arrow). 
The median and mean intensities of fluorescence of all the cells imaged were calculated (downward 
pointing arrows).  
 
3.2.5 The effect of masks on quantification of fluorescence 
The Imagestreamx image flow cytometer allows localisation of antigens within the 
cell. During the analysis of the collected images, the IDEAS® software allows discrete 
areas of the cells to be selected for analysis by application of a mask which 
delineates a region of the cells, for example the cell membrane or nucleus. Figure 3.6 
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demonstrates how the application of a mask allows for the measurement of 
fluorescence in a specific cell location, for example the cell membrane. The masks 
are created based on the brightfield image of the cell. The mask created is seen 
overlying the brightfield image (Figure 3.6A). The same mask is shown overlying an 
image of the immunofluorescence corresponding to EpCAM expression. In this way, 
only the strong peripheral rim of fluorescence corresponding to the cell membrane 
will be considered. A problem with the application of this mask is that it does not take 
account of the original cell having been a three dimensional object (Figure 3.7). Cells 
are imaged using the image flow cytometer across a plane that runs through the 
midpoint of the cell (Figure 3.7A). The equivalent two-dimensional image that is 
captured has a strongly fluorescent outer rim corresponding to the cell membrane at 
that plane of view (Figure 3.7B). The paler green fluorescence detected within this 
bright rim corresponds also to membranous EpCAM expression but it is potentially 
from the membrane that is not on the plane of imaging and hence is not in focus. A 
mask that only selects the outer rim will underestimate therefore the overall 
expression of EpCAM for that particular cell. Application of such a mask is only of 
value if the specificity of the image flow cytometer to detect membrane staining is 
more important than the sensitivity. 
The use of a mask has little impact on the overall shape of the histogram of EpCAM 
expression (Figures 3.5A and 3.6B). As a result the proportion of cells that are 
positive for EpCAM expression based on a visual threshold (Figure 3.6B) is also 
unchanged. The absolute values for the mean and median fluorescence of the cell 
population are considerably lower when a mask is applied as would be anticipated. 
The median intensity for example drops from 4.9 x 105 to 8.7 x 104. With patient 
samples and circulating tumour cells sensitivity may be the more important factor 
which would mean that there is little role for masks in the analysis of circulating 
tumour cells.   
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Figure 3.6. The effect of masks on quantification of image flow cytometry fluorescence  
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells 
fixed with 1 % formalin.  Cells were permeabilised by incubation with 0.3 % saponin and incubated 
with antibody against EpCAM and with DAPI. Cells were visualised with an ImagestreamX flow 
cytometer with the lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected 
with a x40 objective with the wavelengths for the collection channels set at:  480-560 nm, EpCAM and 
430-505 nm, DAPI. A. A mask corresponding to the cell membrane was created using IDEAS® based 
on the brightfield image and is shown over the brightfield image and the EpCAM image adjacent to the 
same images without the masks for two cells. This mask was then applied to the images of 
immunofluorescence corresponding to EpCAM. B. A histogram of the intensity of immunofluorescence 
between 480 and 560 nm within the mask area for individual cells from the EpCAM antibody was 
generated using the IDEAS® software. C. A threshold for visible EPCAM positivity was defined after 
inspection of the images. The median and mean intensities of fluorescence of all the cells imaged was 
calculated.  
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Figure 3.7. The limitation of use of a two dimensional mask when applied to a three 
dimensional cell.  
The small arrow (B) corresponds to the bright rim of fluorescence seen using the image flow cytometer 
corresponding to the membrane signal. 
 
3.2.6 EPCAM expression in oesophageal cancer cell lines 
Oesophageal adenocarcinoma is an epithelial derived tumour and EpCAM 
expression is therefore anticipated in oesophageal adenocarcinoma cell lines. 
Individual histograms of the frequency of cells against the intensity of EpCAM 
immunofluorescence are shown for each of five oesophageal adenocarcinoma cell 
lines (Figure 3.8A). In addition an equivalent histogram for cultured white blood cells 
is included. The single quantification values of the data are provided (Figure 3.8B).  
Four of the five oesophageal cell lines express detectable EpCAM expression. 
EpCAM expression was not detected in the FLO-1 cells. The absence of EpCAM 
expression may have occurred in the patient or been lost subsequently during 
culture. The absence of EpCAM expression in FLO-1 highlights the importance of a 
detection method for circulating tumour cells that does not solely rely on expression 
of a single antigen. As expected no EpCAM expression is detected in the white blood 
cells which indicates that EpCAM expression could be used to distinguish between 
cancer cells and normal white blood cells. 
EpCAM expression was quantified as described in 3.2.4 (Figure 3.8B). This analysis 
illustrates that an arbitrary threshold of positivity is ineffective for discriminating 
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between the differences in expression of the oesophageal cancer cell lines. The 
mean and median values provide a much more effective discrimination and should 
therefore be chosen when such a quantification comparison is required. OAC.P4C 
cells, which express higher EPCAM levels, have a much wider variation in the 
expression of EpCAM between individual cells than the other cell lines.  
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Figure 3.8. EpCAM expression across oesophageal adenocarcinoma cell lines  
SK-GT-4, OAC.P4C, FLO-1, OE33, OE19 and cells were grown to 80 % confluence in routine culture 
medium, trypsinised and 1 x 106 cells fixed with 1 % formalin.  ES051 and white blood cells were 
grown to optimal density in suspension in routine culture medium and 1 x 106 cells fixed with 1 % 
formalin. Cells were permeabilised by incubation with 0.3 % saponin, incubated with antibody against 
EpCAM and with DAPI. Cells were visualised with an ImagestreamX flow cytometer with the lasers set 
to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective with the 
wavelengths for the collection channels set at:  480-560 nm, EpCAM and 430-505 nm, DAPI. A. 
Following image collection, 5000 single cells were identified and a histogram of the intensity of 
collection channel 2 corresponding to the conjugated EpCAM antibody was generated for each cell 
line. B. A threshold for EPCAM positivity was created by visual inspection of the images and in 
addition the median and mean intensity of fluorescence of the cells imaged was calculated. Statistical 
analysis was performed with the IDEAS ® software. 
 
3.2.7 Cytokeratin expression in oesophageal cancer cell lines 
Cytokeratin expression is again expected in all oesophageal adenocarcinoma cells. 
The expression of epithelial cytokeratins in five oesophageal adenocarcinoma cell 
lines is shown in Figure 3.9. Individual histograms of the frequency of objects at each 
intensity of fluorescence corresponding to the cytokeratin expression are shown for 
each of the five oesophageal adenocarcinoma cell lines and for cultured white blood 
cells (Figure 3.9A). The single value quantification of cytokeratin expression for the 
six cell population was calculated from the data (Figure 3.9B).  
All of the oesophageal cancer cell lines express epithelial cytokeratins. The white 
blood cells do not express the cytokeratins which confirms the ability of cytokeratin 
expression to distinguish circulating tumour cells from normal blood cells. Again, 
evaluation of the expression based upon the percentage of cells that express more 
than an arbitrary amount does not effective discrimination between the different 
expression levels within the different cell lines. The median and mean values 
represent these differences better and indicate that the level of expression of 
cytokeratins detected is lower than that of EpCAM in the equivalent cells. (Figures 
3.8B and 3.9B).  
There appear to be two populations of ESO51 cells with respect to cytokeratin 
expression. There is a population with low levels of cytokeratin expression and then a 
second population of cells with higher cytokeratin levels. There is little evidence of 
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two cell populations for other cell lines. A possible explanation is that the ESO51 
cells are cultured in solution and it is therefore more difficult to ensure that all of the 
cells being analysed are healthy. This contrasts with the adherent cell lines in which 
unhealthy cells detach and are therefore not collected. It is possible that differences 
in the viability of cells within the ESO51 population has caused this heterogeneity in 
cytokeratin expression.  
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Figure 3.9. Cytokeratin expression in oesophageal adenocarcinoma cell lines  
SK-GT-4, OAC.P4C, FLO-1, OE33 cells were grown to 80 % confluence in routine culture medium, 
trypsinised and 1 x 106 cells fixed with 1 % formalin.  ES051 and (need to check with David) 
leucocytes were grown to optimal density in suspension in routine culture medium and 1 x 106 cells 
fixed with 1 % formalin. Cells were permeabilised by incubation with 0.3 % saponin, incubated with 
antibody against EpCAM and with DAPI. Cells were visualised with an ImagestreamX flow cytometer 
with the lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 
objective with the wavelengths for the collection channels set at:  560-595 nm, cytokeratins and 430-
505 nm, DAPI. A. Following image collection, 5000 single cells were identified and a histogram of the 
intensity of collection channel 2 corresponding to the conjugated cytokeratin antibody was generated 
for each cell line. B. A threshold for cytokeratin positivity was created by visual inspection of the 
images and in addition the median and mean intensity of fluorescence of the cells imaged was 
calculated. Statistical analysis was performed using the IDEAS ® software. 
 
3.2.8 Survivin expression in oesophageal cancer cell lines 
Some survivin expression is detected in all of the oesophageal adenocarcinoma cell 
lines (Figure 3.10). The overall level of expression detected is lower than for EpCAM 
and cytokeratin. Survivin has been reported to be found both within the nucleus and 
at times within the cell cytoplasm. It has been reported that the presence of survivin 
within the nucleus is associated with increased metastatic potential of the tumour 
cell.  
Survivin is not detected in the white blood cells demonstrating that it may be used to 
help discriminate oesophageal adenocarcinoma cells from other cells in the blood.  
70 
 
 
Figure legend on next page 
71 
 
Figure 3.10. Survivin expression in oesophageal adenocarcinoma cell lines  
SK-GT-4, OAC.P4C, FLO-1, OE33 cells were grown to 80 % confluence in routine culture medium, 
trypsinised and 1 x 106 cells fixed with 1 % formalin.  ES051 and white blood cells were grown to 
optimal density in suspension in routine culture medium and 1 x 106 cells fixed with 1 % formalin. Cells 
were permeabilised by incubation with 0.3 % saponin, incubated with antibody against EpCAM and 
with DAPI. Cells were visualised with an ImagestreamX flow cytometer with the lasers set to emit 
excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective with the 
wavelengths for the collection channels set at:  560-595 nm, survivin and 430-505nm, DAPI. A. 
Following image collection, 5000 single cells were identified and a histogram of the intensity of 
collection channel 2 corresponding to the conjugated cytokeratin antibody was generated for each cell 
line. B. A threshold for survivin positivity was created by visual inspection of the images and in addition 
the median and mean intensity of fluorescence of the cells imaged was calculated. Statistical analysis 
was performed using the IDEAS ® software. 
 
3.3 Discussion 
The Imagestreamx image flow cytometer is well suited to the identification and 
characterisation of malignant cells. The demonstrated ability to distinguish accurately 
and rapidly malignant cells from white blood cells suggests that image flow cytometry 
could be used effectively to detect circulating tumour cells in patient blood samples.   
The images of tumour cells captured using the Imagestreamx image flow cytometer 
are of a high quality and allow very accurate characterisation and identification of the 
cells. Examples of images of oesophageal adenocarcinoma circulating tumour cells 
imaged using an alternative method are demonstrated in Figure 3.13. The cells were 
imaged with the Cellsearch® platform (Riethdorf et al., 2007; Bobek et al., 2014). The 
cells were selected magnetically based on EpCAM expression (Figure 3.13A) or 
were filtered prior to imaging (Figure 3.13B). The size, shape and antigen expression 
of the cells can be determined, but it is difficult to be confident that the images 
detected definitely represent cells and are not debris. Cellsearch® relies on visual 
inspection to make this distinction. The images captured with the Imagestreamx 
image flow cytometer are of a higher resolution than those with the CellSearch® 
platform. This higher resolution improves the confidence with which tumour cells can 
be identified.   
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Figure 3.11. Published images of circulating tumour cells detected and imaged using the 
Cellsearch® platform  
A. Oesophageal  cells have been labelled with a fluorescently conjugated antibody to cytokeratin 
(green) and with DAPI (purple) nuclear stain. Images reproduced from A. (Riethdorf et al., 2007), B. 
(Bobek et al., 2014) 
 
These results demonstrate consistency in the expression of the tumour specific 
biomarkers across multiple oesophageal adenocarcinoma cell lines whilst they are 
not identified in white blood cells. This consistency is in keeping with the reported 
literature on oesophageal adenocarcinoma (Kumble et al., 1996; Kimura et al., 2007; 
Malhotra et al., 2013) and increases confidence that these biomarkers are likely to be 
detected in oesophageal adenocarcinoma circulating tumour cells from patient 
samples. The exception to this is the expression of EpCAM, which is not found in the 
FLO-1 cell line. The lack of EpCAM expression in FLO-1 cells has been reported 
(Garcia et al., 2016) and likely represents a lack of EpCAM expression in the original 
tumour from which the cell line derives. The simultaneous use of multiple biomarkers 
allows FLO-1 cells, and hopefully all circulating tumour cells without EpCAM 
expression, to be identified. In contrast, these cells would not be captured by the 
CellSearch® platform that relies solely on EpCAM expression for the initial separation 
of circulating tumour cells.  
A clear distinction between oesophageal adenocarcinoma cells and white blood cells 
can be made based upon the expression of tumour specific biomarkers, the absence 
of CD45 expression and morphology and size. This distinction supports the use of 
the technique to detect oesophageal adenocarcinoma circulating tumour cells in 
blood without false positive identification of normal blood cells.  
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Three different methods of expressing the immunofluorescence detected as a single 
value using the image flow cytometer have been considered. There is no 
standardised approach to deciding what level of immunofluorescence is required for 
an individual cell to be classed as positive. Within cultured cancer cells in which 
limited heterogeneity might be expected, there is wide variability in the levels of 
immunofluorescence between individual cells. It is very difficult to therefore build a 
specific numerical threshold into a definition of what constitutes a circulating tumour 
cell. Visual inspection of cells therefore remains important although this approach 
does introduce the potential for a lack of consistency between samples.  
The use of cultured oesophageal adenocarcinoma cell lines as a model for circulating 
tumour cells assumes that the cultured cells express the same antigens and at the 
same levels patient tumour cells. There is also an assumption that physical 
properties of the cells such as area will be the same or similar. Optimisation of 
methods using cultured cells does not therefore fully validate the methods when 
applied to patient samples.  
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Chapter 4. Development of a method to enrich circulating tumour 
cells from whole blood 
 
4.1 Introduction 
Cultured cell lines provide useful models with which to develop methods of detection 
and characterisation of oesophageal adenocarcinoma cells by image flow cytometry, 
as described in chapter 3. During this validation, high concentrations of around 1 x 
106 cells per ml were analysed in phosphate buffered saline. This situation is very 
different from circulating tumour cells which are present in whole blood in 
concentrations of less than 1 cell per ml (Allard et al., 2004). A method of processing 
whole blood to achieve a cell suspension containing these rare circulating tumour 
cells that can then be labelled with antibodies and imaged by image flow cytometry is 
required. It is advantageous to enrich the circulating tumour cells prior to their 
analysis. Enrichment can be achieved by positively selecting the circulating tumour 
cells based upon specific characteristics or by positively depleting the normal blood 
constituents (Parkinson et al., 2012). The latter method has the advantage of not 
being reliant upon any single property of the circulating tumour cells, which would 
mean that only circulating tumour cells with that single property would be analysed.  
It enables subsequent identification of all circulating tumour cells irrespective of 
physical characteristics or specific antigen expression.  
During enrichment, a proportion of circulating tumour cells will be lost. These losses 
are quantified by measuring the recovery of circulating tumour cells, defined as the 
percentage of the original circulating tumour cells in the blood sample that is present 
after sample enrichment. The higher the purity of circulating tumour cells required, 
the greater the losses and hence the lower the recovery are likely to be. The great 
strengths of image flow cytometry are the speed at which large numbers of cells can 
be imaged and the potential to process samples that still contain relatively large 
numbers of normal blood constituents. The IDEAS® software allows subsequent 
identification of the circulating tumour cell population. This capability allows the 
balance between the circulating tumour cell purification and recovery to be kept in 
favour of recovery, which minimises the loss of circulating tumour cells.  
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An enrichment protocol should include methodology to deplete all the different 
normal cell populations in whole blood. The three main cell populations to be 
depleted are red blood cells, white blood cells and platelets. Circulating tumour cells 
are closest, in terms of size and density, to white blood cells.  It is from this 
population that it is most difficult to separate the circulating tumour cells. This 
represents the major technical challenge in attempting to enrich circulating tumour 
cells from whole blood.  
One millilitre of blood contains up to approximately ten million white blood cells. A 
number of different methods for depleting white blood cells had been investigated 
prior to the commencement of this research. Positive selection of the malignant cells 
involved attempts to identify a universally expressed antigen or differential separation 
on the basis of cell density or size. Whilst adequate depletion rates of white blood 
cells could be achieved, the recovery of cancer cells was extremely low. The cancer 
cells that were recovered were damaged physically as assessed by the images 
produced (data not shown). In addition, these methods whilst successful in reducing 
the number of white blood cells created in their place a large quantity of cellular 
debris. This cellular damage was particularly prevalent with methods based upon 
passage of blood over columns of magnetic beads. The maximum rate of sample 
processing by the image flow cytometer is determined by the flow rate of objects that 
can be either cells or debris. Replacing large numbers of cells with large quantities of 
cellular debris does not therefore reduce the overall processing time of the sample.  
The EasySep™ method of depleting white blood cells has a potential advantage that 
it should not cause cell damage and hence cellular debris is not produced which 
makes it very suitable for use alongside the Imagestreamx image flow cytometer. 
EasySep™ CD45 depletion followed by flow cytometry has been reported in the 
detection of circulating tumour cells in melanoma and colorectal cancer (Fusi et al., 
2010; Fusi et al., 2011). In a study focused on squamous cell carcinomas of the head 
and neck, the EasySep™ magnetic beads were compared with three other 
commercially-available magnetic beads (Yang et al., 2009). The EasySep™ beads 
achieved the highest depletion of white blood cells whilst maintaining the highest 
recovery of circulating tumour cells. 
A model of circulating tumour cells in whole blood can be generated by adding 
cultured oesophageal adenocarcinoma cells into healthy volunteer whole blood. This 
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model allows evaluation of the impact of the depletion steps on recovery and 
validation of any overall protocol created.  
 
4.2 Results 
 
4.2.1 Morphology and cross-sectional area of cancer cells in comparison to 
white blood cells 
Distinction between white blood cells and cancer cells can be made on the basis of 
morphology (Figure 4.1A). The white blood cells are smaller and more rounded with 
a higher nuclear to cytoplasmic ratio than the cancer cells. The ability to distinguish 
visually white blood cells form malignant cells provides an additional means by which 
reassurance that white blood cells will not be mistaken for circulating tumour cells 
when patient samples are analysed.  
The size of cells is another potential method by which to distinguish circulating 
tumour cells from white blood cells. Examination of the brightfield cell images clearly 
indicates that OE019 and ESO51 cells are smaller than the other cancer cell lines 
(Figure 4.1A). Cell areas can be calculated rapidly for large numbers of cells with the 
Imagestreamx image flow cytometer. The cross-sectional area of six oesophageal 
cancer cell line cells are shown in Figure 4.1. For comparison, an established breast 
cancer cell line, SK-Br-3, and white blood cells are included. There are significant 
differences between the mean cross-sectional areas of the six oesophageal cancer 
cells (p<0.0001). The mean cross-sectional area of the breast cancer cell line is 
within the range of cross-sectional areas of the oesophageal adenocarcinoma cell 
lines. There does however remain a statistically significant difference between the 
cross-sectional area of the OE019 cells which are the smallest of the oesophageal 
cancer cells and the white blood cells (p<0.0001). This difference supports the use of 
cross-sectional area in helping to distinguish circulating tumour cells from white blood 
cells in patient samples.  
Comparison of the nuclear cross-sectional areas of the different cell lines again 
demonstrates that there are significant differences across the oesophageal 
adenocarcinoma cell lines (p<0.0001). The smallest cells, OE019 and ESO51, not 
surprisingly have the smallest nuclei (Figure 4.1C). Although visually there is less 
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difference between the cross-sectional nuclear area of the white blood cells 
compared with the OE019 cell line, there remains a significant difference between 
the two (p<0.0001). Once again this result suggests a potential role of nuclear cross-
sectional area in helping to distinguish circulating tumour cells from white blood cells 
in patient samples.  
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Figure 4.1. Morphology and cross-sectional cell and nuclear areas of cancer cells in 
comparison to white blood cells  
A. SK-GT-4, OAC.P4C, FLO-1, OE33, OE19 and SKBr3 cells were grown to 80 % confluence in 
routine culture medium, trypsinised and 1 x 106 cells fixed with 4 % formaldehyde.  ES051 and white 
blood cells were grown to optimal density in suspension in routine culture medium and 1 x 106 cells 
fixed with 1 % formalin. Cells were visualised with an ImagestreamX flow cytometer without laser 
excitation with collection of brightfield images only. B. The cross-sectional cell and nuclear area of 
1000 cells from each cell line was calculated using IDEAS®. This data was exported to GraphPad 
Prism. The mean cross-sectional areas and standard errors of the mean for each cell line are shown 
An unpaired t-test was used for 2 groups and a one-way ANOVA for multiple groups to compare the 
mean cell and nuclear cross-sectional areas of the cancer cell lines and white blood cells.  
 
4.2.2 Panel of antibodies for cancer cell detection 
Results obtained with the fluorescently-conjugated antibodies previously selected for 
detection of circulating tumour cells are shown in Figure 4.2. For this validation, 
cultured SK-GT-4 adenocarcinoma cells were added to whole blood. In the SK-GT-4 
cancer cells, EpCAM is located in the cell membrane, cytokeratin is cytoplasmic and 
survivin is within the nucleus (Figure 4.2A). As expected, there is no fluorescence 
corresponding to CD45 expression in these cancer cells. CD45 is only expressed in 
white blood cells and is therefore an excellent biomarker to help distinguish these cell 
populations.  
In addition to expression of CD45, the white blood cells do not demonstrate any 
fluorescence corresponding to EpCAM, cytokeratin and survivin (Figure 4.2B). As 
noted above, the white blood cells are small round nucleated cells that could be 
distinguished from the cancer cells based upon the brightfield images alone. When 
combined with the fluorescent images, the ease of distinction between white blood 
cells and cancer cells is illustrated clearly (Figure 4.2C).  
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Figure 4.2. Detection of oesophageal adenocarcinoma cells in whole blood by image flow 
cytometry  
A. SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 
cells fixed with 1 % formalin.  Cells were permeabilised by incubation with 0.3 % saponin, incubated 
with antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and incubated subsequently 
with antibody against EpCAM, CD45 and with DAPI. B. Density gradient separation buffer was added 
to healthy volunteer blood and the sample centrifuged. The fraction of the centrifuged blood sample 
containing most of the white blood cells (buffy coat) was extracted and fixed with 4% formaldehyde. 
Cells were permeabilised with 0.3% saponin and incubated with the antibodies as described. All cells 
were visualised with an ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 
561 and 658 nm. Images were collected with a x40 objective with the wavelengths for the collection 
channels set at:  480-560 nm, EpCAM; 560-595 nm, cytokeratins; 642-745 nm, survivin; 745-800 nm, 
CD45 and 430-505 nm, DAPI. 
 
4.2.3 White blood cell depletion 
Depletion of white blood cells is an essential process prior to the detection of 
circulating tumour cells by image flow cytometry. The effectiveness of white blood 
cell depletion with the EasySep™ method is illustrated in Figure 4.3. Prior to 
depletion, the mean concentration of white blood cells was 4.16 x 106 per millilitre. At 
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a magnification of x 40 the maximum rate of imaging for the Imagestreamx image flow 
cytometer is 2000 objects per second. Theoretically at this concentration, one 
millilitre would take approximately 34 minutes to be analysed by the Imagestreamx 
image flow cytometer. There will clearly be a difference in the actual times taken for 
samples to process reflecting the normal range of white blood cells per millilitre of 
whole blood of between approximately 3.9 and 10.6 x106 (Chapter 1). This would 
correspond with a processing time of up to approximately 83 minutes per millilitre of 
whole blood.  
The Figure shows the dramatic reduction in white blood cell concentration achieved 
with the EasySep™ CD45 enrichment. A percentage depletion of 98% +/- 0.8% was 
achieved consistently (Figure 4.3A). At the same rate of imaging with the 
Imagestreamx image flow cytometer, the depleted sample will have a theoretical 
processing time of less than one minute (Figure 4.3B).  
 
It would be possible to place the supernatant from the magnet back in the EasySep™ 
magnet and repeat the process of white blood cell depletion. This procedure could in 
theory increase the depletion of white blood cells but at the expense of losing cancer 
cells and reducing recovery. Given the capability of the Imagestreamx image flow 
cytometer, the purity achieved after placing the sample within the magnet once was 
considered sufficient to allow sample processing in a realistic time (table 4.3B). 
Remaining white blood cells within the sample can be distinguished from cancer cells 
as detailed in section 4.2.4.  
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Figure 4.3. Depletion of white blood cells by EasySep™ CD45 depletion.  
Five ml whole blood samples from healthy volunteers were fixed in 0.4% formaldehyde for 20 minutes 
and the red blood cell component was lysed. Platelets were removed with centrifugation. A. White 
blood cells were counted in a Neubauer haemocytometer. EasySep™ anti-CD45 antibody complex 
was added to the fixed cells followed by dextran-coated nanoparticles. The suspension was then 
diluted with Robosep™ buffer and placed in the EasySep™ magnet for ten minutes. The un-retained 
cell fraction was decanted into a clean tube by inversion of the sample and magnet. Residual white 
blood cells were counted in a Neubauer haemocytometer. Data are presented as means +/- SEM. B. 
Based upon imaging objects at 2000 objects per second with the Imagestreamx image flow cytometer, 
the times required to process a one ml sample before and after white blood cell depletion were 
calculated. 
 
 
4.2.4 Imagestreamx IDEAS® software enrichment 
Following physical enrichment of the sample as described above (section 4.2.3) a 
further enrichment was achieved with the IDEAS® software.  A compensation matrix 
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was created based upon samples labelled with a single fluorophore single colour 
reference samples for each fluorochrome, as described in chapter 3, to allow removal 
of spectral overlap into adjacent channels from each of the fluorophores used. Figure 
4.5 demonstrates the application of the software to identify the tumour cell 
population. 
Cells are identified first based upon the intensity of the nuclear dye retained by the 
cells (Figure 4.4A). There is a sharp peak around zero that corresponds to Amnis 
Speedbeads and cellular debris. A second peak at an intensity between 3 and 4 x 
105 fluorescence units corresponds to single leukocytes. The third peak of intensity 
between 5 and 8 x 105 fluorescence units corresponds to doublets of white blood 
cells and other cells with a larger nuclear signal than a single leucocyte. This peak is 
where circulating tumour cells would be found. Objects within this population are 
selected for further analysis. Any objects to the right of this peak are included to 
ensure that clusters of cells that may contain circulating tumour cells are identified. 
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Figure 4.4. Discrimination of the malignant cell population in whole blood from the residual 
leukocytes after positive depletion of blood cells.  
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells 
fixed with 1 % formalin. Cells were washed and resuspended in PBS. Appropriate volumes of the 
prepared cell suspension were added to the healthy volunteer blood sample before any sample 
processing occurred. After physical sample enrichment, cells were permeabilised by incubation with 
0.3 % saponin, incubated with antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and incubated 
subsequently with antibody against EpCAM, CD45 and with DAPI. All cells were visualised with an 
ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 and 658 nm. 
Images were collected with a x40 objective with the wavelengths for the collection channels set at:  
480-560 nm, EpCAM; 560-595 nm, cytokeratins; 745-800 nm, survivin; 745-800 nm, CD45; 430-505 
nm, DAPI. A.  A histogram of the intensity of nuclear stain was generated for all objects. The objects 
were gated to exclude those objects without a nuclear stain. B. Objects with a positive nuclear stain 
were analysed for the intensity of fluorescence for the CD45 antibody against the intensity of 
fluorescence of the EpCAM antibody. C. Cells positive for EpCAM and negative for CD45 were then 
inspected visually. Cancer cells can be distinguished easily from white blood cells by this visual 
inspection. 
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Subsequent analysis identifies cells based upon absence of CD45 expression and 
expression of EpCAM, cytokeratins, and survivin. The effectiveness of the 
discrimination that can be achieved is demonstrated in Figure 4.4B. A population of 
cells that express CD45 but not EpCAM is identified clearly and corresponds to the 
residual white blood cell population. The population of objects that express EpCAM 
but not CD45 will include the cancer cells. Analysis of the images with IDEAS® 
Software enables automatic discrimination of the two populations. Similar analysis for 
survivin and cytokeratin detection allows additional cells to be identified. Any objects 
that express one or more of the tumour specific antigens and do not express CD45 
are selected automatically with the IDEAS® Software. These selected objects are 
then inspected visually to confirm that the cellular morphology is consistent with a 
cancer cell.  
 
4.2.5 Losses associated with the Imagestreamx image flow cytometer 
The losses associated with the processing of samples with the Imagestreamx image 
flow cytometer are illustrated in Figure 4.5. These losses can be considered both in 
terms of the volume of sample lost and the proportion of cells lost. A small volume of 
each sample is lost during each analysis, This ‘dead space’ should be the same 
irrespective of the volume of sample processed (Figure 5Ai). The mean volume loss 
was 5.4 +/- 0.06 µl. As a result, the relative percentage loss of the sample increases 
as the sample volume decreases (Figure 5Aii). At a sample volume of 20 µl, the loss 
of volume corresponded to a 26.2% loss of the sample. By contrast at the maximal 
permitted sample volume of 200 µl, the loss is small at 2.7 %. Analysis of patient 
samples to detect circulating tumour cells should ideally be with a volume of 200 µl to 
minimise the impact of these losses.  
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Figure 4.5. The effect of sample volume on sample loss during image flow cytometry.  
A. Differing volumes of phosphate buffered saline (from 20 to 200 µl) as measured using a Gilson 
pipette were analysed on the Imagestreamx without the addition of any cells. The Imagestreamx 
records the actual volume of the processed sample allowing the percentage of sample lost due to the 
‘dead space’ to be calculated. B. SK-GT-4 cells were grown to 80 % confluence in routine culture 
medium, trypsinised and 1 x 106 cells fixed with 1 % formalin. Cells were washed and resuspended in 
PBS and cell counts were performed using a Neubauer haemocytometer. Samples of 500 cells were 
resuspended in phosphate buffered saline at a volume of 20 and 200 µl and analysed using the 
Imagestreamx image flow cytometer. Cells were imaged in the brightfield channel and images with a 
clear cellular morphology were counted.  
 
The cellular losses that occur during sample processing with the image flow 
cytometer are illustrated in Figure 4.5B. For a 20 µl sample the mean cellular 
recovery was 84.7 +/- 5.2 %. For a sample of 200 µl, the mean cellular recovery was 
106.4 +/- 8.1%. This value if likely to reflect the margin of error when counting cells 
using a Neubauer haemocytometer in the context of low cell concentrations. These 
figures are comparable with the volume losses illustrated in Figure 4.5A which 
suggests that any cellular losses that occur during sample processing are attributable 
predominantly to the volume loss. This finding reinforces the importance of analysing 
patient samples in larger volumes.  
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4.2.6 Recovery of oesophageal adenocarcinoma cells from whole blood 
Reliable detection of circulating tumour cells in patient samples is dependent upon a 
consistent method of recovery of the tumour cells during purification from the normal 
blood constituents. The recovery of cells is expressed as the percentage of tumour 
cells present in a sample that are still present at the end of sample processing. 
Figure 4.6A shows the recovery achieved after addition of known numbers of 
cultured oesophageal adenocarcinoma cells to whole blood.  
The first attempt at processing whole blood achieved a relatively low recovery of 
approximately 10% (Figure 4.6A). The final recovery of approximately 50% followed 
a process of gradual improvement and refinement of the overall method. A clear 
plateau in the recovery was achieved (Figure 4.6A). It is possible that some of the 
improvements were as a result of practice. Better technique at each stage of the 
process would contribute to the improved recovery. The method described has been 
tested now by other students who have been able to achieve similar recoveries.  
Recovery rates at three different cell concentrations were calculated (Figure 4.6B). 
Consistent recovery was achieved across all cell concentrations and the combined 
overall recovery was 48.2 +/- 2.4%. Whilst the cell concentrations tested are low, 
they are close to the concentrations of circulating tumour cells present in patients.  
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Figure 4.6. Recovery of cultured oesophageal adenocarcinoma cells from whole blood  
SK-GT-4 cells were grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells 
fixed with 1 % formalin. Cells were washed and resuspended in PBS and cell counts were performed 
using a Neubauer haemocytometer. Appropriate volumes of the prepared cell suspension were added 
to the healthy volunteer blood sample before any sample processing occurred. After sample 
enrichment, cells were permeabilised by incubation with 0.3 % saponin, incubated with antibodies 
against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and incubated subsequently with antibody against 
EpCAM, CD45 and with DAPI. All cells were visualised with an ImagestreamX flow cytometer with the 
lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective 
with the wavelengths for the collection channels set at:  480-560nm, EpCAM; 560-595 nm, 
cytokeratins; 745-800nm, CD45; 430-505nm, DAPI. A. Initial cell spiking experiments were performed 
at a single concentration of 2000 cancer cells in five ml of whole blood. B. Once the full protocol had 
been developed, further spiking experiments were performed at concentrations of 2000, 200 and 20 
cells per 5 ml of whole blood.  
 
4.2.7 Healthy Volunteer Samples 
Five samples of blood from healthy volunteers were tested according to the full 
developed protocol. In none of these samples were any objects identified that would 
be classified as circulating tumour cells. 
   
4.3 Discussion 
Analysing circulating tumour cells without enrichment is achievable with an 
Imagestreamx image flow cytometer, but the time required to process an un-enriched 
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sample precludes realistic routine clinical application. My approach to enrichment 
consisted of two stages. The first was a physical enrichment by depleting normal 
blood cells. This enrichment was followed by further electronic ‘enrichment’ of the 
circulating tumour cells with the IDEAS® software. The method developed for 
circulating tumour cell enrichment from white blood cells was based on positive 
depletion of normal blood constituents with no reliance on any single antigen 
expression by the circulating tumour cells. The method has the potential to be 
adapted for other tumour types and to characterise the circulating tumour cells 
detected. 
The method developed was demonstrated to achieve a consistent recovery of 
approximately 48%. A wide variety of recovery rates have been reported in the 
literature from approximately 11% to 90% (Racila et al., 1998; Benez et al., 1999; 
Kruger et al., 2000; Liberti et al., 2001). These rates derive from a range of methods 
of enrichment and detection of the circulating tumour cells, including positive 
immunomagnetic cell selection, density-gradient centrifugation and filtration. The 
CellSearch Information for Use documentation produced by Veridex reports 
recoveries of between 80 – 200% across a range of tumour cell concentrations. 
The recovery rate achieved is similar to rates reported with methods based upon in 
simple positive depletion of normal blood constituents. An overall recovery rate of 
46% was achieved with a combination of red blood cell lysis and immunomagnetic 
depletion of leucocytes in a study of breast cancer cell lines (Lara et al., 2004). It is 
important to note that not all studies that report recovery rates are comparable. In a 
study of head and neck squamous cell carcinomas that tested several commercially 
available anti-CD45 antibodies and magnetic particles including the EasySep™ 
magnetic beads, a recovery rate of 86% was reported (Yang et al., 2009). The study 
added cells from cancer cell lines to buffy coat as opposed to whole blood. This 
difference will lead to higher recovery rates because the losses associated with 
isolation of the buffy coat are not factored into the recovery calculations.    
It is possible to compare the recovery achieved with our method with the theoretical 
recovery that might be expected based upon the published literature. It is recognised 
that there are cell losses associated with every centrifugation step. These have been 
reported as being approximately 7% per centrifugation (Lara et al., 2004). Table 2 
summarises the predicted versus observed losses for the method developed 
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excluding the white blood cell depletion step. This comparison allows an approximate 
calculation of the losses that occur during the EasySep™ enrichment stage of the 
protocol. Without accounting for losses associated with the white blood cell depletion 
the expected recovery would be 60% compared with the observed recovery of 
48.2%. The largest contributor to the difference between these two values is likely to 
be the white blood cell depletion. The one aspect that is not factored into this 
comparison is the potential losses that occur during the transferring of cells from one 
tube to another.  
 
Table 4.1 Theoretical losses of recovery at sequential stages of the enrichment and labelling of 
circulating tumour cells.  
 
Process Theoretical loss 
of cells 
Residual cell 
count 
Start 0 100 
RBC lysis 11%* 89 
Centrifugation 7%* 83 
Centrifugation 7%* 77 
(EasySep) ? - 
Centrifugation 7%* 72 
Centrifugation 7%* 67 
Centrifugation 7%* 62 
Imagestreamx 2.7% 60 
*(Lara et al., 2004) 
 
The wide variations in reported recovery rates between different studies must be 
taken into account when comparing studies that report circulating tumour cells. As a 
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result it is virtually impossible to compare or combine studies of circulating tumour 
cell enumeration. This is one of the major strengths of the CellSearch platform which 
does allow such comparisons to be made. For an individual method what is important 
is the reproducibility of the recovery. The method developed achieves this with a 
consistent recovery across a range of cell concentrations.  
Red blood cell depletion can be achieved through density centrifugation or red blood 
cell lysis. A density gradient medium is added to the whole blood prior to 
centrifugation. The buffy coat layer generated contains white blood cells and 
platelets. This layer can be aspirated from the sample for further processing. It is 
within this buffy coat that circulating tumour cells would be found. Red blood cell lysis 
relies upon a buffer which is added to whole blood to increase osmotic pressure 
within the red blood cells which leads to lysis with minimal effect on white blood cells 
and platelets. Both red cell depletion methods of are simple. There are however 
significant advantages to red blood cell lysis over density centrifugation with respect 
to circulating tumour cells. Whilst a high purity of sample can be achieved with 
density centrifugation, the recovery rate of the buffy coat from the sample is relatively 
low.  
There are inevitably associated losses with red blood cell lysis. It is extremely difficult 
to quantify accurately these losses using image flow cytometry as it is difficult to 
process a sample immediately after either lysis to the large number of white blood 
cells and platelets still present in the sample. The overall recovery achieved by 
density separation was less than 10% (O'Donnell, 2017). This low recovery is 
reported in the literature in which much higher losses of circulating tumour cells have 
been reported after density gradient separation compared with red blood cell lysis 
(Lara et al., 2004). The 11% loss reported with red blood cell lysis compares 
favourably with a 27% loss after density gradient separation.   
Two red blood cell lysis buffers were tested. Ammonium chloride solution, 0.8 % 
NH4Cl, (STEMCELL technologies™) and BD Phosflow™ (BD Biosciences), which is 
a buffer that contains formaldehyde, diethylene glycol and methanol to lyse and fix 
cells simultaneously. Both buffers achieved a satisfactory red blood cell lysis. The 
quality of antibody staining and hence the quality of the final images produced with 
the Imagestreamx image flow cytometer were felt to be superior after lysis with the 
BD Phosflow™ compared with the ammonium chloride. There also appeared to be 
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less cellular debris in the final samples after lysis with BD Phosflow™. Cellular debris 
is included in the images created by the image flow cytometer and therefore 
increases significantly the sample processing time. These were subjective measures 
that were difficult to quantify.  Nevertheless, the BD Phosflow™ was selected for the 
final method.  
The size and density of platelets are lower than those of white blood cells and cancer 
cells. Although platelets and white blood cells are both found within the buffy coat 
they can be separated easily by differential centrifugation. At a low centrifugal force 
of 200 g, platelets will remain within the supernatant while white blood cells and 
cancer cells will be collected in the pellet. A low G centrifugation step was therefore 
incorporated into the method as detailed in Chapter 2.  
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Chapter 5. Patient samples 
 
5.1 Introduction 
The method developed for enriching whole blood allowed oesophageal 
adenocarcinoma cells to be identified in an in vitro model (Chapter 4). This method 
required validation in clinical samples from patients with oesophageal 
adenocarcinoma patients and from healthy volunteers.  
There are a number of different time points during the staging and treatment of 
oesophageal adenocarcinoma at which circulating tumour cells could be measured. 
As discussed in Chapter 1, the greatest opportunity to influence treatment decisions 
in this group of patients is in patients with potentially resectable disease rather than 
in those with metastatic cancer (section 1.4.2). It was decided therefore to focus on 
this group of patients.  
Many patients with oesophageal adenocarcinoma will undergo peri-opertaive 
chemotherapy with up to three cycles of neo-adjuvant chemotherapy prior to surgery. 
This treatment has the potential to affect the number of circulating tumour cells 
detected. Samples were taken therefore from patients prior to any treatment. The 
lack of available literature meant that it was not clear whether circulating tumour cells 
would be detected in this patient group. In patients in whom circulating tumour cells 
could be identified, the significance of this finding was also unclear. This information 
could be important potentially in improving the accuracy of staging of oesophageal 
adenocarcinoma and in designing future studies of circulating tumour cells at 
different time points during treatment. 
 
5.2 Results 
5.2.1 Patient Demographics 
A total of 25 patients with oesophageal adenocarcinoma undergoing staging were 
included in the study (Table 5.1). The majority of patients (n=23) were male and the 
median age was 68 years (range 58-84). These demographics are in keeping with 
the overall statistics for age and sex of patients presenting with oesophageal 
adenocarcinoma. 
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The clinical and demographic details of the patients included are described in table 1. 
Patients are ordered according to the full radiological staging of each patient (TNM 
7th edition (Figure 1.4)).  The study included patients without obvious stage four 
metastatic disease at the time of blood sampling. All patients had undergone an 
endoscopy and a computed tomography scan. The complete staging of patients 
(Figure 1.5) was not completed until after the blood sample had been processed. As 
a result, the final overall staging revealed that whilst the majority of patients had 
stage three disease, three patients had stage four, three patients stage two and two 
patients stage one cancer.   
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Table 5.1 Patient demographic and staging information.  
Patients are ordered according to stage groups (TNM 7th Edition) 
 
 
5.2.2 Circulating tumour cell heterogeneity 
Examples of the circulating tumour cells identified in this study are shown in Figures 
5.1 and 5.2. Composite images of all of the circulating tumour cells identified in a 
single patient are shown in Figure 5.1. Clear heterogeneity is seen between the 
individual circulating tumour cells within this single patient sample. This is both in 
terms of the shape and size of the cells but also in the pattern of fluorescence. A 
strong nuclear signal is seen in all of the cells however several of the smaller cells 
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have much lower levels of fluorescence corresponding to the other antibodies used in 
the panel.  
 
 
 
Figure 5.1 Comparison of individual circulating tumour cells from a single patient (patient 006) 
Five ml whole blood sample from a patient undergoing staging of oesophageal adenocarcinoma was 
collected in Transfix (Cytomark, UK) tubes. The red blood cell component was lysed. Platelets were 
removed with centrifugation at 250 g for 5 minutes. EasySep™ anti-CD45 antibody complex was 
added to the cell suspension followed by dextran-coated nanoparticles. The suspension was then 
diluted with Robosep™ buffer and placed in the EasySep™ magnet for ten minutes. The un-retained 
cell fraction was decanted into a clean tube by inversion of the sample and magnet. Cells were 
permeabilised by incubation with 0.3 % saponin, incubated with antibodies against cytokeratins 4, 5, 6, 
8, 10, 13, and 18 and survivin and incubated subsequently with antibody against EpCAM, CD45 and 
with DAPI. All cells were visualised with an ImagestreamX flow cytometer with the lasers set to emit 
excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 objective with the 
wavelengths for the collection channels set at:  480-560nm, EpCAM (green); 560-595 nm, cytokeratins 
(yellow); 642-745nm, surviving (red); 745-800nm, CD45 (pink); 430-505nm, DAPI (purple).  
 
A comparison of representative circulating tumour cells from three patient samples is 
provided in Figure 5.2 (A-C). Examples of the oesophageal adenocarcinoma cell line 
SK-GT-4 cells are shown for comparison (Figure 5.2D). In two of the patient samples 
(A and B), whilst there are circulating tumour cells identified that are very similar to 
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the SK-GT-4 cells, heterogeneity is also demonstrated within the circulating tumour 
cell populations. This heterogeneity is again in terms of the size, morphology and 
antigen expression of the cells.  
One of the patient samples tested contained a large population of 85 nucleated cells 
that were morphologically consistent with a circulating tumour cell in terms of cell 
shape and size. There was however no fluorescence corresponding to any of the 
three tumour-specific antibodies (Figure 5.2C). These cells do not appear to be a 
haematological cell population. It seems likely that these are circulating tumour cells 
that do not express EpCAm, cytokeratins or survivin. Alternatively they could 
represent non-epithelial cells within the blood. It has been proposed that metastatic 
tumour cells may undergo epithelial mesenchymal transition (Willipinski-Stapelfeldt et 
al., 2005) which provides a possible explanation for the cell population identified. The 
advantage of the high resolution images captured is that these calls can be identified 
even though they do not express the three biomarkers.  
It is difficult to determine the importance of heterogeneity within a circulating tumour 
cell population. That all of these cells are identified is a strength of the developed 
method. For the purposes of circulating tumour cell enumeration all circulating 
tumour cells are effectively considered to be the identical in terms of their malignant 
potential. It is possible that some of the differences between the cells relates to cells 
that are in fact undergoing cell death and hence may have lost their characteristic 
antigen expression. 
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Figure legend on next page 
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Figure 5.2 Circulating tumour cells detected in patients with oesophageal adenocarcinoma 
A-C. Five ml whole blood samples from patients undergoing staging of oesophageal adenocarcinoma 
were collected in Transfix (Cytomark, UK) tubes. The red blood cell component was lysed. Platelets 
were removed with centrifugation at 250 g for 5 minutes. EasySep™ anti-CD45 antibody complex was 
added to cell suspension followed by dextran-coated nanoparticles. The suspension was then diluted 
with Robosep™ buffer and placed in the EasySep™ magnet for ten minutes. The un-retained cell 
fraction was decanted into a clean tube by inversion of the sample and magnet. D. SK-GT-4 cells were 
grown to 80 % confluence in routine culture medium, trypsinised and 1 x 106 cells fixed with 4 % 
formalin.  A-C. Cells were permeabilised by incubation with 0.3 % saponin, incubated with antibodies 
against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and incubated subsequently with antibody 
against EpCAM, CD45 and with DAPI. All cells were visualised with an ImagestreamX flow cytometer 
with the lasers set to emit excitation at 405, 488, 561 and 658 nm. Images were collected with a x40 
objective with the wavelengths for the collection channels set at:  480-560 nm, EpCAM; 560-595 nm, 
cytokeratins; 642-745 nm, survivin; 745-800 nm, CD45; 430-505 nm, DAPI.  
 
5.2.3 Circulating tumour cell area 
The mean area of the circulating tumour cells detected in the patient samples is 
comparable with that of cultured oesophageal cancer cell lines (Figure 5.3A). A 
similar correlation exists is observed with the mean nuclear area (Figure 5.3B). The 
detected circulating tumour cells are closest in size to the OE19 and ESO51 cell 
lines. Only the patients with larger numbers of cells were included in this comparison 
due to the need for meaningful averages. The larger standard error of the mean for 
both these samples may reflect the greater heterogeneity in size within patient 
samples compared with cultured cell lines. It may also reflect the smaller number of 
cells compared with the cultured cell lines.  The mean nuclear and cell sizes of the 
circulating tumour cells is significantly greater than that of white blood cells 
(p<0.0001) which is consistent with the findings for the cultured cell lines. The 
heterogeneity in circulating tumour cell size described above indicates that 
dependence upon the size of cells for isolation may not be useful to distinguish 
circulating tumour cells from white blood cells. The cellular area of one of the 
smallest circulating tumour cells detected was 164.5 units which is close to the mean 
cellular area of the white blood cells of 149.5 units. Reliance upon size alone might 
therefore lead to this cell not being included in the circulating tumour cell population. 
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It is important to incorporate both antigen expression, size of cells and morphological 
appearance of the cells when defining the circulating tumour cell population. 
 
 
 
Figure 5.3 Size of circulating tumour cells detected in patient samples compared with 
oesophageal adenocarcinoma cell lines  
A and B. SK-GT-4, OAC.P4C, FLO-1, OE33, OE19 cells were grown to 80 % confluence in routine 
culture medium, trypsinised and 1 x 106 cells fixed with 4% formalin.  ES051 and white blood cells 
were grown to optimal density in suspension in routine culture medium and 1 x 106 cells fixed with 1 % 
formalin. Cells were visualised with an ImagestreamX flow cytometer without laser excitation with 
brightfield collection only with a x40 objective. Five ml whole blood samples from patients undergoing 
staging of oesophageal adenocarcinoma were collected in Transfix (Cytomark, UK) tubes. The red 
blood cell component was lysed. Platelets were removed with centrifugation at 250 g for 5 minutes. 
EasySep™ anti-CD45 antibody complex was added to cell suspension followed by dextran-coated 
nanoparticles. The suspension was then diluted with Robosep™ buffer and placed in the EasySep™ 
magnet for ten minutes. The un-retained cell fraction was decanted into a clean tube by inversion of 
the sample and magnet. Cells were permeabilised by incubation with 0.3 % saponin, incubated with 
antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and incubated subsequently with 
antibody against EpCAM, CD45 and with DAPI. All cells were visualised with an ImagestreamX flow 
cytometer. The cell and nuclear areas of 1000 cells from each cell line and of all of the circulating 
tumour cells from the two patient samples (001 and 002) was calculated with IDEAS®. These data 
were exported to GraphPad Prism and the mean area and standard error of the mean for each cell 
line are shown.  
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5.2.4 Additional objects identified from patient samples 
In addition to healthy white blood cells and circulating tumour cells, a number of other 
populations of objects were detected when patient samples are analysed. Whilst 
some of these are clearly cellular in nature, some are harder to identify. Inaccurate 
identification of these objects as circulating tumour cells is a potential source of error 
when interpreting the results of studies of circulating tumour cells.  
In all patient samples a population of what morphologically appear to be white blood 
cells was identified. These cells were positive for all of the fluorescently-conjugated 
antibodies and the nuclear stain. (Figure 5.4A). Morphologically the white blood cells 
appeared darker than other white blood cells with a denser appearance to the cell. 
These cells may represent a population of apoptotic white blood cells. Alternatively 
they could simply be white blood cells that have been damaged during sample 
processing. During method development and validation, these cells were detected in 
blood samples in to which cultured oesophageal adenocarcinoma cells had been 
added suggesting that their presence is not related to underlying malignancy in the 
patient. Whilst these individual cells can be distinguished easily from circulating 
tumour cells, the discrimination may be less straight forward when these white blood 
cells are found in clusters (Figure 5.4B). Because the cells are in clusters, the false 
impression of a larger cell that appears to express the antigens associated with a 
tumour cell is given. However these cells are all positive for CD45, which provides a 
simple means to discriminate them from circulating tumour cells.  
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Figure 5.4 Fluorescently-labelled white blood cell population identified during processing of 
patient samples 
Five ml whole blood samples from patients undergoing staging of oesophageal adenocarcinoma were 
collected in Transfix (Cytomark, UK) tubes. The red blood cell component was lysed. Platelets were 
removed with centrifugation. EasySep™ anti-CD45 antibody complex was added to cell suspension 
followed by dextran-coated nanoparticles. The suspension was then diluted with Robosep™ buffer 
and placed in the EasySep™ magnet for ten minutes. The un-retained cell fraction was decanted into 
a clean tube by inversion of the sample and magnet. Cells were permeabilised by incubation with 0.3 
% saponin, incubated with antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and 
incubated subsequently with antibody against EpCAM, CD45 and with DAPI. All cells/objects were 
visualised with an ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 
and 658 nm. Images were collected with a x40 objective with the wavelengths for the collection 
channels set at:  480-560nm, EpCAM; 560-595 nm, cytokeratins; 642-745nm, survivin; 745-800nm, 
CD45; 430-505nm, DAPI. 
 
The processing of the blood prior to analysis may create cellular debris. Debris is 
present as irregular objects of differing size that frequently have a uniform 
fluorescence across the whole object. An example of a commonly identified 
population of such objects is shown in Figure 5.5. These objects appear 
morphologically to be rather flat two dimensional sheets and are significantly larger 
than either circulating tumour cells or white blood cells. The fluorescence 
corresponding to the tumour specific antibodies and nuclear stain is uniform across 
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the entire object. Commonly these objects do not show any fluorescence 
corresponding to the antibody against CD45. These objects do not appear to be 
cellular however it is possible, given the lack of CD45 labelling, that they represent 
debris from tumour cells. 
 
 
 
Figure 5.5 Fluorescently-labelled debris identified during processing of patient samples 
Five ml whole blood samples from patients undergoing staging of oesophageal adenocarcinoma were 
collected in Transfix (Cytomark, UK) tubes. The red blood cell component was lysed. Platelets were 
removed with centrifugation. EasySep™ anti-CD45 antibody complex was added to cell suspension 
followed by dextran-coated nanoparticles. The suspension was then diluted with Robosep™ buffer 
and placed in the EasySep™ magnet for ten minutes. The un-retained cell fraction was decanted into 
a clean tube by inversion of the sample and magnet. Cells were permeabilised by incubation with 0.3 
% saponin, incubated with antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and 
incubated subsequently with antibody against EpCAM, CD45 and with DAPI. All cells/objects were 
visualised with an ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 
and 658 nm. Images were collected with a x40 objective with the wavelengths for the collection 
channels set at:  480-560nm, EpCAM; 560-595 nm, cytokeratins; 642-745nm, survivin; 745-800nm, 
CD45; 430-505nm, DAPI. 
 
An unusual population of cellular objects was detected in large numbers in single 
patient sample (Figure 5.6). These objects appear to be often multinucleated with 
either an oblong or spindle morphology. In one of the objects there was evidence of 
survivin expression but there was otherwise no positive detection with any of the 
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panel of antibodies used. These objects do not look like circulating tumour cells. A 
possible explanation is that these objects may represent circulating tumour-
associated macrophages. Tumour-associated macrophages are specialised 
differentiated macrophages that can be found within most tumours (Heusinkveld and 
van der Burg, 2011). A study of patients with breast, prostate and pancreatic cancer 
identified a population of large circulating cells thought to represent disseminated 
tumour-associated macrophages. (Adams et al., 2014). It has been proposed that 
these giant macrophages may be a prognostic biomarker for some solid tumours. 
The images of the giant macrophages reported are very similar to those collected in 
the patient with oesophageal adenocarcinoma (Figure 5.6).  
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Figure 5.6 Circulating tumour-associated macrophages identified in patient samples 
Five ml whole blood samples from patients undergoing staging of oesophageal adenocarcinoma were 
collected in Transfix (Cytomark, UK) tubes. The red blood cell component was lysed. Platelets were 
removed with centrifugation. EasySep™ anti-CD45 antibody complex was added to cell suspension 
followed by dextran-coated nanoparticles. The suspension was then diluted with Robosep™ buffer 
and placed in the EasySep™ magnet for ten minutes. The un-retained cell fraction was decanted into 
a clean tube by inversion of the sample and magnet. Cells were permeabilised by incubation with 0.3 
% saponin, incubated with antibodies against cytokeratins 4, 5, 6, 8, 10, 13, and 18 and survivin and 
incubated subsequently with antibody against EpCAM, CD45 and with DAPI. All cells/objects were 
visualised with an ImagestreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 
and 658 nm. Images were collected with a x40 objective with the wavelengths for the collection 
channels set at:  480-560nm, EpCAM; 560-595 nm, cytokeratins; 642-745nm, survivin; 745-800nm, 
CD45; 430-505nm, DAPI. 
 
5.2.5 Patient Outcomes  
The number of circulating tumour cells detected in each patient sample is listed in 
Table 5.2. Circulating tumour cells were not detected in the majority of patients. In 
five cases, circulating tumour cells were identified. Four of these patients had at least 
stage 3 disease. In two samples only two circulating tumour cells were identified. 
Three samples had a relatively high number of circulating tumour cells, 85, 43, 17 
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and cells respectively. This corresponds to 128, 64 and 27 cells per 7.5 millilitre of 
blood (volume as measured by CellSearch platform). The highest number of cells 
was identified in the patient sample in which the circulating tumour cells had no 
fluorescence corresponding to the tumour specific antigens used. These cell 
numbers are comparable with those reported in other tumour types for patients with 
metastatic disease (Allard et al., 2004). 
 
Table 5.2 Circulating tumour cell numbers and outcomes for patients included in the study 
 
The overall survival of patients included in the study from time of diagnosis is 
illustrated in Figure 5.4. The median overall survival for all patients included in the 
study is 35% with a two year survival of 52%. For those patients who underwent neo-
adjuvant chemotherapy and surgery the median survival was again 35% with a 2 
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year survival of 66%. In this subgroup of patients the pattern of disease recurrence 
was distant metastatic in 5 patients and locoregional in 3 patients. 
The median follow up for the patients sampled in the study is 18 months. All follow up 
for patients who have undergone oesophagectomy is based on clinical assessment 
rather than radiological or endoscopic imaging. The latest follow up status of the 
patients included in the study is detailed in table 2. 
The small number of patients with positive circulating tumour cells makes interpreting 
their relevance to overall survival difficult. Four of the patients with detectable 
circulating tumour cells underwent surgery and peri-operative chemotherapy. The 
remaining patient underwent palliative chemotherapy alone. Of the four patients 
undergoing treatment with curative intent, three died of disease recurrence at 16, 28 
and 35 months. All had distant metastatic disease at the time of recurrence. The 
remaining patient was alive without disease recurrence at 47 months (Table 2). The 
presence of circulating tumour cells did not correlate with a worse overall survival in 
those patients undergoing treatment with curative intent (Figure 5.5B) 
 
 
Figure 5.7 Survival of patients included in study 
Kaplan-Meier plot of the overall survival of all patients (A.) included in the study and those patients 
who underwent treatment with curative intent (B.). Overall survival was calculated from date of 
diagnosis to death or follow up. Data was plotted using GraphPad Prism.  
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5.3 Discussion 
These results from patient samples demonstrate that circulating tumour cells can be 
detected in patients with oesophageal adenocarcinoma who have no evidence of 
distant metastatic disease by traditional staging modalities. In this patient cohort, only 
five out of 25 patients were found to have detectable circulating tumour cells. It is not 
possible to draw strong conclusions about the impact of these circulating tumour cells 
on clinical outcomes. There is equally little available literature with which to compare 
this finding. Only one study has reported the detection of circulating tumour cells in 
patients with non-metastatic oesophageal adenocarcinoma prior to undergoing 
surgical treatment. Cells were isolated based upon size using a filtration method 
(Bobek et al., 2014). This study included 14 patients and identified circulating tumour 
cells in 78.6%.  
It is very difficult to eliminate all subjectivity from the detection of circulating tumour 
cells. Where there is subjectivity there is the potential for error. Where there was 
doubt over whether objects did represent circulating tumour cells, the objects were 
reviewed independently by another researcher. The problem of subjectivity is not 
limited to our study. Many available methods for circulating tumour cell detection 
including the CellSearch® platform rely on trained operators who distinguish the 
circulating tumour cells from other non-cellular objects.  
One of the challenges highlighted through the analysis of these patient samples is 
distinguishing circulating tumour cells from other cellular or non-cellular debris. The 
high quality images captured with the Imagestreamx image flow cytometer are 
invaluable to this analysis.  Some of the circulating tumour cells detected with this 
method are very similar in both morphology and antigen expression to the 
established oesophageal adenocarcinoma cell lines used during the development 
and validation of the method. Circulating tumour cells that display considerable 
heterogeneity are also detected. The ability to detect all circulating tumour cells even 
in the presence of heterogeneity is a clear advantage of the method developed and 
helps to improve the accuracy of the study.  
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Chapter 6. Concluding Discussion 
 
6.1 Summary of work 
This thesis describes the development, validation and application of a novel method 
for detection of circulating tumour cells in patients with oesophageal 
adenocarcinoma. This method captures high resolution images of the individual 
circulating tumour cells. These cells can be enumerated accurately but the method 
has also the potential for tumour cell biology to be studied. Importantly, the method 
developed can be modified to allow for the detection of a number of different tumour 
cell types (Dent et al., 2016). 
Blood samples from patients undergoing staging for oesophageal adenocarcinoma 
prior to treatment were tested for the presence of circulating tumour cells. None of 
the patients included in the study had evidence of distant metastatic disease based 
upon radiological staging by computed tomography scan. Where detected, these 
cells were compared with commercial oesophageal adenocarcinoma cell lines. A 
clinical role for circulating tumour cells in oesophageal adenocarcinoma is yet to be 
determined. This research and described method provides a platform for future 
studies about a potential role of circulating tumour cells at different stages of 
oesophageal adenocarcinoma treatment. 
 
6.2 Patient cohort 
The majority of clinical studies about the role of circulating tumour cells have focused 
on patients with metastatic disease (Allard et al., 2004; Cristofanilli et al., 2004; de 
Bono et al., 2008). The overall tumour burden is greater than in patients without 
metastatic spread. It is far more likely that circulating tumour cells will be detected in 
oesophageal adenocarcinoma patients with metastatic disease than in those without.  
These patients represent a logical cohort in which to study circulating tumour cells 
because it is known that the cancer has already demonstrated ability to metastasise.  
This study focused deliberately on patients without known metastatic disease. A 
much lower detection rate of circulating tumour cells than might have been achieved 
had metastatic patients been included was anticipated and realised. The lower 
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detection rate of circulating tumour cells is a potential criticism of this work. It is 
difficult to draw firm conclusions about the relevance of the presence of circulating 
tumour cells at the time of diagnosis on patient outcomes. Whilst one of the patients 
with the highest number of circulating tumour cells did develop metastatic disease 
early after surgery, a second patient with circulating tumour cells was alive without 
evidence of disease recurrence 47 months from diagnosis.  
It is patients without metastatic disease who are most frequently encountered within 
my personal clinical practice. It is within this patient group that detection of circulating 
tumour cells could have the potential to influence the treatments patients will undergo 
as discussed in Chapter 1 (Section 1.4.2.).   Little is known about the relevance of 
circulating tumour cells in this patient group. It has been proposed that 
haematological metastasis is found at a very early stage of cancer development 
(Klein, 2008). With a sensitive method for detection, circulating tumour cells might be 
found in the majority of patients with cancer irrespective of stage. At the outset of the 
study there was no information about the frequency with which circulating tumour 
cells could be detected in patients with oesophageal adenocarcinoma without distant 
metastases. A single study of circulating tumour cells in patients with gastrointestinal 
tumours included ten patients with non-metastatic oesophageal squamous cell 
carcinoma (Hiraiwa et al., 2008). A mean number of only 0.1 +/- 0.3 circulating 
tumour cells were found in these patients using the Cellsearch® platform. 
Oesophageal squamous cell carcinoma and oesophageal adenocarcinoma are 
however two distinct diseases (Siewert and Ott, 2007) and these results are not 
transferable to patients with oesophageal adenocarcinoma.  
Metastatic oesophageal cancer has a dismal prognosis. Therapeutic options are 
limited with palliative chemotherapy only able to offer a very modest survival benefit 
(Grunberger et al., 2007). The enumeration of circulating tumour cells in this patient 
group offers only modest benefit to patients. The survival differences are modest in 
studies of cancers that have demonstrated a correlation between circulating tumour 
cells and prognosis (Cristofanilli et al., 2004; de Bono et al., 2008). A difference in 
overall survival of approximately 8 months was reported between patients with 
metastatic breast cancer stratified on the basis of detection of circulating tumour cells 
(Cristofanilli et al., 2004). These studies rarely lead to alterations in therapy. 
Measuring circulating tumour cells is expensive and time consuming. To have a 
widespread role in the modern NHS it must do more than it currently offers. It is likely 
110 
 
that future studies of circulating tumour cells in patients with metastatic cancer will 
focus more on cell biology and response to therapy as opposed to simple 
enumeration (Sacanna et al., 2011; Baccelli et al., 2013). In this regard the method 
developed during this study is well suited to future applications.  
 
6.3 Cohort size 
The number of patients included within this study was designed to allow validation of 
the method developed and to test whether circulating tumour cells could be identified 
in patients with oesophageal adenocarcinoma without radiological evidence of 
metastatic disease. A common criticism of studies linking circulating tumour cell 
levels to survival is that they do not provide adequate adjustment for confounding 
factors. In the context of oesophagectomy for example, factors such as post-
operative complication and even surgeon experience have been reported to influence 
oncological survival (Luc et al., 2015) (Booka et al., 2015) (Markar et al., 2016). To 
adequately adjust for all such variables would require a larger cohort of patients and 
be beyond the scope of this study.  
Measuring circulating tumour cells involves a single blood sample being taken at a 
single point in time. The volume of blood sampled at any one time is small, 
representing approximately 0.1% of the circulating blood volume. It is highly likely 
that the number of circulating tumour cells present in the bloodstream varies with 
time and potentially circulating tumour cells could be found in all patients with cancer 
at some stage. It is possible that circulating tumour cells would be detected in more 
patients if multiple samples were taken at different time points. There is an area of 
potential for future studies. It would be interesting to study the effect of treatments 
including neo-adjuvant chemotherapy and then surgery itself on the levels of 
circulating tumour cells found in patients.   
 
6.4 Biomarker selection 
There is no single oesophageal adenocarcinoma specific biomarker upon which to 
base the detection of circulating tumour cells. For other tumour types such as 
prostate and ovarian cancer, there is a clinically applicable biomarker, prostate 
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specific antigen (PSA) and cancer antigen 125 (CA125), respectively. In this study a 
combined panel of EpCAM, cytokeratin and survivin was used. All three antigens are 
not expressed by normal blood cells.  
One difficulty in detecting circulating tumour cells is the heterogeneity in antigen 
expression. Defining the criteria for positively identifying circulating tumour cells must 
take this heterogeneity into account. A large number of different methods of detection 
and hence definitions of circulating tumour cells have been described (Parkinson et 
al., 2012). Whilst some cells may express all chosen antigens, others may only 
express a single antigen. The fewer antigens expressed the more difficult it is to 
confidently identify a cell as being a circulating tumour cell. It is a difficult balancing 
act between capturing all heterogeneous circulating tumour cells and not accidently 
including non-cancerous objects. In this study, if doubt existed as to whether an 
object was a circulating tumour cell it was discounted. This may have resulted in a 
lower rate of circulating tumour cell detection. There were objects identified that 
looked morphologically like cells but did not express any antigens (Chapter 5). It is 
highly likely that these are circulating tumour cells but care must be taken when 
making this assumption. One limitation of the technique developed is that once 
imaged, objects are not retained and therefore cannot be subjected to any further 
downstream analysis. Future studies may include filtration methods for detecting 
circulating tumour cells that may allow for further analysis.  
During the processing of samples cellular debris is generated. The method we chose 
for white blood cell enrichment avoided passage of the blood sample over columns 
and reduced the debris produced. When processing cells added to blood and patient 
samples, the cellular debris was detected by some of the antibodies against tumour-
specific antigens (Chapter 5). It is likely that this interaction with the antibody is non-
specific in the majority of cases although it is possible that some of the cellular debris 
is derived from tumour cells as has been suggested by others. (Allard et al., 2004).  
 
6.5 Host response 
The host immune system plays an important role in tumour dissemination. In 
oesophageal adenocarcinoma surgery, post-operative septic complications have 
been reported to impact negatively on oncological outcomes (Lerut et al., 2009). 
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Post-operative blood transfusion has a similar negative impact on long term 
outcomes (Dresner et al., 2000), thought to be due to the immune suppression 
caused by transfusion (Takemura et al., 2003). The ability of circulating tumour cells 
to cause metastases involves interplay between the tumour cells and the host 
immune system. The role of the host response is not addressed in the majority of 
circulating tumour cell research. There is emerging evidence of the importance of this 
interaction, and the role that suppression of the host immune response plays in the 
dissemination of circulating tumour cells (Mohme et al., 2017).  
One advantage of the method developed in this thesis is that it could be applied to 
study this immune response. Whilst the work described in the developed protocol 
sought to remove as many white blood cells as possible a significant number are still 
processed and imaged. The only labelled antibody used to positively identify the 
white blood cells was against CD45. Additional antibodies could be added to the 
panel to study specific markers within the white blood cell population.   
 
6.6 Limitations of circulating tumour cell research 
There are a large number of reported techniques for the detection of circulating 
tumour cells (Parkinson et al., 2012). There are several commercially available 
platforms in addition to published methods such as that described in this thesis. It is 
likely that a single blood sample would yield a different number of circulating tumour 
cells if processed with different methods. If clinical decisions rely on single circulating 
tumour cells the difference in results obtained with differing techniques may be 
important. There is a lack of data providing comparisons between these differing 
techniques. Where such comparisons exist there are inevitably differences found in 
the number of circulating tumour cells detected by the different methods (Gervasoni 
et al., 2011; Hofman et al., 2011). Such a large number of described methods 
undermines clinical confidence in circulating tumour cells. To become widely 
accepted as a clinical tool there needs to be a greater understanding of the strengths 
and weaknesses of each approach.  
A criticism of circulating tumour cell enumeration is the assumption that all circulating 
tumour cells are identical. Studies that classify patients into prognostic groups based 
upon the number of circulating tumour cells rely on the hypothesis that every 
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circulating tumour cell has the same malignant potential. This may be an 
oversimplification. The majority of circulating tumour cells are likely to undergo cell 
death within the bloodstream and not lead to metastases, with the half-life for 
circulating tumour cells suggested to be as short as one or two hours (Meng et al., 
2004). An alternative clinical application of circulating tumour cell research may then 
be to focus on the cell biology of the tumour cells. In breast cancer, correlations have 
been reported between the cytokine CXCR4 expression within tumour cells and the 
development of metastases in bone (Sacanna et al., 2011). In oesophageal 
adenocarcinoma, CXCR4 expression in the primary tumour has been reported to be 
associated with the development of micrometastasis to lymph nodes and bone 
marrow (Kaifi et al., 2005). There is growing interest in the importance of HER 2 
expression and amplification in oesophageal adenocarcinoma cells and alternative 
chemotherapy regimens that may be used in HER-2 positive patients (Smyth et al., 
2016). The method developed in this study is ideal for research of this type. The 
panel of antibodies used in the detection of the circulating tumour cells could be 
expanded or modified to include antibodies against CXCR4 or HER 2, for example.  
There is equally debate as to the exact origin of circulating tumour cells. They are 
often described as originating from the primary tumour itself. Alternatively, they may 
be released from pre-existent metastatic or micro-metastatic disease. In breast 
cancer, circulating tumour cells have been detected in patients up to 22 years after 
treatment with curative intent (Meng et al., 2004). This late development of metastatic 
disease implies that a balance may exist between tumour cell replication and cell 
death within micrometastatic disease for many years after apparent curative 
treatment. It has been proposed that haematological spread of tumour occurs much 
earlier in the process of tumour development and growth than has been accepted 
previously (Klein, 2008). Circulating tumour cells may therefore be a very important 
population of cells to study to fully understand the process of cancer dissemination.  
There is clearly a difficulty in determining whether an individual circulating tumour cell 
has the potential to establish a secondary metastatic tumour. An alternative approach 
for research looking at the process of metastatic dissemination might be those cells 
that have already demonstrated this malignant potential. In oesophageal 
adenocarcinoma multiple lymph nodes are resected along with the primary tumour.  
Cancer cells found within these nodes are by definition metastatic cells that have 
spread via lymphatic drainage of the tumour. An interesting direction for future 
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studies would be to compare circulating tumour cells with tumour cells detected in 
metastatic lymph nodes. Analysis of primary tumour tissue and potentially tissue from 
distant metastatic sites could be included. Previous studies have reported that 
disseminated tumour cells in the bone marrow of patients with oesophageal 
adenocarcinoma have prognostic significance (Thorban et al., 2000; Vashist et al., 
2012). A short section of rib which is removed routinely at oesophagectomy to allow 
better access into the thorax, may be a better source of bone marrow than traditional 
iliac crest sampling (Mattioli et al., 2001). This routine sampling of the rib allows the 
metastatic cells within the bone barrow to be studied. It may be that a valuable role of 
circulating tumour cells is in helping to understand the process of tumour growth and 
dissemination.  
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Appendix A. Patient consent form 
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Use of Diagnostic Samples and Samples Taken During Therapy to Support Research into 
Diseases and Cancer – to be stored in the Newcastle Cancer Centre Biobank 
 
INFORMATION SHEET  
 
 
 
Why have I been approached?  
You will shortly be giving a sample of blood, or other fluid or solid tissue to confirm your diagnosis 
or to monitor your treatment. Although great progress has been made in the understanding of 
diseases and cancer in the last twenty years, we still have a lot to learn if we are to improve the cure 
rate further and learn how to prevent diseases including cancers occurring in the future. Many 
research projects require the use of cells taken from the cancer, blood, other body fluids, such as the 
fluid within the abdomen, and samples of tissues such as lymph glands in order to understand what 
has gone wrong. In addition we need many samples from healthy tissues. In order to help with such 
research, Newcastle is co-ordinating a local collection of stored tissue samples, blood and relevant 
fluids for use in research projects. This collection is called a “Biobank” 
 
We would like to ask you if we can keep a small amount of the samples which we need to take as 
part of your investigation or treatment to use in research projects to help our understanding of 
diseases and cancer and help us to develop better ways of treating patients. The samples we keep 
come from surplus material left over after we have completed routine hospital tests and this will not 
involve any additional procedures.  
 
The research we plan to do has been approved by the Newcastle & North Tyneside 1 Research Ethics 
Committee and will be regularly monitored by them. We occasionally send samples to other 
researchers in the UK and abroad. We only do this if the research they are undertaking is approved 
by their local ethics committee.  Research may involve the testing of your DNA but your identity 
will not be revealed to the research team. Although research will not be conducted for the purposes 
of making money it is possible that some of the results will be of value to commercial companies, for 
example in the development of new tests or treatments. 
 
This work will not directly benefit you now but may help patients with cancer in the future. You do 
not have to give permission for your samples to be stored. If you decline it will not affect your 
medical care in any way. 
 
What will happen if I take part?  
If you give approval for samples to be stored and used for research purposes, these will be taken 
from the material left over after routine tests have been performed. The samples would be taken at 
various stages of treatment, which may include diagnosis, end of treatment and at any other time of 
assessment. The research samples would only be taken when we are sure that there has been enough 
taken for the other tests to establish your diagnosis.  
 
What will happen to my specimens? 
The samples will be stored in the Newcastle Cancer Centre Biobank or at another research 
laboratory, approved for the purpose. These samples may be stored for many years before they are 
used. The samples may be used to extract DNA (the genetic material inside a cell) which will also be 
stored.  The samples are stored and labelled with a code number, which means that the only link 
between the sample code and any medical information is held at the local hospital.  Samples released 
133 
 
 
 
 
 
 
 Version 2.0/3rd September 2012 
Page 2    
from the Newcastle Cancer Centre Biobank for approved research projects may be transferred to 
other research laboratories only if they have approval from the appropriate ethical committee. 
 
Researchers may be given access to some information about your health and diagnosis but they will 
not be given any personal information that will identify you.  Similarly, any results from each 
research project will not be traceable back to you by either a researcher or your doctor.  All 
information on your samples will be kept at the Newcastle Cancer Centre Biobank in accordance 
with current national regulations (the Data Protection Act and Caldicott guidelines). 
 
How do I know that my specimens will only be used for ethically approved medical research? 
Approval has been given by the Newcastle & North Tyneside  Research Ethics Committee to 
perform research in Newcastle University on samples collected in the Biobank. The nature of this 
research will be regularly monitored by the committee.  As we do not have the resources to 
undertake all aspects of cancer research, other centres may be carrying out approved research 
projects different from those carried out at our centre.  It may be necessary from time to time to send 
them samples from patients treated at our centre.  Samples will only be released to other research 
centres if they can demonstrate that they have equivalent approval from an appropriate ethics 
committee. Any samples sent out of Newcastle would remain anonymous to the researcher and there 
is no way that the research teams can find out who the sample came from. 
 
Will I be told the results of research tests on my samples?  
No. Nor will the result be given to your hospital doctor or general practitioner. The overall results of 
the research projects will be published in the scientific literature.  In the future, if the research 
showed that there was a test which might be useful to you then you would be able to discuss the test 
with your doctor. 
 
 
What will happen to the information gathered about me? 
No personal identifiable information about you will be given to the scientists doing the research tests 
and any research carried out on your tissue that is linked to your medical condition will be done in a 
strictly anonymous way.  A link will be retained with your clinical information but this will be 
through a coding system and the research team will not be informed of your identity. Information 
from your medical notes relating to diagnosis, family history of cancer and response to treatment will 
be kept in the Newcastle upon Tyne Hospitals NHS Foundation Trust and stored in a strictly 
confidential manner according to the Data Protection Act. 
 
What are the possible risks of taking part? 
There are no extra risks involved in collecting the samples to be stored for research. 
 
Are there any possible benefits? 
The information learned from studies using the specimens obtained from you may help to improve 
treatment for future patients with cancer and possibly lead to the prevention of these diseases. 
 
Do I have to take part? 
No. Your participation in this study is entirely voluntary. Whether or not you decide to allow your 
specimens to be stored for research purposes will not affect you being given the best possible 
treatment for your disease. If at any time in the future you change your mind and do not wish the 
specimens to be used for research, then as soon as you have told your doctor, we will destroy any 
samples remaining in the biobank, usually by incineration. However, data already produced using 
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your samples will not be destroyed and it will not be possible to destroy samples which have been 
sent in anonymous form to research teams 
 
What should I do if I have any concerns about taking part? 
If you have any problems, concerns or other questions about this study, please feel free to speak to 
the medical or nursing staff who are involved in your care, or you can phone the doctor in charge of 
overseeing the storage of samples in the Biobank; Professor Andy Hall, Newcastle University (0191) 
246 4411 
 
NO CELLS, TISSUE OR OTHER BODILY MATERIAL WILL BE TAKEN OR STORED 
FOR RESEARCH WITHOUT YOUR AGREEMENT 
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SUPPLEMENTARY CONSENT FOR GIFTING OF CLINICAL 
SAMPLES 
 
Title of Project: Use of Diagnostic Samples and Samples Taken During Therapy to 
Support Research into Cancer – to be stored in the Newcastle 
Cancer Centre Biobank 
 
Name of Researcher:  Professor Andrew Hall, on behalf of the Newcastle Cancer Centre 
Biobank 
 
You will shortly be giving a sample of blood or other fluid or solid tissue to confirm your diagnosis or to 
monitor your treatment. 
 
Once your diagnosis has been made the remaining samples are very valuable for research. We therefore ask 
for your consent to allow use of any remaining sample for these purposes, by making a gift of the material to a 
research Biobank. A leaflet is available containing more information about the use of these samples and 
describing our policy for the safe keeping of tissue gifted in this way. 
 
Your diagnosis and treatment will not be adversely affected in any way by giving consent. Any research 
studies in which your samples are used will have been approved by the Newcastle & North Tyneside  
Research Ethics Committee or an equivalent organisation.  This is to ensure that the research is justified and 
meets current ethical standards. Research will be conducted anonymously, which means that your samples 
will be identified only by a code. Your personal details will not be accessible to researchers. Your 
confidentiality will be respected at all times.  
 
Some research may include testing your DNA.  Researchers will not know your identity and your samples will 
only be identified by an anonymised code. Your DNA will not be used for any other purposes other than 
approved medical research.  
 
We may use the samples in association with commercial research partners but human tissues are never sold 
(this is illegal). Our partnerships are organised on a not-for-profit basis, with any resulting benefits being used 
directly to improve patient care or to enable us to perform more research. Although the research will not be 
conducted for the purposes of making money it is possible that some of  the results will be of value to 
commercial companies, for example in the development of new tests or treatments. 
 
Most of the research conducted using the samples we obtain is conducted in the UK, but as the work we 
undertake is part of an international effort we sometimes send samples to centres outside the country- for 
example to mainland Europe or the USA. If you do not wish your samples to leave the country you can 
indicate this on the form we ask you to sign. 
 
Use of your tissue or cells for research in this way will not influence your treatment directly. Withholding 
consent will not affect your diagnosis or treatment in any way. If you do not wish to give consent, we 
guarantee that any sample surplus to needs for diagnosis is disposed of appropriately, following national 
guidelines. 
 
It may be necessary to gather information from your medical records that is relevant to the research being 
conducted, such as the type of treatment you are receiving.  This will only be done by a member of your 
healthcare team, or by someone that has a confidentiality agreement with the NHS Trust.  Your personal 
details and identity will never be passed on to researchers.  It may also be necessary for regulatory officials to 
check your medical records and laboratory data, to ensure that research is being carried out properly and in 
line with regulatory guidelines. 
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The donor should complete the whole of this sheet himself/herself 
(Please initial your response to question 1 and then proceed to questions a-j below) 
 
Q1. I agree to the use of my sample(s) after diagnosis 
for research 
Please initial here 
 
 
 
Please TICK box yes to agree and box no to decline    Yes     No 
a. Have you read and understood the patient information 
sheet? (Please take a copy home with you to keep) 
  
b. Have you had an opportunity to discuss the Biobank 
and ask any questions? 
  
c. Have you had satisfactory answers to your questions 
from Prof/Dr/Sr …………..? 
  
d. Do you understand that you are free to withdraw your 
consent from the Biobank at any time without having 
to give a reason and without affecting your future 
medical care? 
  
e. Do you agree to donate any samples left over after 
clinical requirements, for use in future approved 
research projects? 
  
f. Do you understand that you will not be told the results 
of any tests which may be carried out on your samples might be useful to your child, in which case your doctor will be contacted? 
  
g. Do you give permission for your medical information 
to be stored? be stored? 
  
h. Do you give permission for samples to be sent to 
centres outside the UK? 
  
i. Do you understand that relevant sections of your 
medical notes and data collected during the study may 
be looked at by individuals from regulatory authorities 
or from the NHS Trust, where it is relevant to you 
taking part in this research? Do you give permission 
for these individuals to have access to your records? 
 
  
j. Do you give permission for your DNA to be tested for 
the purposes of research? 
  
 
Patient (& Hospital 
number) 
 
 
Date Signature 
Person taking consent Date Signature 
 
 
  
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
Biobank Manager Contact Details: Professor Andy Hall, Tel: (0191) 246 4411 
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High-resolution imaging for the detection and characterisation
of circulating tumour cells from patients with oesophageal,
hepatocellular, thyroid and ovarian cancers
Barry M. Dent1,2, Laura F. Ogle1, Rachel L. O’Donnell1,3, Nicholas Hayes2, Ujjal Malik4, Nicola J. Curtin1, Alan V. Boddy1,
E. Ruth Plummer1,4, Richard J. Edmondson1,3, Helen L. Reeves1,5, Felicity E.B. May1,6 and David Jamieson1
1 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
2 Newcastle upon Tyne Hospitals NHS Foundation Trust, Northern Oesophago-Gastric Cancer Unit, Newcastle upon Tyne, United Kingdom
3Queen Elizabeth Hospital, Northern Gynaecological Oncology Centre, Gateshead, United Kingdom
4 Newcastle upon Tyne Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom
5 Newcastle upon Tyne Hospitals NHS Foundation Trust, The Liver Unit, Newcastle upon Tyne, United Kingdom
6Newcastle University Institute for Ageing, Newcastle upon Tyne, United Kingdom
Interest has increased in the potential role of circulating tumour cells in cancer management. Most cell-based studies have
been designed to determine the number of circulating tumour cells in a given volume of blood. Ability to understand the biol-
ogy of the cancer cells would increase the clinical potential. The purpose of this study was to develop and validate a novel,
widely applicable method for detection and characterisation of circulating tumour cells. Cells were imaged with an Image-
StreamX imaging flow cytometer which allows detection of expression of multiple biomarkers on each cell and produces high-
resolution images. Depletion of haematopoietic cells was by red cell lysis, leukocyte common antigen CD45 depletion and dif-
ferential centrifugation. Expression of epithelial cell adhesion molecule, cytokeratins, tumour-type-specific biomarkers and
CD45 was detected by immunofluorescence. Nuclei were identified with DAPI or DRAQ5 and brightfield images of cells were
collected. The method is notable for the dearth of cell damage, recoveries greater than 50%, speed and absence of reliance
on the expression of a single biomarker by the tumour cells. The high-quality images obtained ensure confidence in the speci-
ficity of the method. Validation of the methodology on samples from patients with oesophageal, hepatocellular, thyroid and
ovarian cancers confirms its utility and specificity. Importantly, this adaptable method is applicable to all tumour types includ-
ing those of nonepithelial origin. The ability to measure simultaneously the expression of multiple biomarkers will facilitate
analysis of the cancer cell biology of individual circulating tumour cells.
Detection of circulating tumour cells (CTCs) was first
reported more than a century ago.1 Interest in the clinical
role of CTCs has increased with the development of
improved technologies for their detection. The initial focus of
research on cell-based detection has been on the enumeration
of CTCs. Studies have sought evidence that the burden of
tumour cells in the circulation of patients with advanced can-
cer provides prognostic or predictive information. High num-
bers of CTCs in patients undergoing chemotherapy for
metastatic breast, colorectal and prostate cancer are associ-
ated with poor patient prognosis.2–4
The introduction of novel agents that target-specific
molecular aberrations within cancer cells has driven explora-
tion for biomarkers with which to inform accurate stratifica-
tion of patients. Currently, biomarker profiles of tumour cells
are measured on material obtained by surgical resection or
invasive biopsy. CTCs are a source of disseminated malignant
cells from which information about biological properties, or
pharmacodynamic responses to novel therapeutics, may be
obtained noninvasively.
Effective enumeration and characterisation depend upon a
reliable method for the evaluation of CTCs. Detection of
small populations of CTCs within the large number of nor-
mal blood cells represents a significant technical challenge. A
single CTC may be detected in 7.5 ml of blood,5 a volume
that may contain up to 75 million leukocytes and 50 billion
erythrocytes. Enrichment of the sample is required before
tumour cell identification and characterisation can occur.
This enrichment may consist of positive selection of the
Key words: circulating tumour cells, oesophageal adenocarcinoma,
hepatocellular carcinoma, thyroid carcinoma, ovarian cancer,
ImageStreamX imaging flow cytometry
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CTCs, positive depletion of the normal blood cells or a com-
bination of the two approaches. A perfect method would
remove completely the red blood cells, white blood cells and
platelets, produce no cellular debris and recover all the CTCs.
The majority of clinical studies reported have relied upon
positive selection of tumour cells that express a single bio-
marker.6–13 The antigen chosen most commonly is epithelial
cell adhesion molecule (EpCAM).
We sought to develop a method for identification, quanti-
fication and characterisation of CTCs that would not rely
upon expression of a single antigen and would be applicable
to multiple tumour types. Additional aims were to obtain
high-resolution images of the cells, avoid cell damage, achieve
high sensitivity and specificity and have the ability to analyse
the expression of multiple biomarkers in each tumour cell.
We report the development of our method, and its validation
with whole blood from patients with oesophageal, hepatocel-
lular, thyroid and ovarian cancers.
Materials and Methods
Tissue culture
SK-GT-4 oesophageal adenocarcinoma cells (DSMZ,
Braunschweig, Germany) and OVCAR-3 ovarian cancer cells
(ATCC) were grown in RPMI supplemented with 10% foetal
calf serum (FCS). ML1 thyroid cells (DSMZ, Braunschweig,
Germany) were grown in DMEM supplemented with 10% FCS
(Life Technologies, Paisley, UK). Huh-7 hepatocellular carci-
noma cells (ATCC) were grown in DMEM with F12 Ham’s
nutrient and 10% FCS. All other reagents were purchased from
Sigma-Aldrich (Poole, UK) unless stated otherwise.
Cells were maintained in exponential growth at 378C in a
humidified atmosphere, supplied with 5% CO2 and discarded
after the 30th passage. Cells were confirmed to be myco-
plasma free (MycoAlert mycoplasma detection kit; Lonza).
Immunofluorescence
Cells were fixed by incubation in 0.4% formaldehyde for 20
min, or Phosflow Lyse/Fix buffer (BD, Oxford, UK) and per-
meabilised by incubation in Perm/Wash buffer (BD, Oxford,
UK) for 1 hr at room temperature. Cells were incubated with
1:20 antipan-cytokeratin (clone C-11) PE (Cayman Chemical)
and appropriate tumour-specific intracellular antibodies for
30 min at room temperature: 1:50 antisurvivin Alexa FluorVR
647 (Cell Signaling); 1:50 antiMUC16 which is known as
carcinoma antigen 125 (CA-125) (Abcam) Alexa FluorVR 594,
conjugated with an APEXTM kit (Invitrogen) as per manufac-
turer’s instructions; 1:50 antialpha faetoprotein Alexa FluorVR
594 (Cell Signaling). Membrane antibodies and nuclear stains
were added and incubated for 1 hr at room temperature: 1:20
anti-CD45 (clone H130) V450 or PE:Cy7 (BD Biosciences);
1:20 anti-EpCAM CD326 (clone 9C4) Alexa FluorVR 488 (Biol-
egend); DAPI or DRAQ5 (Biostatus, UK). Cells from thyroid
cancer patients were incubated first with 1:50 antisodium:io-
dide symporter (NIS; Milipore) followed by anti-mouse Texas
Red (Life Technologies, UK). Subsequent incubations were as
described above except that the anti EpCAM CD326 (clone
9C4) was conjugated to PerCP:Cy5.5 (Biolegend). Cells were
washed in 500 ml of Perm/Wash buffer and recovered by cen-
trifugation at 500 g for 5 min and either analysed immediately
or stored as a pellet at 48C until analysis.
High-resolution flow cytometry
Cells were resuspended in phosphate-buffered saline (PBS)
and divided into 60 ml aliquots. Aliquots were analysed with
an ImageStreamX (Amnis) image flow cytometer with an 8-
mm core at 60 mm/sec with 7% Speed BeadsVR . Speed BeadsVR
are a 1 lm polystyrene beads that allow calibration of the
flow and focus of the ImageStreamX. Fluorochromes were
excited with 405, 488, 561 and 642 nm lasers and light emit-
ted by the fluorescently-labelled cells was collected through a
340 objective. Of the twelve channels available, channels 1
and 9 were reserved for brightfield images. The other chan-
nels were set to collect magnified emitted light with two
CCD cameras, each spatially resolved into five distinct spec-
tral bandwidths, over a range of wavelengths between 430
and 745 nm. Single-colour reference samples for each fluoro-
chrome were generated by inclusion of cells that had been
incubated with each antibody separately. A compensation
matrix was built with the data from single-colour reference
samples to allow removal of spectral overlap to adjacent chan-
nels from each detection channel. The diameters of individual
cells detected were measured and are given as means6 stan-
dard errors of the mean for different populations of cells.
Detection of cells in whole blood
Ethical approval for the study was obtained from the New-
castle and North Tyneside Research Ethics Committee. An
initial predraw of 4 ml of blood was discarded to reduce
What’s new?
Circulating tumour cells (CTCs) are disseminated malignant cells from which biological and therapeutic information may be
obtained non-invasively. Detection of small CTC populations within the large number of normal blood cells is a challenge. This
study describes a novel method for the detection and high-resolution imaging of CTCs. Unlike most other studies, CTC detec-
tion is not reliant upon expression of a single biomarker. The method is applicable to all cancers; the authors present prelimi-
nary results from four tumour types. The high quality of the images allows biological characterisation of the tumour cells and
increases the clinical potential of the approach.
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contamination with epithelial skin cells. Blood samples were
collected in Transfix collection tubes (Cytomark, UK) to store
for up to 24 hr at 48C or BD Vacutainer EDTA tubes (BD
Biosciences) for immediate use.
For each cell recovery experiment, 12 ml-blood samples
were collected from healthy volunteers. Cells from cancer cell
lines were trypsinised and resuspended in media. Cells were
counted with an improved Neubauer haemocytometer
(Hawksley, UK) and were diluted twice by 1 in 10. The
appropriate volume of cells containing 2,000, 200 or 20 cells
was added to 4 ml blood samples to give 500, 50 and 5
malignant cells/ml of whole blood.
To determine the contribution of the final stage of the
imaging flow cytometric analysis to the overall recovery rates,
500 unprocessed cells were analysed directly with the Image-
StreamX flow cytometer. Cells were imaged in the brightfield
channel and images with cellular morphology were counted.
Analysis of patient samples
Whole blood samples were obtained from patients under-
going treatment for oesophageal adenocarcinoma, hepatocel-
lular carcinoma, thyroid carcinoma or ovarian cancer at the
Newcastle-upon-Tyne and Gateshead NHS Foundation
Trusts, UK. Patient clinical data was recorded for each
patient in accordance with ethical approval. In addition
whole blood samples were obtained from healthy volunteers
who had no medical history of any current or previous can-
cer. CTCs were defined by the presence of at least one
tumour-specific antigen, the absence of CD45, the presence
of a nucleus and cellular morphology as assessed by bright-
field imaging. CTC images were verified independently by
two members of the research group.
Depletion of haematopoietic cells
Patient and healthy volunteer samples were processed to
enrich for nonhaematopoietic cells prior to analysis. Cells
were transferred into 50 ml Falcon tubes, incubated in 5 ml
of 5% bovine serum albumin (BSA) in AutoMACS rinse
solution (Miltentyi Biotec, Germany). Human FcR blocking
reagent (Miltenyi Biotec, Germany) was added directly to the
blood to a final dilution of 1:40 to prevent nonspecific anti-
body binding. Red blood cells were lysed, and all other cells
fixed, by incubation in BD Phosflow Lyse/Fix buffer 1:20
(v:v; BD Biosciences) for 15 min at 378C. Fixed, unlysed cells
were collected by centrifugation at 500 g at room tempera-
ture for 8 min. The supernatant was discarded and the cells
were resuspended in 500 ml RoboSep buffer (Stemcell Tech-
nologies, UK) in a polystyrene Falcon tube (BD Biosciences).
White blood cells were removed with an EasySep human
CD45 depletion kit (Stemcell Technologies, UK) as per the
manufacturer’s instructions. Briefly, antibodies against CD45,
bound in tetrameric complexes were added to the cell sus-
pension and incubated for 15 min at room temperature.
Dextran-coated magnetic nanoparticles were added and incu-
bated with the cells for 10 min at room temperature. The cell
suspension was diluted in 5 ml of Robosep buffer and placed
in an EasySepTM big easy magnet (Stemcell Technologies,
UK) for 10 min at room temperature. The unretained cell
Figure 1. EpCAM, cytokeratin, survivin and CD45 expression in oesophageal adenocarcinoma cells and in white blood cells. SK-GT-4 cells
were grown to 80% confluence in routine culture medium, trypsinised and 1 3 106 cells fixed with 1% formalin. Cells were permeabilised
by incubation with 0.3% saponin, incubated overnight with antibodies against cytokeratins 4, 5, 6, 8, 10, 13 and 18, and CD45, and incu-
bated subsequently with antibodies against EpCAM and survivin. Cells were washed, re-suspended in 100 ll and 2 ll DAPI added. Cells
were visualised with an ImageStreamX flow cytometer with the lasers set to emit excitation at 405, 488, 561 and 658 nm (a). Red blood
cells were removed from whole blood by ammonium chloride lysis, the remaining blood cells were concentrated by centrifugation, fixed,
permeabilised and incubated with antibodies against EpCAM, cytokeratins 4, 5, 6, 8, 10, 13 and 18, survivin and CD45 as in (a). Blood
cells were concentrated, incubated with DAPI and visualised (b). Images were collected with a 340 objective with the wavelengths for the
collection channels set at: 480–560 nm, EpCAM; 560–595 nm, cytokeratins; 745–800 nm, CD45; 430–505 nm, DAPI; and 642–745 nm,
survivin.
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fraction was decanted into a clean tube by inversion of the
sample and magnet. The recovered cells were centrifuged at
250 g for 5 min, resuspended in 1 ml Perm/Wash buffer
(BD, Oxford, UK), incubated for 1 hr at room temperature
and processed for analysis by image flow cytometry.
Results
Image flow cytometry of malignant cells
Four distinct tumour types were selected for development of
a universal method for detection of CTCs. Expression of
EpCAM and cytokeratins 4, 5, 6, 8, 10, 13 and 18 was chosen
for detection of the malignant cells. In addition, detection of
expression of tumour- or tissue-specific markers was
included: for hepatocellular carcinoma, alpha-faetoprotein;
for thyroid carcinoma, thyroglobulin and sodium:iodide sym-
porter (NIS) and for ovarian cancer, cancer antigen 125 (CA-
125). There is no accepted tumour-specific marker for oeso-
phageal adenocarcinoma, but survivin expression is reported
to be high and measurement of its expression was included
for this tumour type.
Initially, detection was optimised with established cell
lines. SK-GT-4 oesophageal adenocarcinoma cells were incu-
bated with fluorescently-conjugated antibodies against
EpCAM, cytokeratins 4, 5, 6, 8, 10, 13 and 18, and with
DAPI, a fluorescent dye that binds DNA. A fourth conju-
gated antibody against leukocyte common antigen CD45 was
included because it would allow subsequent discrimination of
leukocytes. Cells were analysed for expression of the antigens
with an ImageStreamX image flow cytometer. Representative
images from three cells are shown in Figure 1a. The different
images obtained from a single cell are shown in each hori-
zontal panel. The brightfield image of the cell shown on the
left hand side of each panel allows visualisation of the
nucleus, plasma membrane and overall cell morphology. All
three cells have cytoplasmic immunoreaction for EpCAM,
with some evidence of intracellular vesicular accumulation
and membrane localisation. The immunoreaction for the
cytokeratins was less intense, but evident in the cytoplasmic
compartment of all cells. Survivin expression was detected in
the nuclei of the cells coincident with the localisation of the
DAPI DNA dye. The composite images shown on the right
hand side of the panels confirm localisation of EpCAM and
the cytokeratins in the cytoplasmic and membrane compart-
ments of the cells and the distinct localisation of survivin in
the nuclei. Expression of CD45 was not detected in SK-GT-4
oesophageal adenocarcinoma cells.
Hepatocellular Huh-7 cells, ML1 thyroid cells and
OVCAR 3 ovarian cells were analysed as described above
except that the antibody against survivin was replaced with
antibodies against alpha-faetoprotein, thyroglobulin and NIS,
and CA-125, respectively. Images of comparable quality to
those shown in Figure 1a were obtained for all three cell lines
(data not shown). Alpha-faetoprotein, thyroglobulin and NIS,
and CA-125 were detected in Huh-7, ML1 and OVCAR 3
cells, respectively. These results demonstrate the applicability
of the method to the detection of multiple tumour types, the
measurement of tumour-type-specific biomarkers and the
high quality of the images that may be obtained.
Detection of malignant cells in, and recovery from,
whole blood
It was important to demonstrate the specificity of our
method with whole blood from healthy individuals. Blood
was collected, red blood cells were lysed and the remaining
blood cells collected by centrifugation. These blood cells were
incubated with antibodies against EpCAM, cytokeratins 4, 5,
6, 8, 10, 13 and 18, survivin and CD45, centrifuged at low g-
force to remove platelets and analysed for expression of the
antigens by image flow cytometry (Fig. 1b). The brightfield
images demonstrate that the cells detected are of smaller
diameter (12.26 0.2 mm) than the SK-GT-4 oesophageal cells
(20.36 0.2 mm; unpaired t test, p< 0.001); nearly all express
CD45. Fifty-three blood samples from healthy individuals
have been analysed with the tumour-specific antibodies. No
cells were detected with morphology consistent with a malig-
nant cell and expression of a tumour-specific antigen. These
results indicate that the detection method will discriminate
effectively nonhaematopoietic cells from haematopoietic cells.
Despite the ability of the ImageStreamX flow cytometer to
image 2,000 cells/sec, the large number of cells in whole blood
means that analysis is extremely lengthy and produces an
enormous amount of data for analysis and storage. We investi-
gated the best method with which to enrich blood for nonhae-
matopoietic cells. For these experiments, known numbers of
Figure 2. Enrichment for nonhaematopoietic cells. Cultured malig-
nant cells were added to 4 ml of whole blood and cells were incu-
bated with tetrameric antibody complexes against CD45 and
dextran-coated magnetic particles for 1 hr and placed in an Easy-
Sep Big Easy magnet. Cells not attracted to the magnet were recov-
ered. The number of leukocytes was counted with a
haemocytometer prior to and after depletion. Erythrocytes were
removed by lysis and platelets by centrifugation at 250 g.
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cultured malignant cells were added to samples of whole blood
and then the malignant cells were purified and analysed by
image flow cytometry. Positive selection of the malignant cells
involved identification of a universally expressed antigen or
differential separation on the basis of density. All methods
tested gave low recovery of the malignant cells and the cells
that were recovered were damaged physically as assessed by
the images produced (data not shown). We therefore devel-
oped a method for positive depletion of haematopoietic cells.
After initial lysis of the erythrocytes; the leukocytes, platelets
and malignant cells were incubated with tetrameric antibody
complexes against CD45 and dextran-coated magnetic par-
ticles. The cells were placed in a magnet and those not
attracted to the magnet were recovered. The method was opti-
mised to minimise loss of nonhaematopoietic cells whilst maxi-
mising depletion of CD45 positive cells.
Depletion of leukocytes was consistently 956 0.8% (Fig. 2).
The recovered cells were incubated with detection antibodies
and DAPI, centrifuged at 250 g to remove platelets and ana-
lysed by high-resolution image flow cytometry as described
above. Analysis of cells enriched from 1 ml of blood takes 20
min in the ImageStreamX flow cytometer whereas analysis of
1 ml of blood without prior enrichment takes 180 min. Images
of the malignant cells and residual leukocytes were similar to
those shown in Figure 1, which confirms that minimal damage
to the malignant cells is caused by this enrichment method of
positive blood cell depletion (data not shown).
The malignant cells are distinguished from residual leuko-
cytes by expression of epithelial cell- and tumour-specific
antigens, absence of expression of CD45, and by their mor-
phology and larger size. Analysis of the images obtained with
the IDEAS Software enables automatic discrimination of the
two cell populations. The first selection is based upon the
intensity of the nuclear dye retained by the cells (Fig. 3a).
The sharp peak around zero contains beads and small par-
ticles of debris. The peak of intensity between 3 and 4 3 105
fluorescence units contains single leukocytes. The third peak
of intensity between 5 and 8 3 105 fluorescence units con-
tains malignant cells and doublets of white blood cells and is
analysed further. Subsequent selection is based upon absence
of CD45 expression and presence of expression of EpCAM,
cytokeratins and survivin, alpha-faetoprotein, thyroglobulin,
NIS or CA-125. The effectiveness of the discrimination is
illustrated in Figure 3b; one population of cells expresses
CD45 but not EpCAM while the second population expresses
EpCAM but not CD45. Cells that express one or more of the
epithelial- or tumour-specific antigens and do not express
CD45 are selected automatically with the IDEAS Software.
The images of each of these cells are examined visually to
confirm that they have a cellular morphology as shown in
Figure 1 and that the IDEAS Software is able to distinguish
the malignant cells from any residual haematopoietic cells.
We processed, imaged and analysed 5 ml blood samples
from 24 healthy volunteers as described above. Blood was
enriched by CD45-positive cell depletion, incubated with the
detection antibodies and analysed by ImageStreamX flow
cytometry. The majority of the residual white blood cells
were detected with the CD45 antibody. None of the cells
imaged within the healthy volunteer samples met the criteria
for classification as a CTC.
Figure 3. Discrimination of the malignant cell population in whole blood from the residual leukocytes after positive depletion of blood cells.
Cultured malignant SK-GT-4 cells were added to 4 ml of whole blood. Erythrocytes were removed by ammonium chloride lysis and platelets
by centrifugation at 250 g. The cells in the supernatant were incubated with tetrameric antibody complexes against CD45 and dextran-
coated magnetic particles for 1 hr and placed in an EasySep Big Easy magnet. The cells not attracted to the magnet were recovered and
analysed in an ImageStreamX flow cytometer as described in the legend to Figure 1. The number of images at each DAPI fluorescence inten-
sity is shown (a). The intensity of fluorescence for the CD45 antibody is compared with the intensity of fluorescence of the EpCAM antibody
for all cells distinguished (b).
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The efficiency of recovery of malignant oesophageal, hepa-
tocellular, thyroid and ovarian cells from whole blood was
evaluated. The cell recovery across the four tumour types was
57.36 3.6, 49.26 3.9 and 59.06 5.6% from 500, 50 and 5
cells/ml of blood, respectively (Fig. 4). We investigated specif-
ically the recovery during the final analysis with the image
flow cytometer. The recovery during analysis of known num-
bers of cells by image flow cytometry was 89.21/26.2%,
which means that the recovery during the red blood cell lysis,
white blood cell depletion, centrifugation and antibody label-
ling steps was 61.9% to give an overall recovery of 55.2%.
Detection and analysis of circulating tumour cells
To validate the method, blood samples from six individual
patients with oesophageal, hepatocellular, thyroid and ovarian
cancer were analysed essentially as described above. Repre-
sentative images of tumour cells detected for each of the four
tumour types are shown in Figure 5. The morphology of the
oesophageal tumour cells detected was similar to that of the
cultured cells. All of the oesophageal CTCs detected
expressed EpCAM, cytokeratins and survivin. CTCs were
detected in two of the six oesophageal adenocarcinoma
patients analysed (Table 1). None of these patients had mac-
roscopic evidence of metastatic disease. The mean diameter
of all the circulating oesophageal adenocarcinoma cells
detected was 17.26 0.4 mm.
CTCs were detected in blood from four out of six patients
with hepatocellular carcinoma (Figs. 5b and 5c). Some of the
CTCs from patient seven expressed EpCAM but cytokeratins
were not detected, and other cells expressed cytokeratins but
EpCAM expression was not detected. None of the CTCs from
this patient expressed alpha-faetoprotein. Alpha-faetoprotein
was detected in cells from patient ten that did not express
EpCAM or the cytokeratins (Fig. 5c). The morphology of the
hepatocellular tumour cells varied. The diameter of the hepato-
cellular carcinoma cells was 216 0.6 mm which is significantly
larger than the diameter of the CTCs from all three other
tumour types (unpaired t test, p< 0.001)
CTCs were detected in three of the six patients with thy-
roid cancer. The majority of these tumour cells expressed
cytokeratins, thyroglobulin and NIS. EpCAM expression was
low or undetectable. The highest number of CTCs was
detected in blood from a patient with known metastatic dis-
ease. A third of their CTCs had clear membrane and cyto-
plasmic immunoreactivity for thryoglobulin, NIS and
cytokeratins, no obvious morphological damage and well-
defined oval nuclei (Fig. 5d). These CTCs stained intensely
with DAPI possibly because they were aneuploid or were in
the G2 stage of the cell cycle. The other cells expressed lower
levels of cytokeratins, did not express detectable levels of thy-
roglobulin, NIS or EpCAM and stained less intensely with
DAPI (Fig. 5d). These differences may represent heterogene-
ity of expression of biomarkers within the cells or the second
group of cells may be undergoing cell death. The diameter of
the circulating thyroid cancer cells was 166 0.3 mm.
CTCs were detected in blood from four out of six patients
with ovarian cancer. The cells all expressed EpCAM and
cytokeratins. CA-125 expression was detected in around half
of the tumour cells (Fig. 5e). The diameter of the CTCs
detected in blood from ovarian cancer patients was
13.66 0.59 mm. This diameter was significantly smaller than
the diameters of CTCs detected in oesophageal adenocarci-
noma, thyroid cancer and hepatocellular carcinoma patients
(p< 0.001).
Discussion
We report a method for the detection and accurate character-
isation of CTCs by high-resolution image flow cytometry.
We demonstrate that this method is reproducible in samples
from four tumour types. EpCAM was included within our
panel of antigens, but could be replaced with other bio-
markers for detection of nonepithelial malignant cells. Simi-
larly as novel biomarkers are discovered, analysis of these
could be incorporated. The method could be adapted also for
measurement of pharmacodynamic biomarkers. The process
of enrichment that we describe is based exclusively upon the
positive depletion of haematological cells. Following this
Figure 4. Retrieval of malignant cells from whole blood. SK-GT-4,
Huh-7, ML1 and OVCAR 3 cells were added to 4 ml of whole blood
to give a final concentration of 500, 50 and 5 malignant cells/ml.
The samples were enriched for malignant cells by depletion of
blood cells and the residual cells were incubated with fluorescent
antibodies and nuclear dye and analysed by high-resolution flow
cytometry as described in the Materials and Method. The mean
recoveries (6SEM) across the four tumour types were 57.363.6,
49.263.9 and 59.065.6% from 500, 50 and 5 cells/ml of blood,
respectively. Experiments were replicated at least thrice.
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Figure 5. Detection of circulating tumour cells in blood from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Blood
was obtained from patients, enriched for nonhaematopoietic cells and incubated with antibodies against EpCAM, cytokeratins 4, 5, 6, 8, 10,
13 and 18, CD45 and either survivin (oesophageal; a), alpha-faetoprotein (AFP) (hepatocellular; b and c), thyroglobulin and sodium:iodide
symporter (thyroid; d) or CA-125 (ovarian; e). Cells were incubated with DAPI (a and d) or DRAQ5 (b, c and e) and analysed by high-resolution
flow cytometry. Representative images of cells are shown. Small particles visible in some brightfield images represent the Speed BeadsV
R
that
are added to allow calibration of the objective and camera.
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depletion, CTCs are distinguished from residual leukocytes
and cellular debris by analysis of the expression of multiple
antigens and by examination of cellular morphology in the
high quality images.
The main focus of CTC research has been the value of
CTC enumeration for prognosis discrimination in patients
with metastatic disease and for prediction of response to
cytotoxic therapy. Levels of CTCs are associated with overall
Table 1. Patient demographics and numbers of circulating tumour cells in blood from patients with oesophageal, hepatocellular, thyroid and
ovarian cancers
Patient
no.
Tumour
origin Tumour type Sex Age
Disease
stage1
Distant
metastatic
disease
Previous
therapy
CTCs
detected2
CTCs
in
7.5 ml
1 Oesophagus Adenocarcinoma Male 59 T2N2M0 No No 43 64
2 Oesophagus Adenocarcinoma Male 63 T3N2M0 No No 17 27
3 Oesophagus Adenocarcinoma Male 83 T1N0M0 No No 0 0
4 Oesophagus Adenocarcinoma Female 74 T3N1M0 No No 0 0
5 Oesophagus Adenocarcinoma Male 65 T2N0M0 No No 0 0
6 Oesophagus Adenocarcinoma Male 72 T3N2M0 No No 0 0
7 Liver Hepatocellular
carcinoma
Male 70 T1N0M0 No TACE3/SIRT4 20 37
8 Liver Hepatocellular
carcinoma
Female 62 T2N0M0 No TACE3 0 0
9 Liver Hepatocellular
carcinoma
Male 93 Unknown No No 0 0
10 Liver Hepatocellular
carcinoma
Male 75 T3bN0M0 No No 9 16
11 Liver Hepatocellular
carcinoma
Male 81 T1N0M0 No TACE3 2 4
12 Liver Hepatocellular
carcinoma
Female 85 T1N0M0 No TACE3 2 4
13 Thyroid Medullary thyroid
cancer
Male 49 T2N2M1 Yes Surgery 4 4
14 Thyroid Multifocal follicular
variant of papillary
thyroid cancer
Female 29 T1aN0M0 No Surgery
Thyroxine
0 0
15 Thyroid Follicular thyroid
cancer
Female 47 T2N0M0 No Surgery
Thyroxine
Radioiodine
1 1
16 Thyroid Papillary thyroid
cancer
Male 61 T4N2M1 Yes Surgery
Thyroxine
Radioiodine
radiotherapy
118 118
17 Thyroid Follicular variant
of papillary
thyroid cancer
Female 52 T3N0M0 No Surgery
Thyroxine
Radioiodine
0 0
18 Thyroid Follicular variant of
papillary thyroid
cancer
Female 50 T2N0M0 No Surgery
Thyroxine
Radioiodine
1 1
19 Ovary Serous Female 50 FIGO Stage 4 Yes No 30 45
20 Ovary Serous Female 66 FIGO Stage 3c Yes No 15 23
21 Ovary Mucinous Female 75 FIGO Stage 3c Yes No 5 8
22 Ovary Serous Female 54 FIGO Stage 3c Yes No 0 0
23 Ovary Serous Female 85 FIGO Stage 4 Yes No 4 6
24 Ovary Serous Female 72 FIGO Stage 3c Yes No 0 0
1Disease stage is provided according to the latest UICC TNM classification for oesophageal, hepatocellular and thyroid cancer, and the FIGO classifi-
cation is shown for ovarian cancer.
2The volume of blood analysed was 5 ml for patients with oesophageal and ovarian cancers, 4 ml for those with hepatocellular carcinoma and
7.5 ml for thyroid cancer patients.
3Transarterial chemoembolisation.
4Selective internal radiotherapy treatment.
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survival in pre- and on-treatment patients with metastatic
breast cancer, metastatic colorectal cancer and castration-
resistant prostate cancer.2,3,14–19 The numbers of CTCs
detected in patients with metastatic cancer are often low, and
because detection of a single CTC may determine whether a
patient is categorised into a good or a bad prognostic
group,2,3 it is important that all CTCs are detected, not only
specific subpopulations. A strength of our method is that it
permits detection of heterogeneity within a patient’s CTC
population (Fig. 5d).
There is considerable interest in the analysis of CTCs as a
means of studying the biology and behaviour of metastatic
cancer. Metastatic disease is frequently difficult to biopsy
and treatment is based usually on analysis of the primary
tumour. Specific protein expression in metastatic disease may
differ from that of the primary tumour.20,21 The capability to
detect multiple antigens simultaneously enables detailed
molecular characterisation of CTCs and may provide an
accurate assessment of the biology of the underlying meta-
static disease.
It is important that the specificity of CTC detection is
high. There is no consensus definition as to what constitutes
a CTC partly because of the large number of techniques used
for their detection. Variation in the phenotypic criteria by
which CTCs are defined results in different CTC counts with
varying degrees of clinical significance.22 The majority of
studies define CTCs based upon positive and negative antigen
expression. In some studies, molecular definition is combined
with cell morphology. The high-resolution imaging that we
describe allows us to discriminate objects that might other-
wise have been included in the enumeration of CTCs. Some
studies11,23–32 have reported substantially larger numbers of
CTCs than have been identified in the present study or in
other reports.2,3 It is possible that such high numbers reflect
inclusion of noncellular objects and cellular debris.
Analysis of CTCs without enrichment is achievable with
an ImageStreamX flow cytometer, but the time required to
process an unenriched sample precludes realistic routine clin-
ical application. Analysis of one unenriched 5 ml blood sam-
ple would take 15 hr compared to 1 hr 40 min for an
enriched sample. The losses in our method occur predomi-
nantly during the enrichment and antigen detection stages.
The recovery of cells during the final analysis with the
ImageStreamX flow cytometer is 89.2%. The overall loss from
the procedure is 44.8%, of which 38.1% is lost during the
enrichment and 6.7% during the image collection. The Easy-
Sep CD45 depletion kit achieved the optimal recovery of
CTCs without generating large quantities of cellular debris.
Recovery rates are comparable with other methods in which
leukocytes are depleted positively33,34 and were consistent
over a range of cell concentrations for all tumour types. Leu-
kocyte depletion in head and neck cancers has been evaluated
by fluorescent activated cell sorting with a variety of com-
mercially available anti-CD45 antibodies and magnetic par-
ticles including EasySep.34 Recovery rates of up to 86% were
reported but in these analyses, cells were added to buffy coat
rather than whole blood, which should give higher recovery
rates because the losses associated with red cell lysis are not
considered.35
The most widely used method for cell-based CTC analysis
is the CellSearch system (Veridex) which has FDA approval
for use in metastatic breast, colorectal and prostate cancer.
Enrichment of samples depends upon positive selection of
CTCs that express EpCAM, which means that detection of
malignant cells is limited to those of epithelial origin that
express EpCAM. There is considerable heterogeneity in
EpCAM expression in established epithelial cancer cell
lines.36 Epithelial tumour cells that undergo epithelial mesen-
chymal transition (EMT) lose EpCAM expression and
EpCAM expression changes during the cell cycle.37
A single study has attempted comparison of the Image-
StreamX and CellSearch38 by analysis of PANC-1 pancreatic
cancer cells and reported that the accuracy of enumeration
was lower with the ImageStreamX. The authors enriched the
PANC-1 cells with different methods prior to analysis with
the two platforms which, because the method of enrichment
affects recovery rates, means that the two detection rates are
difficult to evaluate.
There are few reports in the literature about the analysis
of CTCs in oesophageal adenocarcinoma. Survivin mRNA
was detected by RT-PCR in peripheral blood of patients with
a variety of gastrointestinal tumours including oesophageal
adenocarcinoma.39 A recent study using the CellSearch plat-
form assessed CTC numbers in patients with advanced oeso-
phagogastric adenocarcinoma undergoing palliative
chemotherapy.40 The study was ended prematurely due to
the loss of commercial funding. In 11 patients with advanced
oesophageal or oesophagogastric junctional tumours, four
were found to have CTCs. In thyroid cancer, there is again a
lack of evidence for the value of CTC detection. A single
study evaluated the detection carcinoma embryonic antigen
(CEA) mRNA by RT-PCR in 121 patients undergoing surgery
for thyroid cancer41 and detected CTCs in 5% of patients.
EpCAM-positive CTCs were detected with the CellSearch
system in 18 of 59 patients with hepatocellular carcinoma42
and an association between presence of CTCs and overall
survival reported. In another study, CTCs were found in 28%
of HCC patient samples analysed with the CellSearch system
but in 100% of samples analysed with an EpCAM-independ-
ent filtration method.43 In a third study, multi-
immunofluorescence identified considerable heterogeneity
within CTC populations in HCC patients44 and changes in
the ratio of epithelial to mesenchymal cells were associated
with a longer time to disease progression.
There is more extensive literature about the role of CTCs
in ovarian cancer patients. Several studies have isolated a
mononuclear cell fraction by density gradient separation fol-
lowed by positive selection of CTCs based on their expression
of epithelial antigens, usually a single antigen.45,46 In one
study in which cells were enriched sequentially by epithelial
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and leukocyte-specific antigen expression, up to 149 CTCs
were detected per millilitre of blood in 61% of patients under
evaluation for ovarian cancer.47 A wide variation in the
detection rates of CTCs in patients with ovarian cancer of
between 12 and 100% have been reported.5,46,48,49 The high-
est number of CTCs reported is 3,118/ml of blood.45
A large number of methods with different strengths are
described for the enumeration and characterisation of CTCs.
It is unlikely that a single technique will be suitable for all
research and clinical applications. The principle strengths of
the method we describe are the quality of the images pro-
duced, the lack of positive selection of CTCs, its applicability
to all tumour types, and the ability to characterise the biology
of the cancer cells.
Acknowledgements
We are grateful to the Bobby Robson Foundation and Cancer Research UK,
C27826/A11524, for their generous support of our work. We thank E.
Rourke, H. Ramesh and M. Moat for their contributions in the early stages
of our study.
References
1. Ashworth A. A case of cancer in which cells sim-
ilar to this in the tumours were seen in the blood
after death. Aus Med J 1869; 146–9.
2. Cristofanilli M, Budd GT, Ellis MJ, et al. Circu-
lating tumor cells, disease progression, and sur-
vival in metastatic breast cancer. N Engl J Med
2004; 351:781–91.
3. de Bono JS, Scher HI, Montgomery RB, et al. Cir-
culating tumor cells predict survival benefit from
treatment in metastatic castration-resistant pros-
tate cancer. Clin Cancer Res 2008; 14:6302–9.
4. Krebs MG, Sloane R, Priest L, et al. Evaluation
and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer.
J Clin Oncol 2011; 29:1556–63.
5. Allard WJ, Matera J, Miller MC, et al. Tumor
cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients
with nonmalignant diseases. Clin Cancer Res
2004; 10:6897–904.
6. Tibbe AG, de Grooth BG, Greve J, et al. Optical
tracking and detection of immunomagnetically
selected and aligned cells. Nat Biotechnol 1999;
17:1210–3.
7. Riethdorf S, Fritsche H, Muller V, et al. Detection
of circulating tumor cells in peripheral blood of
patients with metastatic breast cancer: a valida-
tion study of the CellSearch system. Clin Cancer
Res 2007; 13:920–8.
8. Talasaz AH, Powell AA, Huber DE, et al.
Isolating highly enriched populations of circulat-
ing epithelial cells and other rare cells from
blood using a magnetic sweeper device.
Proc Natl Acad Sci USA 2009; 106:3970–5.
9. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of
circulating tumor cells using a microvortex-
generating herringbone-chip. Proc Natl Acad Sci
USA 2010; 107:18392–7.
10. Gleghorn JP, Pratt ED, Denning D, et al. Capture
of circulating tumor cells from whole blood of
prostate cancer patients using geometrically
enhanced differential immunocapture (GEDI)
and a prostate-specific antibody. Lab on a Chip
2010; 10:27–9.
11. Nagrath S, Sequist LV, Maheswaran S, et al. Iso-
lation of rare circulating tumour cells in cancer
patients by microchip technology. Nature 2007;
450:1235–9.
12. Maheswaran S, Sequist LV, Nagrath S, et al.
Detection of mutations in EGFR in circulating
lung-cancer cells. N Engl J Med 2008; 359:
366–77.
13. Sequist LV, Nagrath S, Toner M, et al. The CTC-
chip: an exciting new tool to detect circulating
tumor cells in lung cancer patients. J Thorac
Oncol 2009; 4:281–3.
14. Cristofanilli M, Hayes DF, Budd GT, et al. Circu-
lating tumor cells: a novel prognostic factor for
newly diagnosed metastatic breast cancer. J Clin
Oncol 2005; 23:1420–30.
15. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulat-
ing tumor cells versus imaging–predicting overall
survival in metastatic breast cancer. Clin Cancer
Res 2006; 12:6403–9.
16. Hayes DF, Cristofanilli M, Budd GT, et al. Circu-
lating tumor cells at each follow-up time point
during therapy of metastatic breast cancer
patients predict progression-free and overall sur-
vival. Clin Cancer Res 2006; 12:4218–24.
17. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic
significance of circulating tumor cells in patients
with metastatic colorectal cancer. Ann Oncol
2009; 20:1223–9.
18. Olmos D, Arkenau HT, Ang JE, et al. Circulating
tumour cell (CTC) counts as intermediate end
points in castration-resistant prostate cancer
(CRPC): a single-centre experience. Ann Oncol
2009; 20:27–33.
19. Tol J, Koopman M, Miller MC, et al. Circulating
tumour cells early predict progression-free and
overall survival in advanced colorectal cancer
patients treated with chemotherapy and targeted
agents. Ann Oncol 2010; 21:1006–12.
20. Fehm T, Muller V, Aktas B, et al. HER2 status of
circulating tumor cells in patients with metastatic
breast cancer: a prospective, multicenter trial.
Breast Cancer Res Treat 2010; 124:403–12.
21. Schoppmann SF, Jesch B, Zacherl J, et al. HER-2
status in primary oesophageal cancer, lymph
nodes and distant metastases. Br J Surg 2011; 98:
1408–13.
22. Coumans FA, Doggen CJ, Attard G, et al. All cir-
culating EpCAM1CK1CD45- objects predict
overall survival in castration-resistant prostate
cancer. Ann Oncol 2010; 21:1851–7.
23. Pachmann K, Camara O, Kavallaris A, et al.
Monitoring the response of circulating epithelial
tumor cells to adjuvant chemotherapy in breast
cancer allows detection of patients at risk of early
relapse. J Clin Oncol 2008; 26:1208–15.
24. Kahn HJ, Presta A, Yang LY, et al. Enumeration
of circulating tumor cells in the blood of breast
cancer patients after filtration enrichment: corre-
lation with disease stage. Breast Cancer Res Treat
2004; 86:237–47.
25. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-
cell detector for cancer. Proc Natl Acad Sci USA
2004; 101:10501–4.
26. Alix-Panabieres C, Brouillet JP, Fabbro M, et al.
Characterization and enumeration of cells secret-
ing tumor markers in the peripheral blood of
breast cancer patients. J Immunol Methods 2005;
299:177–88.
27. Schwarzenbach H, Alix-Panabieres C, Muller I,
et al. Cell-free tumor DNA in blood plasma as a
marker for circulating tumor cells in prostate
cancer. Clin Cancer Res 2009; 15:1032–8.
28. Hsieh HB, Marrinucci D, Bethel K, et al. High
speed detection of circulating tumor cells. Biosen-
sors & Bioelectronics 2006; 21:1893–9.
29. Racila E, Euhus D, Weiss AJ, et al. Detection and
characterization of carcinoma cells in the blood.
Proc Natl Acad Sci USA 1998; 95:4589–94.
30. Terstappen LW, Rao C, Gross S, et al. Peripheral
blood tumor cell load reflects the clinical activity
of the disease in patients with carcinoma of the
breast. Int J Oncol 2000; 17:573–8.
31. Moreno JG, Miller MC, Gross S, et al. Circulat-
ing tumor cells predict survival in patients with
metastatic prostate cancer. Urology 2005; 65:
713–8.
32. Hayes DF, Walker TM, Singh B, et al. Monitor-
ing expression of HER-2 on circulating epithelial
cells in patients with advanced breast cancer. Int
J Oncol 2002; 21:1111–7.
33. Lara O, Tong XD, Zborowski M, et al. Enrich-
ment of rare cancer cells through depletion of
normal cells using density and flow-through,
immunomagnetic cell separation. Exp Hematol
2004; 32:891–904.
34. Yang L, Lang JC, Balasubramanian P, et al. Optimi-
zation of an enrichment process for circulating
tumor cells from the blood of head and neck can-
cer patients through depletion of normal cells. Bio-
technology and Bioengineering 2009; 102:521–34.
35. Tong X, Yang L, Lang JC, et al. Application of
immunomagnetic cell enrichment in combina-
tion with RT-PCR for the detection of rare cir-
culating head and neck tumor cells in human
peripheral blood. Cytom B Clin Cytom 2007;
72B:310–23.
36. Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithe-
lial cell adhesion molecule antibodies and the
detection of circulating normal-like breast tumor
cells. J Natl Cancer Instit 2009; 101:61–6.
37. Trzpis M, McLaughlin PM, de Leij LM, et al. Epi-
thelial cell adhesion molecule: more than a carci-
noma marker and adhesion molecule. Am J
Pathol 2007; 171:386–95.
38. Lopez-Riquelme N, Minguela A, Villar-Permuy F,
et al. Imaging cytometry for counting circulating
tumor cells: comparative analysis of the Cell-
Search vs.ImageStream systems. Apmis 2013; 121:
1139–43.
39. Hoffmann AC, Warnecke-Eberz U, Luebke T,
et al. Survivin mRNA in peripheral blood is fre-
quently detected and significantly decreased fol-
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
Dent et al. 215
Int. J. Cancer: 138, 206–216 (2016) VC 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
147 
 
 
lowing resection of gastrointestinal cancers. J.
Surg Oncol 2007; 95:51–4.
40. Sclafani F, Smyth E, Cunningham D, et al. A
pilot study assessing the incidence and clinical
significance of circulating tumor cells in esopha-
gogastric cancers. Clin Colorectal Cancer 2014;
13:94–9.
41. Sato T, Harao M, Nakano S, et al. Circulating
tumor cells detected by reverse transcription-
polymerase chain reaction for carcinoembryonic
antigen mRNA: Distinguishing follicular thyroid
carcinoma from adenoma. Surgery 2005; 137:552–8.
42. Schulze K, Gasch C, Staufer K, et al. Presence of
EpCAM-positive circulating tumor cells as bio-
marker for systemic disease strongly correlates to
survival in patients with hepatocellular carci-
noma. Int J Cancer 2013; 133:2165–71.
43. Morris KL, Tugwood JD, Khoja L, Lancashire M,
Sloane R, Burt D, Shenjere P, Zhou C, Hodgson
C, Ohtomo T, Katoh A, Ishiguro T, Valle JW,
Dive C, Circulating biomarkers in hepatocellular
carcinoma. Cancer Chemother Pharmacol. 2014;
74:323–32.
44. Nel I, Baba HA, Ertle J, et al. Individual profiling
of circulating tumor cell composition and thera-
peutic outcome in patients with hepatocellular
carcinoma. Transl Oncol 2013; 6:420–8.
45. He W, Kularatne SA, Kalli KR, et al. Quantitation
of circulating tumor cells in blood samples from
ovarian and prostate cancer patients using
tumor-specific fluorescent ligands. Int J Cancer
2008; 123:1968–73.
46. Marth C, Kisic J, Kaern J, et al. Circulating tumor
cells in the peripheral blood and bone marrow of
patients with ovarian carcinoma do not predict
prognosis. Cancer 2002; 94:707–12.
47. Fan T, Zhao Q, Chen JJ, et al. Clinical signifi-
cance of circulating tumor cells detected by an
invasion assay in peripheral blood of patients
with ovarian cancer. Gynecol Oncol 2009; 112:
185–91.
48. Ntouroupi TG, Ashraf SQ, McGregor SB,
et al. Detection of circulating tumour cells in
peripheral blood with an automated scanning
fluorescence microscope. Br J Cancer 2008;
99:789–95.
49. Obermayr E, Castillo-Tong DC, Pils D, et al.
Molecular characterization of circulating tumor cells
in patients with ovarian cancer improves their
prognostic significance—a study of the OVCAD
consortium. Gynecol Oncol 2013; 128:15–21.
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
216 Detection and characterisation of circulating tumour cells
Int. J. Cancer: 138, 206–216 (2016) VC 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
